wvcs19970000887359;	AASTROM BIOSCIENCES INC;	S-1;	1996;	1996;	Aastrom CPS;	Clinical Trial;	Aastro;	22;	;	;		2001;	0.0492;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	424;	1996;	1996;	Aastrom CPS;	Clinical Trial;	Aastro;	30;	;	;		2001;	0.0492;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	1997;	AastromReplicell/(TM)/ System;	Clinical Trial;	Aastro;	30;	;	;		2001;	0.0492;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	1998;	AastromReplicell/(TM)/ System;	Clinical Trial;	Aastro;	30;	;	;		2001;	0.0492;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	1999;	AastromReplicell/(TM)/ System;	Clinical Trial;	Aastro;	30;	;	;		2001;	0.0492;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2000;	SC-I Therapy Kit;	Clinical Trial;	Aastro;	20;	;	;		2003;	-1;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2000;	CB-I Therapy Kit;	Clinical Trial;	Aastro;	;	;	;		2003;	-0.3333;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2001;	SC-I Therapy Kit;	Clinical Trial;	Aastro;	20;	;	;		2003;	-1;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2001;	CB-I Therapy Kit;	Clinical Trial;	Aastro;	;	;	;		2003;	-0.3333;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2001;	Dendricell™ products;	Clinical Trial;	Aastro;	22;	;	;		2004;	-0.7097;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2001;	OC-I;	phase 1/2;	Aastro;	20;	;	;		2003;	-0.7742;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2001;	CB-II cell;	Clinical Trial;	Aastro;	;	;	;		2003;	-1;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2002;	Tissue Repair Cells;	Clinical Trial;	Aastro;	20;	;	;		2011;	2;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2002;	Dendricell™ products;	Clinical Trial;	Aastro;	22;	23;	;		2004;	1.25;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2002;	Devices for cell production;	Clinical Trial;	Aastro;	22;	;	;		2006;	-0.4286;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2003;	Tissue Repair Cells;	Phase I/II;	Aastro;	20;	;	;		2011;	2;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2003;	Therapeutic Cells (TCs);	Clinical Trial;	Aastro;	22;	23;	20;		2005;	2.5;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2003;	Cell Production Products;	Commercially Available;	Aastro;	22;	20;	;		2006;	-0.4286;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2004;	Tissue Repair Cells;	Phase I/II;	AastromReplicell™ System;	20;	;	;		2011;	2;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2004;	Cell Production Products;	Commercially Available;	Aastrom’s Single-Pass Perfusion for Human Cell Growth AastromReplicell™ System;	22;	20;	;		2006;	0;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2005;	Tissue Repair Cells;	Phase I/II;	TRC Technology;	20;	;	;		2011;	2;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2006;	Tissue Repair Cells;	Pre Clinical;	TRC Technology;	20;	;	;		2011;	2;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2006;	Tissue Repair Cells;	Phase I/II;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2006;	Tissue Repair Cells;	Phase I/II;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2006;	Tissue Repair Cells;	Phase I/II;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2007;	Tissue Repair Cells;	Phase II;	TRC Technology;	20;	;	;		2011;	2;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2007;	Tissue Repair Cells;	Phase III;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2007;	Tissue Repair Cells;	Phase III;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2007;	Tissue Repair Cells;	Pre Clinical;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2007;	Tissue Repair Cells;	Pre Clinical;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2008;	Tissue Repair Cells;	Phase II;	TRC Technology;	20;	;	;		2011;	2;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2008;	Tissue Repair Cells;	Phase III;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2008;	Tissue Repair Cells;	Phase II;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2008;	Tissue Repair Cells;	Pre Clinical;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2009;	Tissue Repair Cells;	Phase II;	TRC Technology;	20;	;	;		2011;	2;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2009;	Tissue Repair Cells;	Phase III;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2009;	Tissue Repair Cells;	Phase II;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2009;	Tissue Repair Cells;	Phase II;	TRC Technology;	20;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2010;	Critical Limb Ischemia Therapy;	Phase II;	TRC Technology;	;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2010;	Dilated Cardiomyopathy Therapy;	Phase II;	TRC Technology;	;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2011;	Critical Limb Ischemia Therapy;	Phase II;	TRC Technology;	;	;	;		;	;		
wvcs19970000887359;	AASTROM BIOSCIENCES INC;	10-K;	1996;	2011;	Dilated Cardiomyopathy Therapy;	Phase II;	TRC Technology;	;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	S-1;	2004;	2004;	ACP-103;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	S-1;	2004;	2004;	ACP-104;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		2010;	-0.9231;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	S-1;	2004;	2004;	ACP-103;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	S-1;	2004;	2004;	AGN-XX ;	Phase I;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	S-1;	2004;	2004;	AGN-YY;	Phase I;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	S-1;	2004;	2004;	AC-262271;	Preclinical ;	proprietary target-based and chemistry-based technologies;	40;	1;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	424;	2004;	2004;	ACP-103;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	424;	2004;	2004;	ACP-104;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		2010;	-0.9231;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	424;	2004;	2004;	ACP-103;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	424;	2004;	2004;	AGN-XX ;	Phase I;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	424;	2004;	2004;	AGN-YY;	Phase I;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	424;	2004;	2004;	AC-262271;	Preclinical ;	proprietary target-based and chemistry-based technologies;	40;	1;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2005;	ACP-103;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2005;	ACP-104;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		2010;	-0.9231;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2005;	ACP-103;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2005;	AGN-XX ;	Phase I;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2005;	AGN-YY;	Phase I;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2005;	AC-262271;	Preclinical ;	proprietary target-based and chemistry-based technologies;	40;	1;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2005;	5-HT2;	Preclinical ;	proprietary target-based and chemistry-based technologies;	40;	;	;		2007;	0.6667;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2005;	AR Program;	Preclinical ;	proprietary target-based and chemistry-based technologies;	20;	;	;		2007;	-0.8889;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2006;	ACP-103;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2006;	ACP-104;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		2010;	-0.9231;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2006;	ACP-103;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2006;	AGN-XX ;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2006;	AGN-YY;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2006;	AC-262271;	IND;	proprietary target-based and chemistry-based technologies;	40;	1;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2006;	ACP-105;	IND;	proprietary target-based and chemistry-based technologies;	24;	40;	;		2011;	-0.55;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2006;	Serotonin program for neuropsychiatry and sleep indications;	Preclinical ;	proprietary target-based and chemistry-based technologies;	40;	;	;		2010;	0.25;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2006;	Muscarinic program for neuropsychiatry and other indications;	Preclinical ;	proprietary target-based and chemistry-based technologies;	42;	;	;		2011;	-0.6;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2007;	ACP-103;	Phase III;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2007;	ACP-103;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2007;	ACP-104;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		2010;	-0.9231;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2007;	AGN-XX ;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2007;	AGN-YY;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2007;	AC-262271;	IND;	proprietary target-based and chemistry-based technologies;	40;	1;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2007;	ACP-105;	IND;	proprietary target-based and chemistry-based technologies;	24;	40;	;		2011;	-0.55;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2007;	Serotonin program for neuropsychiatry and sleep indications;	Preclinical ;	proprietary target-based and chemistry-based technologies;	40;	;	;		2010;	0.25;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2007;	Muscarinic program for neuropsychiatry and other indications;	Preclinical ;	proprietary target-based and chemistry-based technologies;	42;	;	;		2011;	-0.6;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2007;	ACP-106 ;	IND;	proprietary target-based and chemistry-based technologies;	46;	;	;		2011;	-0.25;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	Pimavanserin;	Phase III;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	Pimavanserin;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	ACP-104;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		2010;	-0.9541;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	Pimavanserin;	Phase II;	proprietary target-based and chemistry-based technologies;	46;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	AGN-XX ;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	AGN-YY;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	AC-262271;	Phase I;	proprietary target-based and chemistry-based technologies;	40;	1;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	ACP-105;	IND;	proprietary target-based and chemistry-based technologies;	24;	40;	;		2011;	-0.55;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	Serotonin program for neuropsychiatry and sleep indications;	Preclinical ;	proprietary target-based and chemistry-based technologies;	40;	;	;		2010;	-0.75;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	Muscarinic program for neuropsychiatry and other indications;	Preclinical ;	proprietary target-based and chemistry-based technologies;	42;	;	;		2011;	-0.6;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2008;	ACP-106 ;	IND;	proprietary target-based and chemistry-based technologies;	46;	;	;		2011;	-0.25;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2009;	Pimavanserin;	Phase III;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2009;	Pimavanserin;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2009;	Pimavanserin;	Phase II;	proprietary target-based and chemistry-based technologies;	46;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2009;	AGN-XX ;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2009;	AGN-YY;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2009;	ACP-106 ;	IND;	proprietary target-based and chemistry-based technologies;	46;	;	;		2011;	0;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2009;	AC-262271;	Phase I;	proprietary target-based and chemistry-based technologies;	40;	1;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2009;	ACP-105;	IND;	proprietary target-based and chemistry-based technologies;	24;	40;	;		2011;	0;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2009;	Muscarinic program for neuropsychiatry and other indications;	Preclinical ;	proprietary target-based and chemistry-based technologies;	42;	;	;		2011;	-0.5556;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2010;	Pimavanserin;	Phase III;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2010;	Pimavanserin;	Phase III;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2010;	Pimavanserin;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2010;	AGN-XX ;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2010;	AGN-YY;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2010;	AC-262271;	Phase I;	proprietary target-based and chemistry-based technologies;	40;	1;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2010;	AM-831;	IND;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2011;	Pimavanserin;	Phase III;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2011;	Pimavanserin;	Phase III;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2011;	Pimavanserin;	Phase II;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2011;	AGN-XX ;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2011;	AGN-YY;	Phase II;	proprietary target-based and chemistry-based technologies;	62;	42;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2011;	AC-262271;	Phase I;	proprietary target-based and chemistry-based technologies;	40;	1;	;		;	;		
wvcs20040001070494;	ACADIA PHARMACEUTICALS INC;	10-K;	2004;	2011;	AM-831;	IND;	proprietary target-based and chemistry-based technologies;	40;	;	;		;	;		
nvcs19990001065087;	ALBANY MOLECULAR RESEARCH INC;	S-1;	1999;	1999;	Medicinal Chemistry;	;	;	;	;	;		;	;		
nvcs19990001065087;	ALBANY MOLECULAR RESEARCH INC;	S-1;	1999;	1999;	 Chemical Development;	;	;	;	;	;		;	;		
nvcs19990001065087;	ALBANY MOLECULAR RESEARCH INC;	S-1;	1999;	1999;	Analytical Chemistry Services;	;	;	;	;	;		;	;		
nvcs19990001065087;	ALBANY MOLECULAR RESEARCH INC;	S-1;	1999;	1999;	 cGMP Manufacturing Services;	;	;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	S-1;	1996;	1996;	 (Triage DOA);	Marketed;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	S-1;	1996;	1996;	 (Triage O&P)  ;	preclinical development;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	S-1;	1996;	1996;	 (Triage C. diff);	preclinical development;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	S-1;	1996;	1996;	(Triage Enteric)  ;	preclinical development;	 Triage Panel;	5;	;	;		2001;	31.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	S-1;	1996;	1996;	Triage Cardiac;	preclinical development;	 Triage CareLink System;	5;	9;	21;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	S-1;	1996;	1996;	Triage Transplant;	preclinical development;	 Triage CareLink System;	5;	;	;		1999;	22.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	S-1;	1996;	1996;	Triage Transplant;	preclinical development;	 Triage CareLink System;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	424;	1996;	1997;	 (Triage DOA);	Marketed;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	424;	1996;	1997;	 (Triage O&P)  ;	preclinical development;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	424;	1996;	1997;	 (Triage C. diff);	preclinical development;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	424;	1996;	1997;	(Triage Enteric)  ;	preclinical development;	 Triage Panel;	5;	;	;		2001;	31.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	424;	1996;	1997;	Triage Cardiac;	preclinical development;	 Triage CareLink System;	5;	9;	21;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	424;	1996;	1997;	Triage Transplant;	preclinical development;	 Triage CareLink System;	5;	;	;		1999;	31.9;		
wvcs19970000834306;	ALERE SAN DIEGO,;	424;	1996;	1997;	Triage Transplant;	preclinical development;	 Triage CareLink System;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1997;	 (Triage DOA);	Marketed;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1997;	 (Triage O&P)  ;	preclinical development;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1997;	 (Triage C. diff);	preclinical development;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1997;	(Triage Enteric)  ;	preclinical development;	 Triage Panel;	5;	;	;		2001;	31.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1997;	Triage Cardiac;	preclinical development;	 Triage CareLink System;	5;	9;	21;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1997;	Triage Transplant;	preclinical development;	 Triage CareLink System;	5;	;	;		1999;	31.9;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1997;	Triage Transplant;	preclinical development;	 Triage CareLink System;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1998;	 (Triage DOA);	Marketed;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1998;	Triage Cardiac;	Marketed;	TRIAGE METER;	5;	9;	21;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1998;	 (Triage C. diff);	Marketed;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1998;	THE TRIAGE PARASITE PANEL;	preclinical development;	 Triage Panel;	5;	;	;		2004;	9.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1998;	(Triage Enteric)  ;	preclinical development;	 Triage Panel;	5;	;	;		2001;	31.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1998;	THE TRIAGE NEORAL SYSTEM;	preclinical development;	TRIAGE METER;	5;	;	;		2001;	-0.1;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1998;	THE TRIAGE NEORAL SYSTEM;	preclinical development;	TRIAGE METER;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1998;	THE TRIAGE BNP SYSTEM;	Developmental Stage;	TRIAGE METER;	5;	21;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1998;	THE TRIAGE LBP SYSTEM;	Developmental Stage;	TRIAGE METER;	5;	;	;		2001;	31.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1999;	 (Triage DOA);	Marketed;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1999;	Triage Cardiac;	Marketed;	TRIAGE METER;	5;	9;	21;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1999;	 (Triage C. diff);	Marketed;	 Triage Panel;	5;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1999;	THE TRIAGE PARASITE PANEL;	Marketed;	 Triage Panel;	5;	;	;		2004;	9.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1999;	(Triage Enteric)  ;	preclinical development;	 Triage Panel;	5;	;	;		2001;	31.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1999;	THE NEORALCHEK SYSTEM;	preclinical development;	TRIAGE METER;	5;	;	;		2001;	2;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1999;	THE TRIAGE NEORAL SYSTEM;	preclinical development;	TRIAGE METER;	5;	;	;		2001;	20.6667;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1999;	THE TRIAGE BNP SYSTEM;	Developmental Stage;	TRIAGE METER;	5;	21;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	1999;	THE TRIAGE LBP SYSTEM;	Developmental Stage;	TRIAGE METER;	5;	;	;		2001;	3.4828;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2000;	 (Triage DOA);	Marketed;	 Triage Panel;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2000;	Triage Cardiac;	Marketed;	TRIAGE METER;	9;	21;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2000;	THE TRIAGE BNP SYSTEM;	Developmental Stage;	TRIAGE METER;	21;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2000;	THE TRIAGE PARASITE PANEL;	Marketed;	 Triage Panel;	;	;	;		2004;	9.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2000;	 (Triage C. diff);	Marketed;	 Triage Panel;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2001;	 (Triage DOA);	Marketed;	 Triage Panel;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2001;	Triage Cardiac;	Marketed;	TRIAGE METER;	9;	21;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2001;	THE TRIAGE BNP SYSTEM;	Developmental Stage;	TRIAGE METER;	21;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2001;	THE TRIAGE PARASITE PANEL;	Marketed;	 Triage Panel;	;	;	;		2004;	9.5;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2001;	 (Triage C. diff);	Marketed;	 Triage Panel;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2002;	 (Triage DOA);	Marketed;	 Triage Panel;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2002;	Triage Cardiac;	Marketed;	TRIAGE METER;	9;	21;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2002;	THE TRIAGE BNP SYSTEM;	Marketed;	TRIAGE METER;	21;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2002;	THE TRIAGE PARASITE PANEL;	Marketed;	 Triage Panel;	;	;	;		2004;	1.1724;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2002;	 (Triage C. diff);	Marketed;	 Triage Panel;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2002;	Stroke;	Pre Clinical;	TRIAGE METER;	45;	60;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2002;	Acute Coronory Syndromes;	Pre Clinical;	TRIAGE METER;	9;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2003;	 (Triage DOA);	Marketed;	Biosite Discovery program;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2003;	Triage Cardiac;	Marketed;	Biosite Discovery program;	9;	21;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2003;	THE TRIAGE BNP SYSTEM;	Marketed;	Biosite Discovery program;	21;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2003;	Stroke;	Pre Clinical;	Biosite Discovery program;	45;	60;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2003;	Acute Coronory Syndromes;	Pre Clinical;	Biosite Discovery program;	9;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2003;	Sepsis;	Pre Clinical;	Biosite Discovery program;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	 (Triage DOA);	Marketed;	Biosite Discovery program;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage Cardiac;	Marketed;	Biosite Discovery program;	9;	21;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	THE TRIAGE BNP SYSTEM;	Marketed;	Biosite Discovery program;	21;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	THE TRIAGE BNP SYSTEM;	Marketed;	Biosite Discovery program;	21;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage Microbiology Panels;	Marketed;	Biosite Discovery program;	9;	25;	70;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage Cardio ProfilER™;	Pre Market;	Biosite Discovery program;	62;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage MeterPlus;	Developmental Stage;	Biosite Discovery program;	70;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Stroke;	Pre Clinical;	Biosite Discovery program;	45;	60;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Acute Coronory Syndromes;	Pre Clinical;	Biosite Discovery program;	9;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Sepsis;	Pre Clinical;	Biosite Discovery program;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	 (Triage DOA);	Marketed;	Biosite Discovery program;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage Cardiac;	Marketed;	Biosite Discovery program;	9;	21;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage® BNP Test;	Marketed;	Biosite Discovery program;	21;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage® BNP Test;	Marketed;	Biosite Discovery program;	21;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage Cardio ProfilER™;	Pre Market;	MultiMarker Index value;	62;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage Profiler Shortness of Breath™ (SOB) Panel.;	Marketed;	MultiMarker Index value;	70;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage D-Dimer Test.;	Marketed;	Biosite Discovery program;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage Stroke Panel;	Pre Market;	MultiMarker Index value;	45;	60;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Acute Coronory Syndromes;	Pre Clinical;	MultiMarker Index value;	9;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Sepsis;	Pre Clinical;	MultiMarker Index value;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2004;	Triage MeterPlus;	Developmental Stage;	Biosite Discovery program;	70;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	 (Triage DOA);	Marketed;	Biosite Discovery program;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage Cardiac;	Marketed;	Biosite Discovery program;	9;	21;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage® BNP Test;	Marketed;	Biosite Discovery program;	21;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage® BNP Test;	Marketed;	Biosite Discovery program;	21;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage Cardio ProfilER™;	Pre Market;	MultiMarker Index value;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage Cardio ProfilER™;	Pre Market;	MultiMarker Index value;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage Profiler Shortness of Breath™ (SOB) Panel.;	Marketed;	MultiMarker Index value;	70;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage Profiler Shortness of Breath™ (SOB) Panel.;	Marketed;	MultiMarker Index value;	70;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage Profiler Shortness of Breath™ (SOB) Panel.;	Marketed;	MultiMarker Index value;	70;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage D-Dimer Test.;	Marketed;	MultiMarker Index value;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage Stroke Panel;	Pre Market;	MultiMarker Index value;	45;	60;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Sepsis;	Pre Clinical;	MultiMarker Index value;	;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Triage MPO Test ;	PreMarket;	MultiMarker Index value;	9;	;	;		;	;		
wvcs19970000834306;	ALERE SAN DIEGO,;	10-K;	1996;	2005;	Acute Kidney Injury;	Pre Clinical;	MultiMarker Index value;	25;	28;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	S-1;	2004;	2004;	Age-Related Macular Degeneration;	Pre Clinical;	RNA interference;	;	;	;		2008;	-0.6875;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	S-1;	2004;	2004;	Parkinson’s Disease;	Pre Clinical;	RNA interference;	40;	;	;		2009;	-0.6154;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	424;	2004;	2004;	Age-Related Macular Degeneration;	Pre Clinical;	RNA interference;	;	;	;		2008;	-0.6875;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	424;	2004;	2004;	Parkinson’s Disease;	Pre Clinical;	RNA interference;	40;	;	;		2009;	-0.6154;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	424;	2004;	2004;	Parkinson’s Disease;	Pre Clinical;	RNA interference;	40;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2005;	Age-Related Macular Degeneration;	Pre Clinical;	RNAi therapeutics;	;	;	;		2008;	-0.6875;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2005;	Parkinson’s Disease;	Pre Clinical;	RNAi therapeutics;	40;	;	;		2009;	-0.6154;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2005;	Respiratory Syncytial Virus Infection;	Pre Clinical;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2005;	Spinal Cord Injury;	Pre Clinical;	 Direct RNAi therapeutic ;	25;	;	;		2009;	-1;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2005;	Cystic Fibrosis;	Pre Clinical;	 Direct RNAi therapeutic ;	;	;	;		2010;	-0.4;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2006;	Parkinson’s Disease;	Pre Clinical;	RNAi therapeutics;	40;	;	;		2009;	-0.6154;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2006;	ALN-RSV01;	Phase I;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2006;	Spinal Cord Injury;	Pre Clinical;	RNAi therapeutics;	25;	;	;		2009;	-1;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2006;	Cystic Fibrosis;	Pre Clinical;	RNAi therapeutics;	;	;	;		2010;	-0.4;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2006;	ocular diseases;	Pre Clinical;	RNAi therapeutics;	;	;	;		2008;	0;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2006;	Neuropathic pain;	Pre Clinical;	RNAi therapeutics;	62;	25;	42;		2009;	-0.9091;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2006;	Pandemic flu;	Pre Clinical;	RNAi therapeutics;	;	;	;		2010;	0;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2006;	Huntington’s disease;	Pre Clinical;	RNAi therapeutics;	30;	;	;		2009;	0.3636;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2007;	Parkinson’s Disease;	Pre Clinical;	RNAi therapeutics;	40;	;	;		2009;	-0.5455;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2007;	ALN-RSV01;	Phase I;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2007;	Spinal Cord Injury;	Pre Clinical;	RNAi therapeutics;	25;	;	;		2009;	-1;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2007;	Cystic Fibrosis;	Pre Clinical;	RNAi therapeutics;	;	;	;		2010;	-0.4;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2007;	Neuropathic pain;	Pre Clinical;	RNAi therapeutics;	62;	25;	42;		2009;	-0.8;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2007;	ALN-FLU01 ;	Pre Clinical;	RNAi therapeutics;	;	;	;		2010;	0;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2007;	Huntington’s disease;	Pre Clinical;	RNAi therapeutics;	30;	;	;		2009;	0;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2007;	Hypercholesterolemia;	Pre Clinical;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2007;	Progressive Multifocal Leukoencephalopathy,;	Pre Clinical;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2007;	Ebola Virus;	Pre Clinical;	RNAi therapeutics;	23;	;	;		2011;	-0.3333;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2008;	ALN-RSV01;	Phase II;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2008;	Cystic Fibrosis;	Pre Clinical;	RNAi therapeutics;	;	;	;		2010;	-0.962;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2008;	ALN-FLU01 ;	Pre Clinical;	RNAi therapeutics;	;	;	;		2010;	-1;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2008;	ALN-HTT;	Pre Clinical;	RNAi therapeutics;	30;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2008;	ALN-PCS;	Pre Clinical;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2008;	Progressive Multifocal Leukoencephalopathy,;	Pre Clinical;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2008;	Ebola Virus;	Pre Clinical;	RNAi therapeutics;	23;	;	;		2011;	-0.3333;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2008;	ALN-VSP;	Pre Clinical;	RNAi therapeutics;	22;	28;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2009;	ALN-RSV01;	Phase II;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2009;	ALN-PCS;	Pre Clinical;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2009;	TTR Amyloidosis;	Pre Clinical;	RNA interference;	30;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2009;	ALN-VSP;	IND Approved;	RNAi therapeutics;	22;	28;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2009;	ALN-HTT;	Pre Clinical;	RNAi therapeutics;	30;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2009;	Ebola Virus;	Pre Clinical;	RNAi therapeutics;	23;	;	;		2011;	-0.2727;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2009;	Progressive Multifocal Leukoencephalopathy,;	Pre Clinical;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2010;	ALN-RSV01;	Phase II;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2010;	ALN-PCS;	Pre Clinical;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2010;	TTR Amyloidosis;	Phase I;	RNA interference;	30;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2010;	ALN-VSP;	Phase I;	RNAi therapeutics;	22;	28;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2010;	ALN-HTT;	Pre Clinical;	RNAi therapeutics;	30;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2010;	ALN-HPN;	Pre Clinical;	RNAi therapeutics;	27;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2011;	ALN-RSV01;	Phase II;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2011;	TTR Amyloidosis;	Phase I;	RNA interference;	30;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2011;	ALN-PCS;	Phase I;	RNAi therapeutics;	;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2011;	ALN-HPN;	Pre Clinical;	RNAi therapeutics;	27;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2011;	ALN-VSP;	Phase I;	RNAi therapeutics;	22;	28;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2011;	ALN-HTT;	Pre Clinical;	RNAi therapeutics;	30;	;	;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2011;	ALN-APC;	Pre Clinical;	RNAi therapeutics;	27;	20;	30;		;	;		
wvcs20040001178670;	ALNYLAM PHARMACEUTICAL;	10-K;	2004;	2011;	ALN-TMP;	Pre Clinical;	RNAi therapeutics;	27;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	S-1;	2003;	2003;	Isatoribine (ANA245);	Phase I;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	S-1;	2003;	2003;	Oral Prodrug of Isatoribine (ANA971);	Preclinical;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	S-1;	2003;	2003;	ANA97X;	Preclinical;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		2006;	-1;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	S-1;	2003;	2003;	ANA246,;	Preclinical;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	S-1;	2003;	2003;	AN 025-1;	Discovery;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	S-1;	2003;	2003;	Bacterial Ribosomal Translation Inhibitors;	Discovery;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		2008;	-1;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	424;	2003;	2004;	Isatoribine (ANA245);	Phase I;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		2009;	-0.772;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	424;	2003;	2004;	Oral Prodrug of Isatoribine (ANA971);	Preclinical;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		2006;	-0.9741;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	424;	2003;	2004;	ANA97X;	Preclinical;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		2006;	-1;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	424;	2003;	2004;	ANA246,;	Preclinical;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	424;	2003;	2004;	AN 025-1;	Preclinical;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	424;	2003;	2004;	  LB80380;	Preclinical;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	424;	2003;	2004;	Bacterial Ribosomal Translation Inhibitors;	Discovery;	 (RiboproteomicsTM, GATETM, and RIBObaseTM), ATLASTM;	23;	;	;		2008;	-1;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2005;	ANA975;	Phase I;	TLR-Based Small-Molecule ;	23;	;	;		2009;	-0.772;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2005;	ANA975;	 IND;	TLR-Based Small-Molecule ;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2005;	TLR-7 Agonists;	Discovery;	TLR-Based Small-Molecule ;	23;	;	;		2008;	-1;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2005;	AN 025-1;	Preclinical;	TLR-Based Small-Molecule ;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2005;	Isatoribine;	Phase I;	TLR-Based Small-Molecule ;	23;	;	;		2007;	-0.6787;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2005;	ANA380;	Phase II;	TLR-Based Small-Molecule ;	23;	;	;		2009;	-0.8796;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2005;	Bacterial Ribosomal Translation Inhibitors;	Discovery;	TLR-Based Small-Molecule ;	23;	;	;		2008;	-1;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2006;	ANA975;	Phase I;	TLR-Based Small-Molecule ;	23;	;	;		2009;	-0.772;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2006;	ANA975;	Phase I;	TLR-Based Small-Molecule ;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2006;	ANA380;	Phase II;	TLR-Based Small-Molecule ;	23;	;	;		2009;	-0.8796;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2006;	ANA773;	Preclinical;	TLR-Based Small-Molecule ;	22;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2006;	AN 025-1;	Preclinical;	TLR-Based Small-Molecule ;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2006;	Bacterial Ribosomal Translation Inhibitors;	Discovery;	TLR-Based Small-Molecule ;	23;	;	;		2008;	-1;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2006;	 AN 033-1;	Discovery;	TLR-Based Small-Molecule ;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2006;	TLR-7 Agonists;	Discovery;	TLR-Based Small-Molecule ;	23;	;	;		2008;	-0.9774;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2007;	ANA975;	Phase I;	TLR-Based Small-Molecule ;	23;	;	;		2009;	-0.8009;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2007;	ANA59X;	Preclinical;	Structure-Based Drug Design & Medicinal Chemistry;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2007;	ANA380;	Phase II;	Structure-Based Drug Design & Medicinal Chemistry;	23;	;	;		2009;	-0.9412;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2007;	ANA975;	 IND;	TLR-Based Small-Molecule ;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2007;	ANA773;	Preclinical;	TLR-Based Small-Molecule ;	22;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2008;	ANA773;	Phase I ;	TLR-Based Small-Molecule ;	22;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2008;	ANA598;	early stage clinical trials;	 non-nucleoside inhibitor;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2009;	ANA773;	Phase II ;	TLR-Based Small-Molecule ;	22;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2009;	ANA598;	Phase Ib ;	 non-nucleoside inhibitor;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2009;	ANA773;	early stage clinical trials;	TLR-Based Small-Molecule ;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2010;	ANA773;	Phase II ;	TLR-Based Small-Molecule ;	22;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2010;	ANA598;	Phase II;	 non-nucleoside inhibitor;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2010;	ANA773;	early stage clinical trials;	TLR-Based Small-Molecule ;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2011;	ANA598;	Phase IIa;	 non-nucleoside inhibitor;	23;	;	;		;	;		
wvcs20040001128495;	ANADYS PHARMACEUTICALS INC;	10-K;	2003;	2011;	ANA773;	early stage clinical trials;	TLR-Based Small-Molecule ;	23;	;	;		;	;		
nvcs19970000907654;	HYSEQ INC;	S-1;	1997;	1997;	Therapuetic Product;	Research;	HyX Platform;	21;	;	;		2002;	-0.3077;		
nvcs19970000907654;	HYSEQ INC;	S-1;	1997;	1997;	Diagnostic Product;	Research;	HyX Platform;	21;	;	;		2000;	-0.3462;		
nvcs19970000907654;	HYSEQ INC;	424;	1997;	1997;	Therapuetic Product;	Research;	HyX Platform;	;	;	;		2002;	-0.3077;		
nvcs19970000907654;	HYSEQ INC;	424;	1997;	1997;	Diagnostic Product;	Research;	HyX Platform;	;	;	;		2000;	-0.3462;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	1998;	Therapuetic Product;	Research;	HyX Platform;	21;	;	;		2002;	-0.3077;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	1998;	Diagnostic Product;	Research;	HyX Platform;	21;	;	;		2000;	0.3077;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	1999;	IL-1Hy2;	Research;	proprietary sequencing by hybridization ("SBH") ;	;	;	;		2002;	-0.3077;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	1999;	CD39L4;	Pre Clinical;	proprietary sequencing by hybridization ("SBH") ;	;	;	;		2011;	-0.68;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	1999;	IL-1Hy1;	Pre Clinical;	proprietary sequencing by hybridization ("SBH") ;	21;	;	;		2002;	-0.3333;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	2000;	IL-1Hy2;	Research;	proprietary sequencing by hybridization ("SBH") ;	;	;	;		2002;	-0.25;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	2000;	CD39L4;	Pre Clinical;	proprietary sequencing by hybridization ("SBH") ;	;	;	;		2011;	-0.68;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	2000;	IL-1Hy1;	Pre Clinical;	proprietary sequencing by hybridization ("SBH") ;	21;	;	;		2002;	-0.68;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	2001;	Alfimeprase;	Phase 1;	proprietary sequencing by hybridization ("SBH") ;	9;	21;	;		2011;	-0.68;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	2002;	Alfimeprase;	Phase 1;	proprietary sequencing by hybridization ("SBH") ;	9;	21;	;		2011;	-0.68;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	2002;	rNAPc2;	Phase 2;	proprietary sequencing by hybridization ("SBH") ;	9;	21;	;		2010;	-0.8298;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	2002;	ARC183,;	Pre Clinical;	proprietary sequencing by hybridization ("SBH") ;	9;	21;	;		;	;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	2003;	Alfimeprase;	Phase 2;	proprietary sequencing by hybridization ("SBH") ;	9;	21;	;		2011;	-0.68;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	2003;	rNAPc2;	Phase 2;	proprietary sequencing by hybridization ("SBH") ;	9;	21;	;		2010;	-0.8298;		
nvcs19970000907654;	HYSEQ INC;	10-K;	1997;	2003;	ARC183,;	Pre Clinical;	proprietary sequencing by hybridization ("SBH") ;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2004;	Alfimeprase;	Phase 3;	proprietary sequencing by hybridization ("SBH") ;	9;	21;	;		2011;	-0.68;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2004;	rNAPc2;	Phase 2a;	proprietary sequencing by hybridization ("SBH") ;	9;	21;	;		2010;	-0.8298;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2004;	ARC183;	Pre Clinical;	proprietary sequencing by hybridization ("SBH") ;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2005;	Alfimeprase;	Phase 3;	 direct-acting fibrinolytic (rDAF);	9;	21;	;		2011;	-0.68;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2005;	Alfimeprase;	Phase 3;	 direct-acting fibrinolytic (rDAF);	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2005;	Alfimeprase;	Phase I;	 direct-acting fibrinolytic (rDAF);	9;	21;	40;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2005;	Alfimeprase;	Pre clinical;	 direct-acting fibrinolytic (rDAF);	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2005;	rNAPc2;	Phase 2a;	Tissue Factor Inhibitor;	9;	21;	;		2010;	0.6;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2005;	ARC183;	Pre Clinical;	Thrombin Inhibitor;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2005;	NU206;	Pre Clinical;	GI signaling Pathway modulator;	22;	;	;		2011;	-0.6;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2005;	rNAPc2;	Pre Clinical;	Tissue Factor Inhibitor;	22;	;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2006;	Alfimeprase;	Phase 3;	 direct-acting fibrinolytic (rDAF);	9;	21;	;		2011;	-0.68;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2006;	Alfimeprase;	Phase 3;	 direct-acting fibrinolytic (rDAF);	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2006;	Alfimeprase;	Phase I;	 direct-acting fibrinolytic (rDAF);	9;	21;	40;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2006;	Alfimeprase;	Pre clinical;	 direct-acting fibrinolytic (rDAF);	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2006;	rNAPc2;	Phase 2a;	Tissue Factor Inhibitor;	9;	21;	;		2010;	0.6;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2006;	ARC183;	Pre Clinical;	Thrombin Inhibitor;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2006;	NU206;	Pre Clinical;	GI signaling Pathway modulator;	22;	;	;		2011;	-0.6;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2006;	rNAPc2;	Pre Clinical;	Tissue Factor Inhibitor;	22;	;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2007;	Alfimeprase;	Phase 3;	 direct-acting fibrinolytic (rDAF);	9;	21;	;		2011;	-0.68;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2007;	Alfimeprase;	Phase 3;	 direct-acting fibrinolytic (rDAF);	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2007;	Alfimeprase;	Phase II;	 direct-acting fibrinolytic (rDAF);	9;	21;	40;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2007;	rNAPc2;	Phase 2a;	Tissue Factor Inhibitor;	9;	21;	;		2010;	0;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2007;	NU 172;	Pre Clinical;	Thrombin Inhibitor;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2007;	rNAPc2;	Phase 2;	 anticoagulant protein;	22;	;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2007;	NU206;	Pre Clinical;	GI signaling Pathway modulator;	22;	;	;		2011;	-0.6;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2008;	Alfimeprase;	Phase II;	 direct-acting fibrinolytic (rDAF);	9;	21;	;		2011;	-0.68;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2008;	Alfimeprase;	Phase II;	 direct-acting fibrinolytic (rDAF);	9;	21;	40;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2008;	NU 172;	Pre Clinical;	Thrombin Inhibitor;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2008;	rNAPc2;	Phase 2a;	Tissue Factor Inhibitor;	9;	21;	;		2010;	0;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2008;	NU206;	Pre Clinical;	GI signaling Pathway modulator;	22;	;	;		2011;	-0.6;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2008;	Leukemia Therapeutic Antibody Program;	Pre Clinical;	monoclonal antibody (mAbs) ;	22;	27;	;		2011;	0;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2008;	Wnt Therapeutics Program;	Pre Clinical;	Wnt signaling pathway ;	26;	;	;		2011;	0;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2008;	Wnt Therapeutics Program;	Pre Clinical;	Wnt signaling pathway ;	26;	;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2008;	Wnt Therapeutics Program;	Pre Clinical;	Wnt signaling pathway ;	20;	;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2008;	Wnt Therapeutics Program;	Pre Clinical;	Wnt signaling pathway ;	22;	;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2009;	Alfimeprase;	Phase II;	 direct-acting fibrinolytic (rDAF);	9;	21;	;		2011;	0;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2009;	Alfimeprase;	Phase II;	 direct-acting fibrinolytic (rDAF);	9;	21;	40;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2009;	NU 172;	Pre Clinical;	Thrombin Inhibitor;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2009;	NU206;	Pre Clinical;	GI signaling Pathway modulator;	22;	;	;		2011;	0;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2009;	Leukemia Therapeutic Antibody Program;	Pre Clinical;	monoclonal antibody (mAbs) ;	22;	27;	;		2011;	0;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2009;	Wnt Therapeutics Program;	Pre Clinical;	Wnt signaling pathway ;	26;	;	;		2011;	0;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2009;	Wnt Therapeutics Program;	Pre Clinical;	Wnt signaling pathway ;	26;	;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2009;	Wnt Therapeutics Program;	Pre Clinical;	Wnt signaling pathway ;	20;	;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2009;	Wnt Therapeutics Program;	Pre Clinical;	Wnt signaling pathway ;	22;	;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2010;	GencaroTM;	Phase III ;	beta-blocker and mild vasodilator,;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2010;	NU 172;	Pre Clinical;	Thrombin Inhibitor;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2010;	rNAPc2;	Phase 2a;	Tissue Factor Inhibitor;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2011;	GencaroTM;	Phase III ;	beta-blocker and mild vasodilator,;	9;	21;	;		;	;		
nvcs19970000907654;	ARCA biopharma, Inc.;	10-K;	1997;	2011;	rNAPc2;	Phase 2a;	Tissue Factor Inhibitor;	9;	21;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	S-1;	1997;	1997;	Primsol trimethoprim solution;	 marketing approval;	Taste masking  ;	9;	23;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	S-1;	1997;	1997;	Prednisolone sodium phosphate syrup;	 marketing approval;	Taste masking  ;	5;	29;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	S-1;	1997;	1997;	 Pediatemp acetaminophen beads;	Phase III;	Controlled-release  ;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	S-1;	1997;	1997;	Cromolyn sodium cream;	Phase I;	Transdermal delivery    ;	8;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	S-1;	1997;	1997;	 Cromolyn sodium nasal spray;	Preclinical;	Bioadhesion       ;	;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	S-1;	1997;	1997;	Pediamist nasal saline spray;	Marketed;	 Intranasal delivery device   ;	;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	S-1;	1997;	1997;	 Feverall   ;	Marketed;	Upsher-Smith's Feverall;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	S-1;	1997;	1997;	Pediavent albuterol;	Phase I;	Controlled-release    ;	5;	29;	;		1999;	-0.2857;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	424;	1997;	1997;	Primsol trimethoprim solution;	 marketing approval;	Taste masking  ;	9;	23;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	424;	1997;	1997;	Prednisolone sodium phosphate syrup;	 marketing approval;	Taste masking  ;	5;	29;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	424;	1997;	1997;	 Pediatemp acetaminophen beads;	Phase III;	Controlled-release  ;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	424;	1997;	1997;	Cromolyn sodium cream;	Phase I;	Transdermal delivery    ;	8;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	424;	1997;	1997;	 Cromolyn sodium nasal spray;	Preclinical;	Bioadhesion       ;	;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	424;	1997;	1997;	Pediamist nasal saline spray;	Marketed;	 Intranasal delivery device   ;	;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	424;	1997;	1997;	 Feverall   ;	Marketed;	Upsher-Smith's Feverall;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	424;	1997;	1997;	Pediavent albuterol;	Phase I;	Controlled-release    ;	5;	29;	;		1999;	-0.2857;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1998;	Primsol trimethoprim solution;	NDA;	Taste masking  ;	9;	23;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1998;	Orapred syrup    ;	ANDA;	Taste masking  ;	5;	29;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1998;	 Pediatemp acetaminophen beads;	Phase III;	Controlled-release  ;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1998;	Cromolyn sodium cream;	NDA;	Transdermal delivery    ;	8;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1998;	 Cromolyn sodium nasal spray;	NDA;	Bioadhesion       ;	;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1998;	Pediamist nasal saline spray;	Marketed;	 Intranasal delivery device   ;	;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1998;	Feverall(R) acetaminophen rectal ;	Marketed;	Upsher-Smith's Feverall;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1998;	Duricef(R) oral suspension;	Marketed;	cephalosporin oral suspension;	23;	29;	3;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1998;	Feverall(R) controlled-release  beads  ;	Phase III;	Controlled-release;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1999;	Primsol trimethoprim solution;	NDA;	Taste masking  ;	9;	23;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1999;	Orapred syrup    ;	ANDA;	Taste masking  ;	5;	29;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1999;	Cromolyn sodium cream;	NDA;	Transdermal delivery    ;	8;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1999;	 Cromolyn sodium nasal spray;	NDA;	Bioadhesion       ;	;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1999;	Pediamist nasal saline spray;	Marketed;	 Intranasal delivery device   ;	;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1999;	Feverall(R) acetaminophen rectal ;	Marketed;	Upsher-Smith's Feverall;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1999;	Omnicef(R) (Cefdinir) Oral Suspension and Capsules;	Marketed;	cephalosporin oral suspension;	23;	29;	3;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1999;	Feverall(R) controlled-releaseS Sprinkles;	NDA;	Controlled-release;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	1999;	Pediavent albuterol    ;	Phase III;	Controlled-release;	5;	29;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	2000;	Primsol trimethoprim solution;	NDA;	Taste masking  ;	9;	23;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	2000;	Orapred syrup    ;	ANDA;	Taste masking  ;	5;	29;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	2000;	Cromolyn sodium cream;	NDA;	Transdermal delivery    ;	8;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	2000;	 Cromolyn sodium nasal spray;	NDA;	Bioadhesion       ;	;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	2000;	Pediamist nasal saline spray;	Marketed;	 Intranasal delivery device   ;	;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	2000;	Feverall(R) acetaminophen rectal ;	Marketed;	Upsher-Smith's Feverall;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	2000;	Omnicef(R) (Cefdinir) Oral Suspension and Capsules;	Marketed;	cephalosporin oral suspension;	23;	29;	3;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	2000;	Feverall(R) controlled-releaseS Sprinkles;	NDA;	Controlled-release;	62;	;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	2000;	Pediavent albuterol    ;	Phase III;	Controlled-release;	5;	29;	;		;	;		
wvcs19970001019731;	ASCENT PEDIATRICS INC;	10-K;	1997;	2000;	 Pediotic;	;	corticosteroid/antibiotic;	23;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	S-1;	2004;	2004;	Testim;	Marketed;	testosterone gel ;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	S-1;	2004;	2004;	Androgen Replacement Film;	 Preclinical;	 androgen replacement film;	3;	;	;		2007;	0.6;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	S-1;	2004;	2004;	Transmucosal Film Technology Platform;	 Preclinical;	transmucosal film technology.;	3;	;	;		2007;	1.2;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	S-1;	2004;	2004;	Overactive Bladder Film;	 Preclinical;	Transmucosal Film Technology Platform;	3;	;	;		2012;	-0.7778;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	424;	2004;	2004;	Testim;	Marketed;	testosterone gel ;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	424;	2004;	2004;	Androgen Replacement Film;	 Preclinical;	 androgen replacement film;	3;	;	;		2007;	0.6;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	424;	2004;	2004;	Transmucosal Film Technology Platform;	 Preclinical;	transmucosal film technology.;	3;	;	;		2007;	1.2;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	424;	2004;	2004;	Overactive Bladder Film;	 Preclinical;	Transmucosal Film Technology Platform;	3;	;	;		2012;	-0.7778;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2005;	Testim;	Marketed;	testosterone gel ;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2005;	AA4500;	 Phase II ;	 injectable enzyme;	3;	;	;		2009;	-0.968;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2005;	AA4500;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2005;	Androgen Replacement Film;	Phase I;	 androgen replacement film;	;	;	;		2007;	-0.936;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2005;	Transmucosal Film Technology Platform;	 Preclinical;	transmucosal film technology.;	3;	;	;		2007;	-0.912;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2005;	Overactive Bladder Film;	Phase I;	Transmucosal Film Technology Platform;	3;	;	;		2012;	-0.7778;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2006;	Testim;	Marketed;	testosterone gel ;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2006;	AA4500;	 Phase II ;	 injectable enzyme;	3;	;	;		2009;	-0.968;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2006;	AA4500;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2006;	AA4500;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2006;	A2600;	Phase II;	Transmucosal Film Technology;	3;	;	;		2008;	-0.992;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2006;	AA4010;	 Phase I;	Transmucosal Film Technology;	3;	;	;		2012;	-0.7778;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2006;	Pain Film;	Phase I;	Transmucosal Film Technology;	62;	3;	;		2012;	-0.5556;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2007;	Testim;	Marketed;	testosterone gel ;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2007;	AA4500;	Phase III;	 injectable enzyme;	3;	;	;		2009;	-0.9864;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2007;	AA4500;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2007;	AA4500;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2007;	AA4010;	 Phase I;	Transmucosal Film Technology;	3;	;	;		2012;	-0.7778;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2007;	Pain Product;	Phase I;	Transmucosal Film Technology;	62;	3;	;		2012;	-0.5556;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2008;	Testim;	Marketed;	testosterone gel ;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2008;	XIAFLEX™;	Phase III;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2008;	XIAFLEX™;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2008;	XIAFLEX™;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2008;	AA4010;	 Phase I;	Transmucosal Film Technology;	3;	;	;		2012;	-0.7778;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2008;	Pain product;	Phase I;	Transmucosal Film Technology;	62;	3;	;		2012;	-0.5556;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2009;	Testim;	Marketed;	testosterone gel ;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2009;	XIAFLEX™;	Phase III;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2009;	XIAFLEX™;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2009;	XIAFLEX™;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2009;	AA4010;	 Phase I;	Transmucosal Film Technology;	3;	;	;		2012;	-0.7778;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2009;	Pain product;	Phase I;	Transmucosal Film Technology;	62;	3;	;		2012;	-0.5556;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2010;	Testim;	Marketed;	testosterone gel ;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2010;	XIAFLEX™;	Marketed;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2010;	XIAFLEX™;	Phase II;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2010;	XIAFLEX™;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2010;	AA4010;	 Phase I;	Transmucosal Film Technology;	3;	;	;		2012;	-0.9949;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2010;	Pain product;	Phase I;	Transmucosal Film Technology;	62;	3;	;		2012;	-0.9897;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2011;	Testim;	Marketed;	testosterone gel ;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2011;	XIAFLEX™;	Marketed;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2011;	XIAFLEX™;	Phase III;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2011;	XIAFLEX™;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2012;	Testim;	Marketed;	testosterone gel ;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2012;	XIAFLEX™;	Marketed;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2012;	XIAFLEX™;	Phase III;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2012;	XIAFLEX™;	 Phase II ;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001182129;	AUXILIUM PHARMACEUTICALS INC;	10-K;	2004;	2012;	XIAFLEX™;	Phase I;	 injectable enzyme;	3;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	S-1;	2004;	2004;	Sebazole;	Phase III;	ketoconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	S-1;	2004;	2004;	  Zimycan;	Phase III;	miconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	S-1;	2004;	2004;	Hyphanox;	Phase III;	itraconazole;	8;	70;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	S-1;	2004;	2004;	Liarozole;	Phase III;	RAMBA class;	8;	;	;		2008;	-0.5918;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	S-1;	2004;	2004;	Rambazole;	Phase I;	RAMBA class;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	S-1;	2004;	2004;	Azoline;	Phase I;	triazole antifungal;	8;	23;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	S-1;	2004;	2004;	 Hivenyl;	Phase I;	H1 antihistamine;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	S-1;	2004;	2004;	Atopik;	Development;	PDE4 inhibitor;	8;	;	;		2008;	-0.5;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	S-1;	2004;	2004;	 Ecalcidene;	Preclinical;	vitamin D 3 derivative;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	424;	2004;	2004;	Sebazole;	Phase III;	ketoconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	424;	2004;	2004;	  Zimycan;	Phase III;	miconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	424;	2004;	2004;	Hyphanox;	Phase III;	itraconazole;	8;	70;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	424;	2004;	2004;	Liarozole;	Phase III;	RAMBA class;	8;	;	;		2008;	-0.5918;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	424;	2004;	2004;	Rambazole;	Phase I;	RAMBA class;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	424;	2004;	2004;	Azoline;	Phase I;	triazole antifungal;	8;	23;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	424;	2004;	2004;	 Hivenyl;	Phase I;	H1 antihistamine;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	424;	2004;	2004;	Atopik;	Development;	PDE4 inhibitor;	8;	;	;		2008;	-0.5;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	424;	2004;	2004;	 Ecalcidene;	Preclinical;	vitamin D 3 derivative;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2005;	Zimycan;	NDA ;	miconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2005;	Sebazole;	Phase III;	ketoconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2005;	Hyphanox;	Phase III;	itraconazole;	8;	70;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2005;	Liarozole;	Phase III;	RAMBA class;	8;	;	;		2008;	-0.5918;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2005;	Rambazole;	Phase 2;	RAMBA class;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2005;	Azoline;	Phase 2;	triazole antifungal;	8;	23;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2005;	 Hivenyl;	Phase 2;	H1 antihistamine;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2005;	Atopik;	Development;	PDE4 inhibitor;	8;	;	;		2008;	-0.5;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2005;	Ketanserin;	Preclinical;	 serotonin 2 ;	8;	;	;		2008;	-0.5;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	Vusion™;	Marketed;	miconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	Solagé;	Marketed;	mequinol;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	VANIQA®;	Marketed;	eflornithine HCI;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	Sebazole;	NDA;	ketoconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	Hyphanox;	Phase III;	itraconazole;	8;	70;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	Liarozole;	Phase III;	RAMBA class;	8;	;	;		2008;	-0.6154;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	Rambazole;	Phase 2;	RAMBA class;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	Azoline;	Phase 2;	triazole antifungal;	8;	23;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	 Hivenyl;	Phase 2;	H1 antihistamine;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	Atopik;	Development;	PDE4 inhibitor;	8;	;	;		2008;	-0.9167;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2006;	Ketanserin;	Preclinical;	 serotonin 2 ;	8;	;	;		2008;	-0.7917;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2007;	Vusion™;	Marketed;	miconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2007;	Solagé;	Marketed;	mequinol;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2007;	VANIQA®;	Marketed;	eflornithine HCI;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2007;	Xolegel™ ;	Marketed;	ketoconazole;	8;	2;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2007;	Denavir® ;	Marketed;	penciclovir cream;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2007;	Hyphanox;	Phase III;	itraconazole;	8;	70;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2007;	Azoline;	Phase 2;	triazole antifungal;	8;	23;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2007;	Rambazole;	Phase 2;	RAMBA class;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2007;	 Hivenyl;	Phase 2;	H1 antihistamine;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2008;	Vusion™;	Marketed;	miconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2008;	Solagé;	Marketed;	mequinol;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2008;	Xolegel™ ;	Marketed;	ketoconazole;	8;	2;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2008;	Hyphanox;	Phase III;	itraconazole;	8;	70;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2008;	Pramiconazole;	Phase II;	pramiconazole;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2008;	Rambazole;	Phase 2;	RAMBA class;	8;	;	;		;	;		
wvcs20040001173657;	BARRIER THERAPEUTICS INC;	10-K;	2004;	2008;	 Hivenyl;	Phase 2;	H1 antihistamine;	8;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	S-1;	1997;	1997;	Lisofylline;	Phase III;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2001;	-0.8867;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	S-1;	1997;	1997;	CT-2584;	Phase I;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2003;	-0.9189;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	S-1;	1997;	1997;	Lisofylline;	Phase II;	technology for quantitative measuring of specific species of lipids and phospholipids; 	5;	9;	25;		;	;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	S-1;	1997;	1997;	CT-3578;	Research;	technology for quantitative measuring of specific species of lipids and phospholipids; 	5;	;	;		2000;	-0.6;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	424;	1997;	1997;	Lisofylline;	Phase III;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2001;	-0.8867;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	424;	1997;	1997;	CT-2584;	Phase I;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2003;	-0.9189;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	424;	1997;	1997;	Lisofylline;	Phase II;	technology for quantitative measuring of specific species of lipids and phospholipids; 	5;	9;	25;		;	;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	424;	1997;	1997;	CT-3578;	Research;	technology for quantitative measuring of specific species of lipids and phospholipids; 	5;	;	;		2000;	-0.6;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	1998;	Lisofylline;	Phase III;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2001;	-0.8867;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	1998;	CT-2584;	Phase I;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2003;	-0.9189;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	1998;	Lisofylline;	Phase II/III;	technology for quantitative measuring of specific species of lipids and phospholipids; 	5;	9;	25;		;	;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	1998;	CT-3578;	Research;	technology for quantitative measuring of specific species of lipids and phospholipids; 	5;	;	;		2000;	-0.9867;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	1999;	LSF™;	Phase III;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2001;	-0.8867;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	1999;	APRA(TM);	Phase I;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2003;	-0.9189;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	1999;	PG-TXL(TM);	Phase I;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2009;	-0.9717;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	1999;	PG-CAMPTOTHECIN;	Pre Clinical;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		;	;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	1999;	PG-ETOPOSIDE;	Research;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2003;	-0.9189;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	1999;	LSF;	Phase II/III;	technology for quantitative measuring of specific species of lipids and phospholipids; 	5;	9;	25;		2001;	-0.5405;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2000;	ATO	Phase II;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	27;	;		;	;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2000;	PG-TXL(TM);	Phase I;	PG-TXL’s polymer technolog;	22;	;	;		2009;	-0.9717;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2000;	PG-CAMPTOTHECIN;	Pre Clinical;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		;	;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2000;	APRA(TM);	Phase II;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2003;	-0.9189;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2001;	TRISENOX;	Phase III;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2007;	-0.2318;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2001;	TRISENOX;	Phase III;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		;	;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2001;	PG-TXL(TM);	Phase I;	PG-TXL’s polymer technolog;	22;	;	;		2009;	-0.9717;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2001;	PG-CAMPTOTHECIN;	Pre Clinical;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		;	;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2001;	CT-2584;	Phase II;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2003;	-0.9829;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2002;	TRISENOX;	Marketing;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		2007;	-0.2318;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2002;	PG-TXL(TM);	Phase I;	PG-TXL’s polymer technology;	22;	;	;		2009;	-0.9717;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2002;	PG-CPT;	Phase I;	technology for quantitative measuring of specific species of lipids and phospholipids; 	22;	;	;		;	;	
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2003;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		2007;	-0.2318;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2003;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2003;	TRISENOX;	Marketed;	Polyglutamate Drug Delivery Technology;	9;	22;	27;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2003;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	27;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2003;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2003;	XYOTAX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		2009;	-0.9717;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2003;	XYOTAX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2003;	PG-CPT;	Phase I;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2004;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		2007;	-0.2318;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2004;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2004;	TRISENOX;	Marketed;	Polyglutamate Drug Delivery Technology;	9;	22;	27;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2004;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	27;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2004;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2004;	XYOTAX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		2009;	-0.9717;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2004;	XYOTAX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2004;	Pixantrone;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2004;	CT-2106;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		2009;	-0.6667;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2005;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		2007;	6.7333;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2005;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2005;	TRISENOX;	Marketed;	Polyglutamate Drug Delivery Technology;	9;	22;	27;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2005;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	27;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2005;	TRISENOX;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2005;	XYOTAX;	;	Polyglutamate Drug Delivery Technology;	22;	;	;		2009;	-0.9717;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2005;	XYOTAX;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2005;	Pixantrone;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2005;	CT-2106;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		2009;	-0.6667;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2006;	XYOTAX;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		2009;	-0.9717;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2006;	XYOTAX;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2006;	Pixantrone;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2006;	CT-2106;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		2009;	-0.6667;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2007;	XYOTAX;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		2009;	-0.8;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2007;	XYOTAX;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2007;	XYOTAX;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2007;	Pixantrone;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2007;	CT-2106;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		2009;	-0.9714;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2008;	Pixantrone;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2008;	Zevalin;	Phase III;	radioimmunotherapeutic agent ;	22;	;	;		2011;	-0.2463;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2008;	Paclitaxel;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		2010;	-0.709;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2008;	PaclitaxelPoliglumex(CT-2103);	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2008;	Brostallicin;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2008;	PaclitaxelPoliglumex(CT-2103);	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2009;	Pixantrone;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2009;	OPAXIO (CT-2103);	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2009;	OPAXIO (CT-2103);	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2009;	Brostallicin;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2009;	Brostallicin;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2009;	Zevalin;	Phase III;	radioimmunotherapeutic agent ;	22;	;	;		2011;	0.8364;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2010;	Pixantrone;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2010;	OPAXIO (CT-2103);	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2010;	OPAXIO (CT-2103);	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2010;	OPAXIO (CT-2103);	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2010;	Brostallicin;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2010;	Brostallicin;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2010;	Brostallicin;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2011;	Pixuvri;	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2011;	OPAXIO (CT-2103);	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2011;	OPAXIO (CT-2103);	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2011;	OPAXIO (CT-2103);	Phase III;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2011;	OPAXIO (CT-2103);	Phase II;	Polyglutamate Drug Delivery Technology;	22;	40;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2011;	OPAXIO (CT-2103);	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970000891293;	CELL THERAPEUTICS INC;	10-K;	1997;	2011;	Brostallicin;	Phase II;	Polyglutamate Drug Delivery Technology;	22;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	S-1;	1996;	1996;	Platelet   Photochemical Treatment  System;	Phase I;	Platelet Pathogen Inactivation System.;	27;	;	;		2006;	0.75;		
wvcs19970001020214;	CERUS CORP;	S-1;	1996;	1996;	Platelet   Photochemical Treatment  System;	Phase I;	Platelet Pathogen Inactivation System.;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	S-1;	1996;	1996;	FFP  Photochemical Treatment System;	Preclinical;	FFP Pathogen Inactivation System;	27;	;	;		2006;	4.25;		
wvcs19970001020214;	CERUS CORP;	S-1;	1996;	1996;	FFP  Photochemical Treatment System;	Preclinical;	FFP Pathogen Inactivation System;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	S-1;	1996;	1996;	Red Cell ALE  Treatment System;	Preclinical;	Red Cell ALE Treatment System.;	27;	;	;		2003;	0.32;		
wvcs19970001020214;	CERUS CORP;	S-1;	1996;	1996;	Red Cell ALE  Treatment System;	Preclinical;	Red Cell ALE Treatment System.;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	424;	1996;	1997;	Platelet   Photochemical Treatment  System;	Phase I;	Platelet Pathogen Inactivation System.;	27;	;	;		2006;	0.75;		
wvcs19970001020214;	CERUS CORP;	424;	1996;	1997;	Platelet   Photochemical Treatment  System;	Phase I;	Platelet Pathogen Inactivation System.;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	424;	1996;	1997;	FFP  Photochemical Treatment System;	Preclinical;	FFP Pathogen Inactivation System;	27;	;	;		2006;	4.25;		
wvcs19970001020214;	CERUS CORP;	424;	1996;	1997;	FFP  Photochemical Treatment System;	Preclinical;	FFP Pathogen Inactivation System;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	424;	1996;	1997;	Red Cell ALE  Treatment System;	Preclinical;	Red Cell ALE Treatment System.;	27;	;	;		2003;	0.32;		
wvcs19970001020214;	CERUS CORP;	424;	1996;	1997;	Red Cell ALE  Treatment System;	Preclinical;	Red Cell ALE Treatment System.;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1998;	Platelet   Photochemical Treatment  System;	Phase II;	Platelet Pathogen Inactivation System.;	27;	;	;		2006;	0.75;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1998;	Platelet   Photochemical Treatment  System;	Phase II;	Platelet Pathogen Inactivation System.;	22;	27;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1998;	FFP  Photochemical Treatment System;	Preclinical;	FFP Pathogen Inactivation System;	27;	;	;		2006;	4.25;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1998;	FFP  Photochemical Treatment System;	Preclinical;	FFP Pathogen Inactivation System;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1998;	Red Cell ALE  Treatment System;	Preclinical;	Red Cell ALE Treatment System.;	27;	;	;		2003;	0.32;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1998;	Red Cell ALE  Treatment System;	Preclinical;	Red Cell ALE Treatment System.;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1999;	Platelet   Photochemical Treatment  System;	Phaes III;	Platelet Pathogen Inactivation System.;	27;	;	;		2006;	0.75;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1999;	Platelet   Photochemical Treatment  System;	Phaes III;	Platelet Pathogen Inactivation System.;	22;	27;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1999;	FFP  Photochemical Treatment System;	Phase I/III;	FFP Pathogen Inactivation System;	27;	;	;		2006;	4.25;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1999;	FFP  Photochemical Treatment System;	Phase I/III;	FFP Pathogen Inactivation System;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1999;	Red Cell ALE  Treatment System;	Phase I;	Red Cell ALE Treatment System.;	27;	;	;		2003;	0.32;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1999;	Red Cell ALE  Treatment System;	Phase I;	Red Cell ALE Treatment System.;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	1999;	Plasma for  Fractionation;	Preclinical;	FFP Pathogen Inactivation System;	27;	20;	;		2002;	0;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2000;	INTERCEPT Platelet System;	Phaes III;	Platelet Pathogen Inactivation System.;	27;	;	;		2006;	0.75;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2000;	INTERCEPT Platelet System;	Phaes III;	Platelet Pathogen Inactivation System.;	22;	27;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2000;	INTERCEPT Plasma System;	Phase I/III;	FFP Pathogen Inactivation System;	27;	;	;		2006;	4.25;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2000;	INTERCEPT Plasma System;	Phase I/III;	FFP Pathogen Inactivation System;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2000;	INTERCEPT Red Blood Cell System;	Phase I;	Red Cell ALE Treatment System.;	27;	;	;		2003;	0.32;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2000;	INTERCEPT Red Blood Cell System;	Phase I;	Red Cell ALE Treatment System.;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2000;	Allogeneic Cellular Immunotherapies  (ACIT);	Phase I;	Donor Leukocyte Treatment System.;	22;	27;	20;		2004;	-0.0833;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2000;	Plasma for  Fractionation;	Preclinical;	FFP Pathogen Inactivation System;	27;	;	;		2002;	-0.5833;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2001;	INTERCEPT Platelet System;	Phaes III;	Helinx technology;	27;	;	;		2006;	0.75;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2001;	INTERCEPT Platelet System;	Phaes III;	Helinx technology;	22;	27;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2001;	INTERCEPT Plasma System;	Phase III;	Helinx technology;	27;	;	;		2006;	4.25;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2001;	INTERCEPT Plasma System;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2001;	INTERCEPT Red Blood Cell System;	Phase II;	Helinx technology;	27;	;	;		2003;	7.25;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2001;	INTERCEPT Red Blood Cell System;	Phase II;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2001;	Allogeneic Cellular Immunotherapies  (ACIT);	Phase I;	Helinx technology;	27;	20;	;		2004;	-0.0833;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2002;	INTERCEPT Platelet System;	Phase III;	Helinx technology;	27;	;	;		2006;	0.75;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2002;	INTERCEPT Platelet System;	Phase III;	Helinx technology;	22;	27;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2002;	INTERCEPT Plasma System;	Phase III;	Helinx technology;	27;	;	;		2006;	4.25;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2002;	INTERCEPT Plasma System;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2002;	Red Cell ALE  Treatment System;	Phase III;	Helinx technology;	27;	;	;		2006;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2002;	Red Cell ALE  Treatment System;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2002;	Allogeneic Cellular Immunotherapies  (ACIT);	Phase I;	Helinx technology;	27;	20;	;		2004;	10;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2002;	Epstein-Barr Virus (EBV) Vaccine;	Phase I;	Helinx technology;	25;	;	;		2004;	2;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2003;	INTERCEPT Platelet System;	Phase III;	Helinx technology;	27;	;	;		2006;	0.75;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2003;	INTERCEPT Platelet System;	Phase III;	Helinx technology;	22;	27;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2003;	INTERCEPT Plasma System;	Phase III;	Helinx technology;	27;	;	;		2006;	4.25;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2003;	INTERCEPT Plasma System;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2003;	Red Cell ALE  Treatment System;	Phase III;	Helinx technology;	27;	;	;		2006;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2003;	Red Cell ALE  Treatment System;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2003;	Broad platform using attenuatedListeria strains to stimulate immune response;	Research;	 bacterium Listeria monocytogenes;	22;	27;	;		2006;	-0.75;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2004;	INTERCEPT Platelet System;	Phase III;	Helinx technology;	27;	;	;		2006;	1.625;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2004;	INTERCEPT Platelet System;	Phase III;	Helinx technology;	22;	27;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2004;	INTERCEPT Plasma System;	Phase III;	Helinx technology;	27;	;	;		2006;	1.625;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2004;	INTERCEPT Plasma System;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2004;	Red Cell ALE  Treatment System;	Phase III;	Helinx technology;	27;	;	;		2006;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2004;	Red Cell ALE  Treatment System;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2004;	Broad platform using attenuatedListeria strains to stimulate immune response;	Preclinical;	 bacterium Listeria monocytogenes;	22;	23;	;		2006;	-0.75;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2005;	CRS-100;	Preclinical;	 bacterium Listeria monocytogenes;	22;	28;	;		2009;	-0.75;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2005;	CRS-207;	Preclinical;	 bacterium Listeria monocytogenes;	22;	;	;		2009;	-0.125;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2005;	MEDI-543 (EphA2);	Preclinical;	 bacterium Listeria monocytogenes;	22;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2005;	MEDI-543 (EphA2);	Preclinical;	 bacterium Listeria monocytogenes;	22;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2005;	MEDI-543 (EphA2);	Preclinical;	 bacterium Listeria monocytogenes;	22;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2005;	Anthrax Vaccine;	Preclinical;	KBMA Platform;	23;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2005;	Tularemia Vaccine;	Preclinical;	KBMA Platform;	23;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2005;	INTERCEPT Blood System for platelets;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2005;	INTERCEPT Blood System for plasma;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2005;	INTERCEPT Blood System for red blood cells;	Phase I;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	CRS-100;	Phase I;	 bacterium Listeria monocytogenes;	22;	28;	;		2009;	-0.75;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	CRS-207;	Preclinical;	 bacterium Listeria monocytogenes;	22;	;	;		2009;	-0.125;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	MEDI-543 (EphA2);	Preclinical;	 bacterium Listeria monocytogenes;	22;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	MEDI-543 (EphA2);	Preclinical;	 bacterium Listeria monocytogenes;	22;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	MEDI-543 (EphA2);	Preclinical;	 bacterium Listeria monocytogenes;	22;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	Anthrax Vaccine;	Preclinical;	KBMA Platform;	23;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	Tularemia Vaccine;	Preclinical;	KBMA Platform;	23;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	INTERCEPT Blood System for platelets;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	INTERCEPT Blood System for plasma;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	INTERCEPT Blood System for red blood cells;	Phase I;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	HIV Vaccine;	Pre clinical;	KBMA Platform;	23;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2006;	Hepatitis C Vaccine;	Pre clinical;	KBMA Platform;	23;	;	;		2008;	3;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2007;	INTERCEPT Blood System for platelets;	Marketed;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2007;	INTERCEPT Blood System for plasma;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2007;	INTERCEPT Blood System for red blood cells;	Phase I;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2007;	CRS-100;	Phase I;	 bacterium Listeria monocytogenes;	22;	;	;		2009;	-0.6154;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2007;	CRS-207;	Preclinical;	 bacterium Listeria monocytogenes;	22;	;	;		2009;	-0.4615;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2007;	MEDI-543 (EphA2);	Preclinical;	 bacterium Listeria monocytogenes;	22;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2007;	Anthrax Vaccine;	Preclinical;	KBMA Platform;	23;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2007;	Tularemia Vaccine;	Preclinical;	KBMA Platform;	23;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2007;	HIV Vaccine;	Preclinical;	KBMA Platform;	23;	;	;		2009;	-1;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2008;	INTERCEPT Blood System for platelets;	Marketed;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2008;	INTERCEPT Blood System for plasma;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2008;	INTERCEPT Blood System for red blood cells;	Phase I;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2009;	INTERCEPT Blood System for platelets;	Marketed;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2009;	INTERCEPT Blood System for plasma;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2009;	INTERCEPT Blood System for red blood cells;	Phase I;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2010;	INTERCEPT Blood System for platelets;	Marketed;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2010;	INTERCEPT Blood System for plasma;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2010;	INTERCEPT Blood System for red blood cells;	Phase I;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2011;	INTERCEPT Blood System for platelets;	Marketed;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2011;	INTERCEPT Blood System for plasma;	Phase III;	Helinx technology;	27;	;	;		;	;		
wvcs19970001020214;	CERUS CORP;	10-K;	1996;	2011;	INTERCEPT Blood System for red blood cells;	Phase I;	Helinx technology;	27;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	S-1;	2004;	2004;	CORLUX;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	S-1;	2004;	2004;	CORLUX;	 IND;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	424;	2004;	2004;	CORLUX;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	424;	2004;	2004;	CORLUX;	Clinical Trial;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2005;	CORLUX;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2005;	CORLUX;	Clinical Trial;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2006;	CORLUX;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2006;	CORLUX;	Clinical Trial;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2006;	CORLUX;	Pre Clinical;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2007;	CORLUX;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2007;	CORLUX;	Clinical Trial;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2007;	CORLUX;	Pre Clinical;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2008;	CORLUX;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2008;	CORLUX;	Pre Clinical;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2008;	CORLUX;	Pre Clinical;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2009;	CORLUX;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2009;	CORLUX;	Pre clinical;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2009;	CORLUX;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2010;	CORLUX;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2010;	CORLUX;	Pre clinical;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2010;	CORLUX;	IND;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2011;	CORLUX;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2011;	CORLUX;	Pre clinical;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2011;	CORLUX;	IND;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2011;	CORT 108297 ;	Phase I;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs20040001088856;	CORCEPT THERAPEUTICS INC;	10-K;	2004;	2011;	CORT 113083;	 preclinical studies ;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	VACCINES;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2003;	3.5;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	VACCINES;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	VACCINES;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	27;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	VACCINES;	Pre Clinincal;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	ADJUVANTS;	Pre Clinincal;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2000;	0.3333;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	DIAGNOSTICS;	Development;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2001;	6.25;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	DIAGNOSTICS;	Development;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	DIAGNOSTICS;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	DIAGNOSTICS;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	 Adoptive Immunotherapy;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	S-1;	1997;	1997;	 Companion Animal Health;	Development;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	VACCINES;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2003;	3.5;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	VACCINES;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	VACCINES;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	27;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	VACCINES;	Pre Clinincal;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	ADJUVANTS;	Pre Clinincal;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2000;	0.3333;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	DIAGNOSTICS;	Development;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2001;	6.25;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	DIAGNOSTICS;	Development;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	DIAGNOSTICS;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	DIAGNOSTICS;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	 Adoptive Immunotherapy;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	424;	1997;	1997;	 Companion Animal Health;	Development;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	VACCINES;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2003;	3.5;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	VACCINES;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	VACCINES;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	27;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	VACCINES;	Pre Clinincal;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	ADJUVANTS;	Pre Clinincal;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2000;	6;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	DIAGNOSTICS;	Development;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2001;	6.25;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	DIAGNOSTICS;	Development;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	DIAGNOSTICS;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	DIAGNOSTICS;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	DIAGNOSTICS;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	 Adoptive Immunotherapy;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1998;	 Companion Animal Health;	Development;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	AnergiX.RA(TM) complex;	Phase II;	AnergiX.RA(TM) complex;	5;	20;	;		2003;	3.5;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	Breast cancer vaccine;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2001;	0.25;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	 Chlamydia Pneumoniae vaccine;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	Colon cancer vaccine;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2003;	0;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	 Her2/neu vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	 Mammaglobin vaccine;	research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	Ovarian cancer vaccine;	research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2001;	1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	Tuberculosis Vaccines   ;	Pre Clinincal;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2005;	-0.1667;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	 Diagnostic for canine leishmaniasis ;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	Diagnostic for Chagas' Disease;	 development ;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		2003;	-0.1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	Diagnostic for  tuberculosis   ;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		2003;	-0.1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	Reference diagnostic tick-borne diseases;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2001;	0.0667;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	 Companion Animal Health;	Development;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	 AnergiX.MG(TM) complex, for myasthenia gravis;	Preclinical;	AnergiX.MG(TM) complex;	5;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	AnergiX.MS(TM) complex, for multiple sclerosis;	Phase I;	AnergiX.MG(TM) complex;	5;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	AnervaX.DB(TM) peptide vaccine, for diabetes;	Preclinical;	AnervaX.DB(TM);	5;	24;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	 Herpes Virus vaccine;	 research  ;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	 Leukemia/lymphoma vaccine;	 research  ;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	27;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	Lung cancer vaccine;	research ;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2001;	0.25;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	Muc-1 peptide vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2002;	-1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	 Adoptive Immunotherapy;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	1999;	PVAC(TM) compound;	Phase II;	PVAC(TM);	5;	;	;		2004;	-1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	AnergiX.RA(TM) complex;	Phase II;	AnergiX.RA(TM) complex;	5;	20;	;		2003;	3.5;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	AnergiX.MS(TM) complex, for multiple sclerosis;	Phase II;	AnergiX.MG(TM) complex;	5;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	BEXXAR(TM) therapy    ;	BLA review ;	monoclonal antibody;	22;	;	;		2005;	0.1801;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	PVAC(TM) compound;	Phase II;	PVAC(TM);	5;	;	;		2004;	-1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	Melacine(R) vaccine;	Phase III;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2004;	-0.5581;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	 Detox(TM) adjuvant;	Phase III;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	 Her2/neu vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	Muc-1 peptide vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2002;	-1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	Diagnostic for  tuberculosis   ;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		2003;	-0.1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	 Novel cancer vaccines;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	 Novel cancer vaccines;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	Novel infectious disease Vaccinesq;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		2003;	0;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	 Diagnostic for leishmaniasis ;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	Diagnostic for Chagas' Disease;	 development ;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		2003;	-0.1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	 Novel infectious disease vaccine;	Pre Clinincal;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	 Novel infectious disease vaccine;	 research  ;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	 Companion Animal Health;	Commercialized;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	 Adoptive Immunotherapy;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2000;	RC-552;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	21;	;	;		2003;	-0.9231;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	AnergiX.RA(TM) complex;	Phase II;	AnergiX.RA(TM) complex;	5;	20;	;		2003;	0.3846;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	AnergiX.MS(TM) complex, for multiple sclerosis;	Phase II;	AnergiX.MG(TM) complex;	5;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	BEXXAR(TM) therapy    ;	BLA review ;	monoclonal antibody;	22;	;	;		2005;	0.1801;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	PVAC(TM) compound;	Phase II;	PVAC(TM);	5;	;	;		2004;	-1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	Melacine(R) vaccine;	Phase III;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2004;	-0.5581;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	ENHANZYN(TM) adjuvant ;	Phase III;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2004;	-0.1429;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	 Her2/neu vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	 Novel cancer vaccines;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	 Novel cancer vaccines;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	WT-1 vaccine      ;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	27;	;		2003;	-0.8333;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	Mammaglobin vaccine ;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2003;	-0.3333;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	CPI-0004         ;	Preclinical;	TAP pro-drug  ;	22;	;	;		2003;	-0.1667;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	Diagnostic for  tuberculosis   ;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		2003;	3.5;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	Novel infectious disease Vaccinesq;	Research;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		2003;	-0.3333;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	 Diagnostic for leishmaniasis ;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	Diagnostic for Chagas' Disease;	Marketed;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		2003;	3.5;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	 Novel infectious disease vaccine;	Pre Clinincal;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	 Novel infectious disease vaccine;	 research  ;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	29;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	Novel infectious disease Vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2005;	-0.1667;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	 Companion Animal Health;	Commercialized;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	 Adoptive Immunotherapy;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2001;	RC-552;	Preclinical;	microsphere delivery systems that specifically activate appropriate T cell responses;	21;	;	;		2003;	-0.8333;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2002;	BEXXAR(TM) therapy    ;	BLA review ;	monoclonal antibody;	22;	;	;		2005;	0.1801;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2002;	PVAC(TM) compound;	Phase II;	PVAC(TM);	5;	;	;		2004;	-1;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2002;	Melacine(R) vaccine;	Phase III;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2004;	-0.882;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2002;	ENHANZYN(TM) adjuvant ;	Phase III;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		2004;	-0.9255;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2002;	 Her2/neu vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2002;	 Novel infectious disease vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2002;	Novel infectious disease Vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2005;	-0.1667;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2002;	PVAC treatment;	Phase I;	PVAC(TM);	5;	20;	2;		2004;	5;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2003;	BEXXAR(TM) therapy    ;	Marketed;	monoclonal antibody;	22;	;	;		2005;	30.6667;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2003;	 Her2/neu vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	22;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2003;	Tuberculosis vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2005;	-0.3333;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2003;	Leishmaniasis vaccine;	Phase I;	microsphere delivery systems that specifically activate appropriate T cell responses;	23;	;	;		2005;	-0.1667;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2003;	CRX-675 TLR4 agonist;	Phase I;	TLR4 Agonists and Antagonists;	5;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2004;	CRX-675 TLR4 agonist;	Phase I;	TLR4 Agonists and Antagonists;	5;	;	;		;	;		
wvcs19970001042561;	CORIXA CORP;	10-K;	1997;	2004;	CRX-527 TLR4 agonist;	U.S. IND;	TLR4 Agonists and Antagonists;	5;	23;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	S-1;	2004;	2004;	Zyflo®: The Immediate-Release Formulation of Zileuton;	 NDA;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		2010;	-1;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	S-1;	2004;	2004;	Zyflo®: The Immediate-Release Formulation of Zileuton;	Phase I;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	S-1;	2004;	2004;	Controlled-Release Formulation of Zileuton;	 NDA;	controlled-release formulation of zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	S-1;	2004;	2004;	Intravenous Formulation of Zileuton;	Research;	Intravenous formulation of Zileuton;	5;	25;	29;		2010;	1.75;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	S-1;	2004;	2004;	 CTI-01 program;	Phase I;	inflammatory signaling pathways;	25;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	S-1;	2004;	2004;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	25;	;	;		2010;	-0.6364;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	S-1;	2004;	2004;	cholinergic anti-inflammatory program;	Research;	inflammatory signaling pathways;	25;	20;	;		2007;	0.4;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	424;	2004;	2004;	Zyflo®: The Immediate-Release Formulation of Zileuton;	 NDA;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		2010;	-1;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	424;	2004;	2004;	Zyflo®: The Immediate-Release Formulation of Zileuton;	Phase I;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	424;	2004;	2004;	Controlled-Release Formulation of Zileuton;	 NDA;	controlled-release formulation of zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	424;	2004;	2004;	Intravenous Formulation of Zileuton;	Research;	Intravenous formulation of Zileuton;	5;	25;	29;		2010;	1.75;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	424;	2004;	2004;	 CTI-01 program;	Phase I;	inflammatory signaling pathways;	25;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	424;	2004;	2004;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	25;	;	;		2010;	-0.6364;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	424;	2004;	2004;	cholinergic anti-inflammatory program;	Research;	inflammatory signaling pathways;	25;	20;	;		2007;	0.4;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	ZYFLO: The Tablet Formulation of Zileuton;	Marketed;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		2010;	-1;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	ZYFLO: The Tablet Formulation of Zileuton;	Phase II;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	ZYFLO: The Tablet Formulation of Zileuton;	Phase II;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	Controlled-Release Formulation of Zileuton;	 NDA;	controlled-release formulation of zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	Intravenous Formulation of Zileuton;	Preclinical;	Intravenous formulation of Zileuton;	5;	25;	29;		2010;	1.75;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	 CTI-01 program;	Phase II;	inflammatory signaling pathways;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	 CTI-01 program;	Preclinical;	inflammatory signaling pathways;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	5;	;	;		2010;	-0.6364;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	5;	20;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2005;	cholinergic anti-inflammatory program;	Preclinical;	inflammatory signaling pathways;	5;	9;	20;		2007;	-0.3636;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2006;	ZYFLO: The Tablet Formulation of Zileuton;	Marketed;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		2010;	-1;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2006;	ZYFLO: The Tablet Formulation of Zileuton;	Phase II;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2006;	ZYFLO: The Tablet Formulation of Zileuton;	Phase II;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2006;	Controlled-Release Formulation of Zileuton;	 NDA;	controlled-release formulation of zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2006;	Intravenous Formulation of Zileuton;	Phase II;	Intravenous formulation of Zileuton;	5;	25;	29;		2010;	1.75;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2006;	 CTI-01 program;	Phase II;	inflammatory signaling pathways;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2006;	 CTI-01 program;	Phase I;	inflammatory signaling pathways;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2006;	Alpha-7 Receptor Program;	Preclinical;	inflammatory signaling pathways;	5;	9;	20;		2010;	-0.5556;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2006;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	5;	20;	;		2010;	-0.6364;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2006;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2007;	ZYFLO: The Tablet Formulation of Zileuton;	Marketed;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		2010;	-1;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2007;	Controlled-Release Formulation of Zileuton;	 NDA;	controlled-release formulation of zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2007;	Intravenous Formulation of Zileuton;	Phase II;	Intravenous formulation of Zileuton;	5;	25;	29;		2010;	1.75;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2007;	Life-Cycle Extension;	Preclinical;	5-lipoxygenase inhibitory profiles;	5;	29;	;		2010;	0.3333;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2007;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	5;	20;	;		2010;	-0.6364;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2007;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2007;	Alpha-7 Receptor Program;	Preclinical;	inflammatory signaling pathways;	5;	9;	20;		2010;	-0.5556;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2008;	ZYFLO: The Tablet Formulation of Zileuton;	Marketed;	Immediate-Release Formulation of Zileuton;	5;	25;	29;		2010;	-1;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2008;	ZYFLO CR: The Extended-Release Formulation of Zileuton;	Marketed;	controlled-release formulation of zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2008;	Injectable Formulation of Zileuton;	Phase II;	Intravenous formulation of Zileuton;	5;	25;	29;		2010;	-0.8608;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2008;	R(+) Isomer of Zileuton;	Phase I;	5-lipoxygenase inhibitory profiles;	5;	29;	;		2010;	-0.9494;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2008;	Alpha-7 Receptor Program;	Preclinical;	inflammatory signaling pathways;	5;	9;	20;		2010;	-0.9494;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2008;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	5;	20;	;		2010;	-0.9494;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2008;	HMGB1 program;	Preclinical;	inflammatory signaling pathways;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2009;	ZYFLO CR: The Extended-Release Formulation of Zileuton;	Marketed;	controlled-release formulation of zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2009;	SPECTRACEF;	Marketed;	cefditoren pivoxil,;	9;	23;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2009;	SPECTRACEF;	Marketed;	cefditoren pivoxil,;	23;	29;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2009;	ALLERX;	Marketed;	antihistamine chlorpheniramine;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2009;	SPECTRACEF;	NDA;	cefditoren pivoxil,;	9;	23;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2009;	SPECTRACEF Suspension;	NDA;	cefditoren pivoxil,;	23;	;	;		2011;	-0.1714;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2009;	CRTX 058;	NDA;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2009;	CRTX 067;	NDA;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	23;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2009;	CRTX 069;	NDA;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	23;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	ZYFLO CR: The Extended-Release Formulation of Zileuton;	Marketed;	controlled-release formulation of zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	SPECTRACEF;	Marketed;	cefditoren pivoxil,;	9;	23;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	SPECTRACEF;	Marketed;	cefditoren pivoxil,;	23;	29;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	ALLERX;	Marketed;	antihistamine chlorpheniramine;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	CUROSURF;	Marketed;	 porcine-derived natural lung surfactant;	29;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	 FACTIVE;	Marketed;	gemifloxacin mesylate;	23;	29;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	HYOMAX;	Marketed;	 hyoscyamine sulfate;	26;	3;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	CRTX 067;	Preclinical;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	23;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	CRTX 069;	Preclinical;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	23;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	CRTX 058;	Preclinical;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	CRTX 070;	Preclinical;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2010;	CRTX 073;	Preclinical;	;	5;	29;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	ZYFLO CR: The Extended-Release Formulation of Zileuton;	Marketed;	controlled-release formulation of zileuton;	5;	25;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	SPECTRACEF;	Marketed;	cefditoren pivoxil,;	9;	23;	29;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	SPECTRACEF;	Marketed;	cefditoren pivoxil,;	23;	29;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	ALLERX;	Marketed;	antihistamine chlorpheniramine;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	CUROSURF;	Marketed;	 porcine-derived natural lung surfactant;	29;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	 FACTIVE;	Marketed;	gemifloxacin mesylate;	23;	29;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	HYOMAX;	Marketed;	 hyoscyamine sulfate;	26;	3;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	CRTX 067;	Under FDA Review;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	23;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	CRTX 069;	Preclinical;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	23;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	CRTX 058;	Preclinical;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	CRTX 070;	Preclinical;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	5;	;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	CRTX 073;	Preclinical;	controlled-release formulation of zileuton;	5;	29;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	CRTX 809;	Preclinical;	controlled-release formulation of zileuton;	5;	29;	;		;	;		
wvcs20040001145404;	CORNERSTONE THERAPEUTICS INC;	10-K;	2004;	2011;	CRTX 072;	Preclinical;	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ;	23;	;	;		;	;		
wvcs20040001138812;	COTHERIX INC;	S-1;	2004;	2004;	Ventavis;	 NDA ;	 inhaled prostacyclin analogue;	21;	29;	;		;	;		
wvcs20040001138812;	COTHERIX INC;	S-1;	2004;	2004;	Ventavis;	Phase II ;	 inhaled prostacyclin analogue;	21;	29;	;		;	;		
wvcs20040001138812;	COTHERIX INC;	S-1;	2004;	2004;	CTX-100;	Phase I;	 proprietary hyaluronic acid solution ;	21;	29;	;		2006;	0.2;		
wvcs20040001138812;	COTHERIX INC;	S-1;	2004;	2004;	CTX-100;	Phase I;	 proprietary hyaluronic acid solution ;	21;	29;	30;		;	;		
wvcs20040001138812;	COTHERIX INC;	424;	2004;	2004;	Ventavis;	 NDA ;	 inhaled prostacyclin analogue;	21;	29;	;		;	;		
wvcs20040001138812;	COTHERIX INC;	424;	2004;	2004;	Ventavis;	Phase II ;	 inhaled prostacyclin analogue;	21;	29;	;		;	;		
wvcs20040001138812;	COTHERIX INC;	424;	2004;	2004;	CTX-100;	Phase I;	 proprietary hyaluronic acid solution ;	21;	29;	;		2006;	-0.9745;		
wvcs20040001138812;	COTHERIX INC;	424;	2004;	2004;	CTX-100;	Phase I;	 proprietary hyaluronic acid solution ;	21;	29;	30;		;	;		
wvcs20040001138812;	COTHERIX INC;	10-K;	2004;	2004;	Ventavis;	Markted;	 inhaled prostacyclin analogue;	21;	29;	;		;	;		
wvcs20040001138812;	COTHERIX INC;	10-K;	2004;	2004;	Ventavis;	Phase II ;	 inhaled prostacyclin analogue;	21;	29;	;		;	;		
wvcs20040001138812;	COTHERIX INC;	10-K;	2004;	2005;	Ventavis;	Markted;	 inhaled prostacyclin analogue;	21;	29;	;		;	;		
wvcs20040001138812;	COTHERIX INC;	10-K;	2004;	2005;	Ventavis;	Phase II ;	 inhaled prostacyclin analogue;	21;	29;	;		;	;		
wvcs20040001138812;	COTHERIX INC;	10-K;	2004;	2006;	Ventavis;	Markted;	 inhaled prostacyclin analogue;	21;	29;	;		;	;		
wvcs20040001138812;	COTHERIX INC;	10-K;	2004;	2006;	Ventavis;	Phase II ;	 inhaled prostacyclin analogue;	21;	29;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	S-1;	1996;	1996;	B-1 Therapy;	Phase I/II;	conjugated antibodies ;	22;	27;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	S-1;	1996;	1996;	Super-Leu-Dox;	Preclinical;	tumor-activated peptide pro-drugs.;	22;	;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	424;	1996;	1997;	B-1 Therapy;	Phase I/II;	conjugated antibodies ;	22;	27;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	424;	1996;	1997;	Super-Leu-Dox;	Preclinical;	tumor-activated peptide pro-drugs.;	22;	;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	424;	1996;	1997;	B-1 Therapy;	Phase I/II;	conjugated antibodies ;	22;	27;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	424;	1996;	1997;	Super-Leu-Dox;	Preclinical;	tumor-activated peptide pro-drugs.;	22;	;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	10-K;	1996;	1998;	BEXXAR;	Phase III;	conjugated antibodies ;	22;	27;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	10-K;	1996;	1998;	Super-Leu-Dox;	Preclinical;	tumor-activated peptide pro-drugs.;	22;	;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	10-K;	1996;	1999;	BEXXAR;	Phase III;	conjugated antibodies ;	22;	27;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	10-K;	1996;	1999;	Super-Leu-Dox;	IND;	tumor-activated peptide pro-drugs.;	22;	;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	10-K;	1996;	1999;	BEXXAR;	Phase III;	conjugated antibodies ;	22;	27;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	10-K;	1996;	1999;	Super-Leu-Dox;	IND;	tumor-activated peptide pro-drugs.;	22;	;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	10-K;	1996;	1999;	Bexxar;	Phase I;	conjugated antibodies ;	22;	27;	;		;	;		
wvcs19970000942416;	COULTER PHARMACEUTICALS INC;	10-K;	1996;	1999;	64G12;	Preclinical;	64G12 antibody;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2003;	2003;	Chronic lymphocytic leukemia, or CLL;	Phase I/II ;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2003;	2003;	Multiple myeloma.;	Phase I/II;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2003;	2003;	Non-Hodgkin’s lymphoma.;	clinical trial;	Xcellerate Technology;	5;	27;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2003;	2003;	Kidney cancer;	Phase I;	Xcellerate Technology;	5;	22;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2003;	2003;	Prostate cancer;	 Phase I/II ;	Xcellerate Technology;	5;	22;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2003;	2003;	HIV.;	Preclinical;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	424;	2003;	2004;	Chronic lymphocytic leukemia, or CLL;	Phase I/II ;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	424;	2003;	2004;	Multiple myeloma.;	Phase I/II;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	424;	2003;	2004;	Non-Hodgkin’s lymphoma.;	clinical trial;	Xcellerate Technology;	5;	27;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	424;	2003;	2004;	Kidney cancer;	Phase I;	Xcellerate Technology;	5;	22;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	424;	2003;	2004;	Prostate cancer;	 Phase I/II ;	Xcellerate Technology;	5;	22;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	424;	2003;	2004;	HIV.;	Preclinical;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2005;	Chronic lymphocytic leukemia, or CLL;	Phase I/II ;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2005;	Multiple myeloma.;	Phase I/II;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2005;	Non-Hodgkin’s lymphoma.;	Phase I;	Xcellerate Technology;	5;	27;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2005;	HIV.;	Phase I;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2005;	Kidney cancer;	Phase II;	Xcellerate Technology;	5;	22;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2005;	Prostate cancer;	 Phase I/II ;	Xcellerate Technology;	5;	22;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2006;	Chronic lymphocytic leukemia, or CLL;	Phase I/II ;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2006;	Multiple myeloma.;	Phase I/II;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2006;	Non-Hodgkin’s lymphoma.;	Phase I;	Xcellerate Technology;	5;	27;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2006;	HIV.;	Phase I;	Xcellerate Technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2006;	Kidney cancer;	Phase II;	Xcellerate Technology;	5;	22;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2006;	Prostate cancer;	 Phase I/II ;	Xcellerate Technology;	5;	22;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2007;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2007;	Seliciclib, (CYC202);	Phase I ;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2007;	Sapacitabine, (CYC682);	Phase I;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2007;	CYC116;	IND;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2007;	CDK Inhibitors, Second Generation;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2007;	Clotrimazole Analogs;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2007;	Plk Inhibitors;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2007;	GSK-3 Inhibitors;	Preclinical;	genomic technology;	24;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2007;	Cell Cycle Inhibitors;	Preclinical;	genomic technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2007;	Cell Cycle Inhibitors;	Preclinical;	genomic technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	Sapacitabine, (CYC682);	Phase I ;	genomic technology;	22;	27;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	CYC116;	Phase I;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	CDK Inhibitors, Second Generation;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	Clotrimazole Analogs;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	Plk Inhibitors;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	GSK-3 Inhibitors;	Preclinical;	genomic technology;	24;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	Cell Cycle Inhibitors;	Preclinical;	genomic technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2008;	Cell Cycle Inhibitors;	Phase I;	genomic technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2009;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2009;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2009;	Sapacitabine, (CYC682);	Phase I ;	genomic technology;	22;	27;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2009;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2009;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2009;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2009;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2009;	CYC116;	Phase I;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2009;	CDK Inhibitors, Second Generation;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2009;	Cell Cycle Inhibitors;	Phase I;	genomic technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2010;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2010;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2010;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2010;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2010;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2010;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2010;	CYC116;	Phase I;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2010;	CDK Inhibitors, Second Generation;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2010;	Cell Cycle Inhibitors;	Phase I;	genomic technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2011;	Sapacitabine, (CYC682);	Phase III;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2011;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2011;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2011;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2011;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2011;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2011;	CYC116;	Phase I;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2011;	CDK Inhibitors, Second Generation;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2011;	Cell Cycle Inhibitors;	Phase I;	genomic technology;	5;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2012;	Sapacitabine, (CYC682);	Phase III;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2012;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2012;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2012;	Sapacitabine, (CYC682);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2012;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2012;	Seliciclib, (CYC202);	Phase II;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2012;	Seliciclib, CYC065;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001130166;	Cyclacel Pharmaceuticals, Inc.;	10-K;	2003;	2012;	Plk1 Inhibitors;	Preclinical;	genomic technology;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	S-1;	2004;	2004;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		2010;	-0.5622;		
wvcs20040001061983;	CYTOKINETICS INC;	S-1;	2004;	2004;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	S-1;	2004;	2004;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	S-1;	2004;	2004;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	S-1;	2004;	2004;	cardiac myosin activator;	Phase I;	cardiac myosin activators;	9;	21;	;		2008;	0;		
wvcs20040001061983;	CYTOKINETICS INC;	424;	2004;	2004;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		2010;	-0.5622;		
wvcs20040001061983;	CYTOKINETICS INC;	424;	2004;	2004;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	424;	2004;	2004;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	424;	2004;	2004;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	424;	2004;	2004;	cardiac myosin activator;	Phase I;	cardiac myosin activators;	9;	21;	;		2008;	0;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		2010;	-0.5622;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	cardiac myosin activator;	Phase I;	cardiac myosin activators;	9;	21;	;		2008;	0;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	2;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase II;	Cytometrix technologies PUMA system;	22;	28;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	SB-715992;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2005;	 SB-743921 ;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		2010;	-0.5622;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	2;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	28;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	Ispinesib;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	 SB-743921 ;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	 SB-743921 ;	Phase I;	Cytometrix technologies PUMA system;	22;	27;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2006;	CK-1213296;	Phase II;	cardiac myosin activators;	9;	21;	;		2008;	-1;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		2010;	-0.5622;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	2;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase II;	Cytometrix technologies PUMA system;	22;	28;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	Ispinesib;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	 SB-743921 ;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	 SB-743921 ;	Phase I;	Cytometrix technologies PUMA system;	22;	27;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	 CK-1827452;	Phase II;	cardiac myosin activators;	9;	21;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2007;	GSK-923295;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		2010;	-0.2574;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2008;	Ispinesib;	Phase I;	Cytometrix technologies PUMA system;	22;	27;	;		2010;	-0.0594;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2008;	Ispinesib;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2008;	Ispinesib;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2008;	 SB-743921 ;	Phase I;	Cytometrix technologies PUMA system;	22;	27;	;		2010;	-0.3267;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2008;	GSK-923295;	Phase I;	Cytometrix technologies PUMA system;	22;	;	;		2010;	-0.2574;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2008;	 CK-1827452;	Phase II;	cardiac myosin activators;	;	;	;		2010;	0.495;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2008;	 CK-1827452;	Phase II;	;	;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2009;	;	;	;	;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2010;	;	;	;	;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2011;	;	;	;	;	;	;		;	;		
wvcs20040001061983;	CYTOKINETICS INC;	10-K;	2004;	2012;	;	;	;	;	;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	S-1;	1996;	1996;	MS-325;	Phase I;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	S-1;	1996;	1996;	MS-325;	Phase I;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	S-1;	1996;	1996;	MS-325;	Phase I;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	S-1;	1996;	1996;	MS-325;	Phase I;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	S-1;	1996;	1996;	MS-325;	Phase I;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	S-1;	1996;	1996;	MS-325;	Phase I;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	1998;	MS-325;	Phase II;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	1998;	MS-325;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	1998;	MS-325;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	1998;	MS-325;	Phase II;	proprietary biophysics technology platform.;	22;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	1999;	AngioMARK;	Phase II;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	1999;	AngioMARK;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	1999;	AngioMARK;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	1999;	AngioMARK;	Phase II;	proprietary biophysics technology platform.;	22;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2000;	MS-325;	Phase II;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2000;	MS-325;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2000;	MS-325;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2000;	MS-325;	Phase II;	proprietary biophysics technology platform.;	22;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2001;	MS-325;	Phase II;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2001;	MS-325;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2001;	MS-325;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2001;	MS-325;	Phase II;	proprietary biophysics technology platform.;	22;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2001;	MS-325;	Pre Clinical;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2001;	MS-325;	Phase II ;	proprietary biophysics technology platform.;	23;	60;	70;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2002;	MS-325;	Phase II;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2002;	MS-325;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2002;	MS-325;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2002;	MS-325;	Phase II;	proprietary biophysics technology platform.;	22;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2002;	MS-325;	Pre Clinical;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2002;	MS-325;	Phase II ;	proprietary biophysics technology platform.;	23;	60;	70;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2003;	MS-325;	Phase II;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2003;	MS-325;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2003;	MS-325;	Phase III;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2003;	MS-325;	Phase II;	proprietary biophysics technology platform.;	22;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2003;	MS-325;	Pre Clinical;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2003;	MS-325;	Phase II ;	proprietary biophysics technology platform.;	23;	60;	70;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2004;	MS-325;	Phase II;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2004;	MS-325;	NDA;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2004;	MS-325;	Phase II;	proprietary biophysics technology platform.;	22;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2004;	MS-325;	Phase II ;	proprietary biophysics technology platform.;	23;	60;	70;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2004;	MS-325;	Phase II ;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX MEDICAL INC;	10-K;	1996;	2004;	EP-2104R;	Pre Clinical;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2005;	MS-325;	Phase II;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2005;	MS-325;	MARKETED;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2005;	MS-325;	Phase II;	proprietary biophysics technology platform.;	22;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2005;	MS-325;	Phase II ;	proprietary biophysics technology platform.;	23;	60;	70;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2005;	MS-325;	Phase II ;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2005;	EP-2104R;	Phase I;	proprietary biophysics technology platform.;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2006;	AngioMARK;	Phase III;	 Target Visualization Technologytm;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2006;	AngioMARK;	MARKETED;	 Target Visualization Technologytm;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2006;	AngioMARK;	Phase II;	 Target Visualization Technologytm;	22;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2006;	AngioMARK;	Phase II ;	 Target Visualization Technologytm;	23;	60;	70;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2006;	AngioMARK;	Phase II ;	 Target Visualization Technologytm;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2006;	EP-2104R;	Phase I;	 Target Visualization Technologytm;	21;	60;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2007;	Downsized No product line;	;	;	;	;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2008;	Downsized No product line;	;	;	;	;	;		;	;		
wvcs19970001027702;	EPIX Pharmaceuticals, Inc.;	10-K;	1996;	2009;	Downsized No product line;	;	;	;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	S-1;	2003;	2003;	Macugen;	 Phase 2/3;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	S-1;	2003;	2003;	Macugen;	Phase 2 ;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	S-1;	2003;	2003;	Macugen;	Phase 2;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	424;	2003;	2004;	Macugen;	 Phase 2/3;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	424;	2003;	2004;	Macugen;	Phase 2 ;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	424;	2003;	2004;	Macugen;	Phase 2;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	10-K;	2003;	2004;	Macugen;	 Phase 2/3;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	10-K;	2003;	2004;	Macugen;	Phase 2 ;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	10-K;	2003;	2004;	Macugen;	Phase 2;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	10-K;	2003;	2005;	Macugen;	 Phase 2/3;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	10-K;	2003;	2005;	Macugen;	Phase 2 ;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001115285;	EYETECH PHARMACEUTICALS INC;	10-K;	2003;	2005;	Macugen;	Phase 2;	synthesized aptamer;	1;	;	;		;	;		
wvcs20040001260990;	GTX INC ;	S-1;	2003;	2003;	Acapodene;	Phase II;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	S-1;	2003;	2003;	Acapodene;	Phase  III ;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	S-1;	2003;	2003;	Andarine;	Phase I;	 SERM;	22;	;	;		2010;	-1;	
wvcs20040001260990;	GTX INC;	S-1;	2003;	2003;	Prostarine;	Preclinical;	 SERM;	22;	;	;		2010;	-0.6923;	
wvcs20040001260990;	GTX INC;	S-1;	2003;	2003;	Ostarine;	Preclinical;	SARM;	20;	;	;		;	;	
wvcs20040001260990;	GTX INC;	S-1;	2003;	2003;	Andromustine;	Preclinical;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	424;	2003;	2004;	Acapodene;	Phase II;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	424;	2003;	2004;	Acapodene;	Phase  III ;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	424;	2003;	2004;	Andarine;	Phase I;	 SERM;	22;	;	;		2010;	-1;	
wvcs20040001260990;	GTX INC;	424;	2003;	2004;	Prostarine;	Preclinical;	SARM;	22;	;	;		2010;	-0.6923;	
wvcs20040001260990;	GTX INC;	424;	2003;	2004;	Ostarine;	Preclinical;	SARM;	20;	;	;		;	;	
wvcs20040001260990;	GTX INC;	424;	2003;	2004;	Andromustine;	Preclinical;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2004;	Acapodene;	PhaseII;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2004;	Acapodene;	Phase  III ;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2004;	Andarine;	Phase I;	 SERM;	22;	;	;		2010;	-1;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2004;	Prostarine;	Preclinical;	SARM;	22;	;	;		2010;	-0.6923;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2004;	Ostarine;	Preclinical;	SARM;	20;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2004;	Andromustine;	Preclinical;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2005;	Acapodene;	Phase III;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2005;	FARESTON®;	MARKETED;	 SERM;	22;	;	;		2009;	0.0274;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2005;	Acapodene;	Phase  III ;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2005;	Andarine;	Phase I;	 SERM;	22;	;	;		2010;	-1;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2005;	Prostarine;	Preclinical;	SARM;	22;	;	;		2010;	-0.6923;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2005;	Ostarine;	Phase I;	SARM;	20;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2005;	Andromustine;	Preclinical;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2006;	Acapodene;	Phase III;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2006;	FARESTON®;	MARKETED;	 SERM;	22;	;	;		2009;	0.0274;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2006;	Acapodene;	Phase  III ;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2006;	Andarine;	Phase II;	 SERM;	22;	;	;		2010;	-1;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2006;	Prostarine;	Preclinical;	SARM;	22;	;	;		2010;	-0.6923;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2006;	Ostarine;	Phase II;	SARM;	20;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2006;	Andromustine;	Preclinical;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2007;	Acapodene;	Phase III;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2007;	FARESTON®;	MARKETED;	 SERM;	22;	;	;		2009;	-0.7973;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2007;	Acapodene;	Phase  III ;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2007;	Andarine;	Phase I ;	 SERM;	22;	20;	;		2010;	-1;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2007;	Ostarine;	Phase II;	SARM;	22;	20;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2007;	Ostarine;	Phase II;	SARM;	20;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2007;	Ostarine;	Phase II;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2007;	Prostarine;	Preclinical;	SARM;	22;	;	;		2010;	-0.6923;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2007;	Andromustine;	Preclinical;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2008;	Acapodene;	Phase III;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2008;	Acapodene;	Phase  III ;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2008;	Ostarine;	Phase II;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2008;	GTx-838;	Preclinical;	SARM;	22;	20;	;		2010;	-1;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2008;	Ostarine;	Phase II;	SARM;	20;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2008;	GTx-758;	Preclinical;	LH inhibitor;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2008;	GTx-878;	Preclinical;	Estrogen receptor beta agonist;	22;	;	;		2010;	-0.8571;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2009;	Toremifene;	Phase III;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2009;	Toremifene;	FDA Review;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2009;	Ostarine;	Phase II;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2009;	MK-0773;	Phase II;	SARM;	20;	;	;		2011;	-1;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2009;	GTx-758;	Phase I;	LH inhibitor;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2009;	 FARESTON;	Marketed;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2010;	Toremifene;	Phase III;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2010;	Toremifene;	FDA Review;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2010;	Ostarine;	Phase II;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2010;	Ostarine;	Phase II;	SARM;	20;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2010;	GTx-758;	Phase II ;	LH inhibitor;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2010;	 FARESTON;	Marketed;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2011;	Toremifene;	FDA Review;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2011;	Toremifene;	FDA Review;	 SERM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2011;	Ostarine;	Phase III;	SARM;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2011;	Ostarine;	Phase III;	SARM;	20;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2011;	CapesarisTM;	Phase II ;	Selective ER alpha agonist;	22;	;	;		;	;	
wvcs20040001260990;	GTX INC;	10-K;	2003;	2011;	 FARESTON;	Marketed;	alpha agonist;	22;	;	;		;	;	
1;	HESKA CORP;	S-1;	1997;	1997;	 Canine Allergy Diagnostic   ;	marketed;	enzyme-linked immunoassay;	8;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	 Feline Allergy Diagnostic ;	Marketed;	enzyme-linked immunoassay;	8;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	  Canine Allergy   Immunotherapeutic;	Marketed;	Antibodies;	8;	70;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	 Feline Allergy Immunotherapeutic;	IND;	Antibodies;	8;	70;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	Ancillary Dermatology Products;	Marketed;	x;	8;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	Canine Flea Bite Allergy Diagnostic;	Marketed;	enzyme-linked immunoassay;	;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	 Feline Flea Bite Allergy Diagnostic;	Research;	enzyme-linked immunoassay;	;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	Canine Flea Bite Allergy   Vaccine;	Research;	x;	70;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	 Feline Flea Bite Allergy Vaccine;	Research;	x;	70;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	Flea Control Vaccines;	Research;	x;	70;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	Environmental Flea Control ;	Research;	x;	;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	  Pharmaceutical Flea Control;	Research;	small molecule;	;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	 Feline Heartworm Diagnostic;	Marketed;	x;	21;	23;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	  Canine Heartworm Diagnostic;	Marketed;	x;	21;	23;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	Heartworm Vaccines;	Research;	Antibodies;	21;	23;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	  Canine Periodontal Disease   Therapeutic;	Marketed;	semi-solid implant;	70;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	Canine Dental Hygiene Kits    ;	Marketed;	x;	;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	 Feline Trivalent Viral Vaccine   ;	Marketed;	injectable vaccines;	23;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	 Bartonellosis ;	NDA;	x;	23;	;	;		;	;		
1;	HESKA CORP;	S-1;	1997;	1997;	 Equine Influenza Vaccine        ;	NDA;	;	23;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	 Canine Allergy Diagnostic   ;	marketed;	enzyme-linked immunoassay;	8;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	 Feline Allergy Diagnostic ;	Marketed;	enzyme-linked immunoassay;	8;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	  Canine Allergy   Immunotherapeutic;	Marketed;	Antibodies;	8;	70;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	 Feline Allergy Immunotherapeutic;	IND;	Antibodies;	8;	70;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	Ancillary Dermatology Products;	Marketed;	x;	8;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	Canine Flea Bite Allergy Diagnostic;	Marketed;	enzyme-linked immunoassay;	;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	 Feline Flea Bite Allergy Diagnostic;	Research;	enzyme-linked immunoassay;	;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	Canine Flea Bite Allergy   Vaccine;	Research;	x;	70;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	 Feline Flea Bite Allergy Vaccine;	Research;	x;	70;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	Flea Control Vaccines;	Research;	x;	70;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	Environmental Flea Control ;	Research;	x;	;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	  Pharmaceutical Flea Control;	Research;	small molecule;	;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	 Feline Heartworm Diagnostic;	Marketed;	x;	21;	23;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	  Canine Heartworm Diagnostic;	Marketed;	x;	21;	23;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	Heartworm Vaccines;	Research;	Antibodies;	21;	23;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	  Canine Periodontal Disease   Therapeutic;	Marketed;	semi-solid implant;	70;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	Canine Dental Hygiene Kits    ;	Marketed;	x;	;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	 Feline Trivalent Viral Vaccine   ;	Marketed;	injectable vaccines;	23;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	 Bartonellosis ;	NDA;	x;	23;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1997;	 Equine Influenza Vaccine        ;	NDA;	x;	23;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	 Canine Allergy Diagnostic   ;	marketed;	enzyme-linked immunoassay;	8;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	 Feline Allergy Diagnostic ;	Marketed;	enzyme-linked immunoassay;	8;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	  Canine Allergy   Immunotherapeutic;	Marketed;	Antibodies;	8;	70;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	 Feline Allergy Immunotherapeutic;	marketed;	Antibodies;	8;	70;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	Ancillary Dermatology Products;	Marketed;	x;	8;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	Canine Flea Bite Allergy Diagnostic;	Marketed;	enzyme-linked immunoassay;	;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	 Feline Flea Bite Allergy Diagnostic;	Marketed;	enzyme-linked immunoassay;	;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	Canine Flea Bite Allergy   Vaccine;	Research;	x;	70;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	 Feline Flea Bite Allergy Vaccine;	Research;	x;	70;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	Flea Control Vaccines;	Research;	x;	70;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	Environmental Flea Control ;	Research;	x;	;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	  Pharmaceutical Flea Control;	Research;	small molecule;	;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	 Feline Heartworm Diagnostic;	Marketed;	x;	21;	23;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	  Canine Heartworm Diagnostic;	Marketed;	x;	21;	23;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	Heartworm Vaccines;	Research;	Antibodies;	21;	23;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	  Canine Periodontal Disease   Therapeutic;	Marketed;	semi-solid implant;	70;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	Canine Dental Hygiene Kits    ;	Marketed;	x;	;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	 Feline Trivalent Viral Vaccine   ;	Marketed;	injectable vaccines;	23;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	 Bartonellosis ;	Expected;	x;	23;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	 Equine Influenza Vaccine        ;	Expected;	x;	23;	;	;		;	;		
1;	HESKA CORP;	424;	1997;	1998;	 Canine Thyroid Supplement        ;	Marketed;	x;	24;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	 Canine Allergy Diagnostic   ;	marketed;	enzyme-linked immunoassay;	,;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	 Feline Allergy Diagnostic ;	Marketed;	enzyme-linked immunoassay;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	 Feline Heartworm Diagnostic;	Marketed;	monoclonal antibodies;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	  Canine Heartworm Diagnostic;	Marketed;	monoclonal antibodies;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	Canine Leishmaniosis Diagnostic    ;	Marketed;	enzyme-linked immunoassay;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	  Canine Allergy   Immunotherapeutic;	Marketed;	Antibodies;	70;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	 Feline Allergy Immunotherapeutic;	marketed;	Antibodies;	70;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	 Feline Trivalent Viral Vaccine   ;	Marketed;	injectable vaccines;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	  Canine Periodontal Disease   Therapeutic;	Marketed;	semi-solid implant;	70;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	 Canine Thyroid Supplement        ;	Marketed;	x;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	F.A. Granules, Dietary Supplement;	Marketed;	x;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	VET/OX(R) 4400 ;	Marketed;	x;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	i-STAT(R) Portable Clinical   Analyzer (1)    ;	Marketed;	x;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	1999;	Vet ABC Hematology Analyzer ;	Marketed;	;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	2000;	 Feline Heartworm Diagnostic;	Marketed;	monoclonal antibodies;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	2000;	  Canine Heartworm Diagnostic;	Marketed;	monoclonal antibodies;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	2000;	 HESKA(R) ALLERCEPT(TM) Detection System;	marketed;	enzyme-linked immunoassay;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	2000;	 HESKA(R) ALLERCEPT(TM) Detection System;	Marketed;	enzyme-linked immunoassay;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	2000;	Flu Avert(TM) ;	Marketed;	Antibodies;	;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	2000;	  Canine Allergy   Immunotherapeutic;	Marketed;	Antibodies;	70;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	2000;	 Feline Allergy Immunotherapeutic;	marketed;	Antibodies;	70;	;	;		;	;		
1;	HESKA CORP;	10-K;	1997;	2000;	 Feline Trivalent Viral Vaccine   ;	Marketed;	injectable vaccines;	;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	S-1;	2003;	2003;	telbivudine;	phase III;	L-nucleoside;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	S-1;	2003;	2003;	valtorcitabine;	phase I/II;	L-nucleoside;	23;	;	;		2010;	-0.4545;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	S-1;	2003;	2003;	NM 283;	phase I/II;	Nucleoside analog;	23;	;	;		2011;	-0.2903;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	S-1;	2003;	2003;	NV-08B;	preclinical;	Nucleoside analog;	23;	;	;		2009;	0;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	S-1;	2003;	2003;	NV-05A;	preclinical;	NNRTI;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	424;	2003;	2004;	telbivudine;	phase III;	L-nucleoside;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	424;	2003;	2004;	valtorcitabine;	phase I/II;	L-nucleoside;	23;	;	;		2010;	-0.4545;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	424;	2003;	2004;	NM 283;	phase I/II;	Nucleoside analog;	23;	;	;		2011;	-0.2903;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	424;	2003;	2004;	NV-08B;	preclinical;	Nucleoside analog;	23;	;	;		2009;	0;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	424;	2003;	2004;	NV-05A;	preclinical;	NNRTI;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2005;	telbivudine;	phase III;	L-nucleoside;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2005;	valtorcitabine;	phase I/II;	L-nucleoside;	23;	;	;		2010;	-0.4545;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2005;	NM 283;	phase I/II;	Nucleoside analog;	23;	;	;		2011;	-0.2903;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2005;	NV-08B;	preclinical;	Nucleoside analog;	23;	;	;		2009;	0;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2005;	NV-05A;	preclinical;	NNRTI;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2006;	telbivudine;	Phaes III;	L-nucleoside;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2006;	valtorcitabine;	phase IIb ;	L-nucleoside;	23;	;	;		2010;	-0.4545;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2006;	NM 283;	phase III;	Nucleoside analog;	23;	;	;		2011;	-0.2903;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2006;	NV-08B;	preclinical;	Nucleoside analog;	23;	;	;		2009;	0;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2006;	NV-05A;	preclinical;	NNRTI;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2007;	Tyzeka®;	Phaes III;	L-nucleoside;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2007;	valtorcitabine;	phase IIb ;	L-nucleoside;	23;	;	;		2010;	-0.4545;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2007;	valopicitabine;	phase IIb;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		2011;	-0.2903;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2007;	NV-08B;	preclinical;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		2009;	-1;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2007;	IDX-899 ;	phase I/II ;	NNRTI;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2008;	Tyzeka®;	Marketed;	L-nucleoside;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2008;	valtorcitabine;	phase IIb ;	L-nucleoside;	23;	;	;		2010;	-0.75;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2008;	valopicitabine;	phase IIb;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		2011;	-0.2903;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2008;	IDX102;	late stage preclinical ;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2008;	IDX184;	late stage preclinical ;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2008;	IDX-899 ;	phase I/II ;	NNRTI;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2009;	Tyzeka®;	Marketed;	L-nucleoside;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2009;	valopicitabine;	phase IIb;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		2011;	-0.6944;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2009;	IDX102;	late stage preclinical ;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2009;	IDX184;	Phase I;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2009;	IDX375 ;	IND;	non-nucleoside HCV polymerase inhibitor;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2009;	IDX136 ;	IND;	 protease inhibitor;	23;	;	;		2011;	-1;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2009;	IDX316;	IND;	 protease inhibitor;	23;	;	;		2011;	-1;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2009;	IDX-899 ;	Marketed;	NNRTI;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2010;	Tyzeka®;	Marketed;	L-nucleoside;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2010;	IDX102;	late stage preclinical ;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2010;	IDX184;	Phase I;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2010;	IDX375 ;	 phase I ;	non-nucleoside HCV polymerase inhibitor;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2010;	 NS5A;	Discovery;	NS5A Inhibitors;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2010;	IDX-899 ;	Marketed;	NNRTI;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2011;	Tyzeka®;	Marketed;	L-nucleoside;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2011;	IDX102;	late stage preclinical ;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2011;	IDX184;	Phase I;	 nucleoside/nucleotide polymerase inhibitors;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2011;	IDX375 ;	 phase I ;	non-nucleoside HCV polymerase inhibitor;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2011;	 NS5A;	Discovery;	NS5A Inhibitors;	23;	;	;		;	;		
wvcs20040001093649;	IDENIX PHARMACEUTICALS INC;	10-K;	2003;	2011;	IDX-899 ;	Marketed;	NNRTI;	23;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	S-1;	1996;	1996;	MGBG;	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	S-1;	1996;	1996;	DFMO;	Phase III;	Research Expertise;	22;	40;	;		2005;	-0.6667;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	S-1;	1996;	1996;	Piritrexim;	Phase II;	Research Expertise;	22;	;	;		2001;	-0.9333;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	S-1;	1996;	1996;	Crisnatol;	Phase III;	Research Expertise;	22;	;	;		2000;	-0.3636;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	S-1;	1996;	1996;	DHAC;	Phase II;	Research Expertise;	22;	;	;		2000;	-0.8889;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	S-1;	1996;	1996;	Oxypurinol;	Preclinical;	Research Expertise;	22;	;	;		2003;	-0.9167;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	S-1;	1996;	1996;	Intoplicine Aminopterin;	Phase I/II;	Research Expertise;	22;	;	;		2001;	-0.3333;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	S-1;	1996;	1996;	DFMO;	Phase III;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	S-1;	1996;	1996;	ILX23-7553;	Preclinical;	Research Expertise;	22;	;	;		2003;	-1;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	424;	1996;	1997;	MGBG;	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	424;	1996;	1997;	DFMO;	Phase III;	Research Expertise;	22;	40;	;		2005;	-0.6667;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	424;	1996;	1997;	Piritrexim;	Phase II;	Research Expertise;	22;	;	;		2001;	-0.9333;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	424;	1996;	1997;	Crisnatol;	Phase III;	Research Expertise;	22;	;	;		2000;	-0.3636;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	424;	1996;	1997;	DHAC;	Phase II;	Research Expertise;	22;	;	;		2000;	-0.8889;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	424;	1996;	1997;	Oxypurinol;	Preclinical;	Research Expertise;	22;	;	;		2003;	-0.9167;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	424;	1996;	1997;	Intoplicine Aminopterin;	Phase I/II;	Research Expertise;	22;	;	;		2001;	-0.3333;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	424;	1996;	1997;	DFMO;	Phase III;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	424;	1996;	1997;	ILX23-7553;	Preclinical;	Research Expertise;	22;	;	;		2003;	-1;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1998;	MGBG;	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1998;	DFMO;	Phase III;	Research Expertise;	22;	40;	;		2005;	-0.6667;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1998;	Piritrexim;	Phase II;	Research Expertise;	22;	;	;		2001;	-0.9333;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1998;	Crisnatol;	Phase III;	Research Expertise;	22;	;	;		2000;	-0.5333;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1998;	DHAC;	Phase II;	Research Expertise;	22;	;	;		2000;	-0.8667;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1998;	Oxypurinol;	Preclinical;	Research Expertise;	22;	;	;		2003;	-0.9167;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1998;	Intoplicine Aminopterin;	Phase I/II;	Research Expertise;	22;	;	;		2001;	-0.3333;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1998;	DFMO;	Phase III;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1998;	ILX23-7553;	Preclinical;	Research Expertise;	22;	;	;		2003;	-1;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1999;	CAMPATH(R);	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1999;	Eflornithine (DFMO);	Phase III;	Research Expertise;	22;	3;	;		2005;	-0.6667;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1999;	Oxypurinol;	Preclinical;	Research Expertise;	22;	;	;		2003;	-0.9167;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1999;	Aminopterin;	Phase I/II;	Research Expertise;	22;	;	;		2001;	-0.3333;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1999;	Piritrexim;	Phase II;	Research Expertise;	22;	;	;		2001;	-0.9167;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1999;	ILX-295501;	Phase II;	Research Expertise;	22;	;	;		2003;	-1;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1999;	Intoplicine;	Phase I;	Research Expertise;	22;	;	;		2001;	-1;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1999;	SR-45023A;	Phase I;	Research Expertise;	22;	;	;		2001;	4;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	1999;	ILX23-7553;	Phase I;	Research Expertise;	22;	;	;		2003;	-1;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2000;	CAMPATH(R);	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2000;	CAMPATH(R);	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2000;	Eflornithine (DFMO);	Phase III;	Research Expertise;	22;	3;	;		2005;	-0.6667;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2000;	OXYPRIM(TM)(oxypurinol);	Preclinical;	Research Expertise;	22;	;	;		2003;	-0.9167;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2000;	ILX-295501;	Phase II;	Research Expertise;	22;	;	;		2003;	-1;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2000;	APOMINE™;	Phase II;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2000;	ILX23-7553;	Phase I;	Research Expertise;	22;	;	;		2003;	-1;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2001;	CAMPATH(R);	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2000;	CAMPATH(R);	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2001;	Eflornithine (DFMO);	Phase III;	Research Expertise;	22;	3;	;		2005;	-0.6667;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2001;	OXYPRIM(TM)(oxypurinol);	Preclinical;	Research Expertise;	22;	;	;		2003;	-0.8889;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2001;	ILX-295501;	Phase II;	Research Expertise;	22;	;	;		2003;	-1;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2001;	APOMINE™;	Phase II;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2001;	ILX23-7553;	Phase I;	Research Expertise;	22;	;	;		2003;	-1;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2001;	Clofarabine;	Phase II;	Research Expertise;	9;	22;	27;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2001;	NM-3;	Phase I;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2002;	CAMPATH(R);	Marketed;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2002;	CAMPATH(R);	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2002;	Eflornithine (DFMO);	Phase III;	Research Expertise;	22;	3;	;		2005;	-0.6667;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2002;	ILX-651;	Phase II;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2002;	APOMINE™;	Phase II;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2002;	CLOFAREX(TM);	Phase II;	Research Expertise;	9;	22;	27;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2002;	NM-3;	Phase I;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2003;	CAMPATH(R);	Marketed;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2003;	CAMPATH(R);	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2003;	Eflornithine (DFMO);	Phase III;	Research Expertise;	22;	3;	;		2005;	-0.9779;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2003;	ILX-651;	Phase II;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2003;	APOMINE™;	Phase II;	Research Expertise;	22;	20;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2003;	CLOFAREX(TM);	Phase II;	Research Expertise;	9;	22;	27;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2003;	NM-3;	Phase I;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2003;	Signal Transduction Inhibitors;	Preclinical;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2003;	Angiogenesis inhibitors;	Preclinical;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2004;	CAMPATH(R);	Marketed;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2004;	CAMPATH(R);	Phase II;	Research Expertise;	22;	27;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2004;	ILX-651;	Phase II;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2004;	APOMINE™;	Phase II;	Research Expertise;	22;	20;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2004;	CLOFAREX(TM);	Phase II;	Research Expertise;	9;	22;	27;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2004;	NM-3;	Phase I;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2004;	Signal Transduction Inhibitors;	Preclinical;	Research Expertise;	22;	;	;		;	;		
wvcs19970001001915;	ILEX ONCOLOGY INC;	10-K;	1996;	2004;	Angiogenesis inhibitors;	Preclinical;	Research Expertise;	22;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	S-1;	2004;	2004;	Veronate;	Phase III;	 MSCRAMM proteins ;	23;	;	;		2008;	-0.8267;		
wvcs20040001274913;	INHIBITEX, INC.;	S-1;	2004;	2004;	Aurexis;	Phase II;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	S-1;	2004;	2004;	Enterococcal monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	-1;		
wvcs20040001274913;	INHIBITEX, INC.;	S-1;	2004;	2004;	Candida monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	0.2247;		
wvcs20040001274913;	INHIBITEX, INC.;	S-1;	2004;	2004;	Staphylococcal vaccine;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	424;	2004;	2004;	Veronate;	Phase III;	 MSCRAMM proteins ;	23;	;	;		2008;	-0.8267;		
wvcs20040001274913;	INHIBITEX, INC.;	424;	2004;	2004;	Aurexis;	Phase II;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	424;	2004;	2004;	Enterococcal monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	-1;		
wvcs20040001274913;	INHIBITEX, INC.;	424;	2004;	2004;	Candida monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	0.2247;		
wvcs20040001274913;	INHIBITEX, INC.;	424;	2004;	2004;	Staphylococcal vaccine;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2005;	Veronate;	Phase III;	 MSCRAMM proteins ;	23;	;	;		2008;	-0.8267;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2005;	Aurexis;	Phase II;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2005;	Enterococcal monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	-1;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2005;	Candida monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	0.2247;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2005;	Staphylococcal vaccine;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2006;	Veronate;	Phase III;	 MSCRAMM proteins ;	23;	;	;		2008;	7.75;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2006;	Aurexis;	Phase II;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2006;	Enterococcal monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	-1;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2006;	Candida monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	0.2247;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2006;	Staphylococcal vaccine;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2006;	Staphylococcus epidermidis monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	2.8;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2007;	Aurexis;	Phase II;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2007;	Enterococcal monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	-1;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2007;	Candida monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	10.4737;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2007;	Staphylococcal vaccine;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2007;	Staphylococcus epidermidis monoclonal antibodies;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		2009;	3.75;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2007;	Diagnostic for bacterial and fungal pathogens;	Clinical;	 MSCRAMM proteins ;	23;	;	;		2010;	-0.5385;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2008;	Aurexis;	Phase II;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2008;	Staphylococcal vaccine;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2008;	Diagnostic for bacterial and fungal pathogens;	Pre market;	 MSCRAMM proteins ;	23;	;	;		2010;	0.5;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2008;	FV-100;	Phase I ;	 antiviral development programs;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2008;	HIV Integrase Inhibitors;	Preclinical;	 antiviral development programs;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2008;	HCV Polymerase Inhibitors;	Preclinical;	 antiviral development programs;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2008;	HCMV;	Preclinical;	 antiviral development programs;	23;	;	;		2010;	-1;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2009;	FV-100;	Phase II;	nucleoside analogue prodrug;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2009;	HIV Integrase Inhibitors;	Preclinical;	nucleoside analogue prodrug;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2009;	HCV Polymerase Inhibitors;	Preclinical;	nucleoside analogue prodrug;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2009;	Aurexis;	Phase II;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2009;	Staphylococcal vaccine;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2010;	FV-100;	Phase II;	nucleoside analogue prodrug;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2010;	HCV Polymerase Inhibitors;	Preclinical;	nucleoside analogue prodrug;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2010;	Aurexis;	Phase II;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2010;	Staphylococcal vaccine;	Preclinical;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2011;	FV-100;	Phase II;	nucleoside analogue prodrug;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2011;	HCV Polymerase Inhibitors;	Preclinical;	nucleoside analogue prodrug;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2011;	Aurexis;	Phase II;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2011;	Staphylococcal vaccine;	Phase I;	 MSCRAMM proteins ;	23;	;	;		;	;		
wvcs20040001274913;	INHIBITEX, INC.;	10-K;	2004;	2011;	INX-189;	Phase I;	nucleoside analogue prodrug;	23;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	S-1;	1997;	1997;	Thallium-201;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	S-1;	1997;	1997;	Indium-111;	pre clinical;	LINAC design;	22;	50;	60;		2000;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	S-1;	1997;	1997;	Iodine-123;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	S-1;	1997;	1997;	Gallium-67;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	S-1;	1997;	1997;	Cobalt-57;	pre clinical;	LINAC design;	22;	50;	60;		1999;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	S-1;	1997;	1997;	Strontium-82;	pre clinical;	LINAC design;	22;	50;	60;		1999;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	424;	1997;	1997;	Thallium-201;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	424;	1997;	1997;	Indium-111;	pre clinical;	LINAC design;	22;	50;	60;		2000;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	424;	1997;	1997;	Iodine-123;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	424;	1997;	1997;	Gallium-67;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	424;	1997;	1997;	Cobalt-57;	pre clinical;	LINAC design;	22;	50;	60;		1999;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	424;	1997;	1997;	Strontium-82;	pre clinical;	LINAC design;	22;	50;	60;		1999;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1998;	Thallium-201;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1998;	Indium-111;	pre clinical;	LINAC design;	22;	50;	60;		2000;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1998;	Iodine-123;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1998;	Gallium-67;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1998;	Brachytherapy Devices;	pre clinical;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1998;	Brachytherapy Devices;	pre clinical;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1998;	Paladium-103;	pre clinical;	LINAC design;	22;	50;	60;		2000;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Iodine-131;	marketed;	LINAC design;	22;	27;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Iodine-123;	marketed;	LINAC design;	40;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Rhenium-188;	marketed;	LINAC design;	21;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	FDG/F-18    ;	marketed;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Phosphorus-32;	marketed;	LINAC design;	21;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Yttrium-90;	marketed;	LINAC design;	21;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Iridium-192;	marketed;	LINAC design;	21;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Holmium-166;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Thallium-201;	pre clinical;	LINAC design;	21;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Strontium-89;	pre clinical;	LINAC design;	62;	22;	20;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Gallium-67;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Strontium-82;	pre clinical;	LINAC design;	21;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Brachytherapy Devices;	pre clinical;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Brachytherapy Devices;	pre clinical;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	1999;	Copper-64;	pre clinical;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Iodine-131;	marketed;	LINAC design;	22;	27;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Iodine-123;	marketed;	LINAC design;	40;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Rhenium-188;	marketed;	LINAC design;	21;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	FDG/F-18    ;	marketed;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Phosphorus-32;	marketed;	LINAC design;	21;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Yttrium-90;	marketed;	LINAC design;	21;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Iridium-192;	marketed;	LINAC design;	21;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Holmium-166;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Thallium-201;	marketed;	LINAC design;	21;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Strontium-89;	marketed;	LINAC design;	62;	22;	20;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Gallium-67;	marketed;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Strontium-82;	marketed;	LINAC design;	21;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Copper-64;	marketed;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Iodine -125;	pre clinical;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Iodine -125;	pre clinical;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2000;	Cobalt-57;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2001;	Reactor Produced Radioisotopes;	marketed;	LINAC design;	22;	50;	60;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2001;	Flood Source Contract Manufacture;	marketed;	LINAC design;	21;	50;	60;		2005;	0.5;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2001;	Gemstone Processing;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2002;	HSA Cobalt;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2002;	Reactor Produced Radioisotopes;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2002;	Gemstone Processing;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2002;	Flood Source Contract Manufacture;	marketed;	LINAC design;	21;	50;	60;		2005;	0.5;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2003;	HSA Cobalt;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2003;	Reactor Produced Radioisotopes;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2003;	Gemstone Processing;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2003;	Nuclear medicine calibration and reference standards manufacturing ;	marketed;	LINAC design;	21;	50;	60;		2005;	-0.25;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2004;	HSA Cobalt;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2004;	Reactor Produced Radioisotopes;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2004;	Reactor Produced Radioisotopes;	Clinical Trials;	LINAC design;	22;	27;	20;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2004;	Iodine-131 ;	Marketed;	LINAC design;	24;	;	;		2007;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2004;	Calibration and Reference Standards;	marketed;	LINAC design;	21;	50;	60;		2007;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2004;	General Measurement and Radiological Services;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2004;	Fluorine products;	Pre clinical;	The FEP patents and intellectual property;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2005;	Cobalt Products;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2005;	Radiochemical Products;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2005;	Iodine-131 ;	Marketed;	LINAC design;	24;	;	;		2007;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2005;	Calibration and Reference Standards;	marketed;	LINAC design;	21;	50;	60;		2007;	-1;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2005;	General Measurement and Radiological Services;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2005;	Fluorine products;	Pre clinical;	The FEP patents and intellectual property;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2006;	Cobalt Products;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2006;	Radiochemical Products;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2006;	General Measurement and Radiological Services;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2006;	Fluorine products;	Pre clinical;	The FEP patents and intellectual property;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2007;	Cobalt Products;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2007;	Radiochemical Products;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2007;	General Measurement and Radiological Services;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2007;	Fluorine products;	Phase I;	The FEP patents and intellectual property;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2007;	Transportation Services;	marketed;	n/a;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2008;	Cobalt Products;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2008;	Radiochemical Products;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2008;	General Measurement and Radiological Services;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2008;	Fluorine products;	Phase II;	The FEP patents and intellectual property;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2008;	Transportation Services;	marketed;	n/a;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2009;	Cobalt Products;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2009;	Radiochemical Products;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2009;	General Measurement and Radiological Services;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2009;	Fluorine products;	Marketed;	The FEP patents and intellectual property;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2009;	Transportation Services;	marketed;	n/a;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2010;	Cobalt Products;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2010;	Radiochemical Products;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2010;	General Measurement and Radiological Services;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2010;	Fluorine products;	Marketed;	The FEP patents and intellectual property;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2010;	Transportation Services;	marketed;	n/a;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2011;	Cobalt Products;	marketed;	LINAC design;	22;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2011;	Radiochemical Products;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2011;	General Measurement and Radiological Services;	marketed;	LINAC design;	50;	60;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2011;	Fluorine products;	Marketed;	The FEP patents and intellectual property;	;	;	;		;	;		
nvcs19970001038277;	INTERNATIONAL ISOTOPES INC;	10-K;	1997;	2011;	Transportation Services;	marketed;	n/a;	;	;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	S-1;	1997;	1997;	LDP-03 (ANTI-CAMPATH MAB);	Phase II;	Leukocyte Antigens;	22;	27;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	S-1;	1997;	1997;	LDP-01 (ANTI-b2 MAB);	pre clinical;	Integrin/Adhesion Molecules;	21;	;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	S-1;	1997;	1997;	LDP-01 (ANTI-b2 MAB);	Phase II;	Integrin/Adhesion Molecules;	5;	;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	S-1;	1997;	1997;	LDP-01 (ANTI-b2 MAB);	Phase II;	Integrin/Adhesion Molecules;	21;	40;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	S-1;	1997;	1997;	LDP-02 (ANTI-b7 MAB);	Pre Clinical;	Integrin/Adhesion Molecules;	5;	26;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	S-1;	1997;	1997;	CCR3 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	29;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	S-1;	1997;	1997;	MCP-1 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	20;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	S-1;	1997;	1997;	IL-8 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	21;	25;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	S-1;	1997;	1997;	CCR5 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	23;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	424;	1997;	1997;	LDP-03 (ANTI-CAMPATH MAB);	Phase II;	Leukocyte Antigens;	22;	27;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	424;	1997;	1997;	LDP-01 (ANTI-b2 MAB);	pre clinical;	Integrin/Adhesion Molecules;	21;	;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	424;	1997;	1997;	LDP-01 (ANTI-b2 MAB);	Phase II;	Integrin/Adhesion Molecules;	5;	;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	424;	1997;	1997;	LDP-01 (ANTI-b2 MAB);	Phase II;	Integrin/Adhesion Molecules;	21;	40;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	424;	1997;	1997;	LDP-02 (ANTI-b7 MAB);	Pre Clinical;	Integrin/Adhesion Molecules;	5;	26;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	424;	1997;	1997;	CCR3 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	29;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	424;	1997;	1997;	MCP-1 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	20;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	424;	1997;	1997;	IL-8 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	21;	25;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	424;	1997;	1997;	CCR5 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	23;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1998;	LDP-03 (ANTI-CAMPATH MAB);	Phase II;	Leukocyte Antigens;	22;	27;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1998;	LDP-01 (ANTI-b2 MAB);	pre clinical;	Integrin/Adhesion Molecules;	21;	;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1998;	LDP-01 (ANTI-b2 MAB);	Phase II;	Integrin/Adhesion Molecules;	5;	;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1998;	LDP-01 (ANTI-b2 MAB);	Phase II;	Integrin/Adhesion Molecules;	21;	40;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1998;	LDP-02 (ANTI-b7 MAB);	Pre Clinical;	Integrin/Adhesion Molecules;	5;	26;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1998;	CCR3 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	29;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1998;	MCP-1 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	20;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1998;	IL-8 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	21;	25;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1998;	CCR5 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	23;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1999;	CAMPATH;	Phase II;	Leukocyte Antigens;	22;	27;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1999;	LDP-01 (ANTI-b2 MAB);	pre clinical;	Integrin/Adhesion Molecules;	21;	;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1999;	LDP-01 (ANTI-b2 MAB);	Phase II;	Integrin/Adhesion Molecules;	5;	;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1999;	LDP-01 (ANTI-b2 MAB);	Phase II;	Integrin/Adhesion Molecules;	21;	40;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1999;	LDP-02 (ANTI-b7 MAB);	Pre Clinical;	Integrin/Adhesion Molecules;	5;	26;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1999;	LDP-977;	Phase I;	Integrin/Adhesion Molecules;	5;	29;	20;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1999;	CCR3 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	29;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1999;	CCR2 RECEPTOR ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	20;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1999;	CXCR-1,2 RECEPTOR ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	21;	25;	;		;	;		
wvcs19970000915320;	LEUKOSITE INC;	10-K;	1997;	1999;	CCR5 ANTAGONIST;	Discovery;	Chemokine/Chemokine Receptor;	5;	23;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	S-1;	2004;	2004;	Technosphere Insulin System;	Phase II;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	S-1;	2004;	2004;	Cancer immunotherapy;	Phase II;	tumor-associated antigens;	5;	22;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	424;	2004;	2004;	Technosphere Insulin System;	Phase II;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	424;	2004;	2004;	Cancer immunotherapy;	Phase II;	tumor-associated antigens;	5;	22;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2005;	Technosphere Insulin System;	Phase III;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2005;	Cancer immunotherapy;	Phase II;	tumor-associated antigens;	5;	22;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2006;	Technosphere Insulin System;	Phase III;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2006;	MKC1106;	Phase II;	tumor-associated antigens;	5;	22;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2007;	Technosphere Insulin System;	Phase III;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2007;	MKC1106;	Phase I;	tumor-associated antigens;	5;	22;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2008;	Technosphere Insulin System;	Phase III;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2008;	MKC1106;	Phase I;	tumor-associated antigens;	5;	22;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2008;	MKC1106-MT;	Phase II;	tumor-associated antigens;	22;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2009;	AFRESA;	Phase III;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2009;	MKC1106;	Phase I;	tumor-associated antigens;	5;	22;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2009;	MKC1106-MT;	Phase II;	tumor-associated antigens;	22;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2010;	AFRESA;	NDA;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2010;	MKC253 (GLP-1);	Phase I;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2010;	MKC180 (obesity compound);	Preclinical;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2010;	MKC1106;	Phase I;	tumor-associated antigens;	5;	22;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2010;	MKC1106-MT;	Phase II;	tumor-associated antigens;	22;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2010;	MKC204 (IRE-1 inhibitor);	Preclinical;	tumor-associated antigens;	22;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2011;	AFRESA;	NDA;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2011;	MKC253 (GLP-1);	Phase I;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2011;	MKC180 (obesity compound);	Preclinical;	Technosphere formulation technology;	24;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2011;	MKC1106;	Phase I;	tumor-associated antigens;	5;	22;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2011;	MKC1106-MT;	Phase II;	tumor-associated antigens;	22;	;	;		;	;		
wvcs20040000899460;	MANNKIND CORP;	10-K;	2004;	2011;	MKC204 (IRE-1 inhibitor);	Preclinical;	tumor-associated antigens;	22;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	S-1;	2003;	2003;	MEM 1003;	Phase I;	Neuronal L-type;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	S-1;	2003;	2003;	MEM 1414;	Phase I;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	S-1;	2003;	2003;	MEM 3454;	Preclinical;	Nicotinic alpha-7;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	S-1;	2003;	2003;	MEM 1917;	Preclinical;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	424;	2003;	2004;	MEM 1003;	Phase I;	Neuronal L-type;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	424;	2003;	2004;	MEM 1414;	Phase I;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	424;	2003;	2004;	MEM 3454;	Preclinical;	Nicotinic alpha-7;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	424;	2003;	2004;	MEM 1917;	Preclinical;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2005;	MEM 1003;	Phase I;	Neuronal L-type;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2005;	MEM 1414;	Phase I;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2005;	MEM 3454;	Phase I;	Nicotinic alpha-7;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2005;	MEM 1917;	Preclinical;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2005;	MEM 63908;	Preclinical;	Nicotinic alpha-7 partial agonist;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2006;	MEM 1003;	Phase II;	Neuronal L-type;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2006;	MEM 1003;	Phase II;	Neuronal L-type;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2006;	MEM 1414;	Phase I;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2006;	MEM 3454;	Phase II;	Nicotinic alpha-7;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2006;	MEM 1917;	Preclinical;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2006;	MEM 63908;	Preclinical;	Nicotinic alpha-7 partial agonist;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2007;	MEM 1003;	Phase II;	Neuronal L-type;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2007;	MEM 1414;	Phase I;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2007;	MEM 3454;	Phase II;	Nicotinic alpha-7;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2007;	MEM 3454;	Phase II;	Nicotinic alpha-7;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2007;	MEM 1917;	Preclinical;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2007;	MEM 1917;	Preclinical;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2007;	MEM 63908;	Preclinical;	Nicotinic alpha-7 partial agonist;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2007;	MEM 63908;	Preclinical;	Nicotinic alpha-7 partial agonist;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	MEM 1003;	Phase II;	Neuronal L-type;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	MEM 3454;	Phase II;	Nicotinic alpha-7;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	MEM 3454;	Phase II;	Nicotinic alpha-7;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	R4996/MEM 63908 ;	Phase I;	Nicotinic alpha-7;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	R4996/MEM 63908 ;	Phase I;	Nicotinic alpha-7;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	MEM 1917;	Preclinical;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	MEM 1917;	Preclinical;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	MEM 1414;	Phase I;	PDE4 inhibitor;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	PDE10 Inhibitor Program;	;	 PDE10 inhibitors;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	5-HT6 Antagonist Program;	;	5-HT6 antagonists;	40;	;	;		;	;		
wvcs20040001062216;	MEMORY PHARMACEUTICALS CORP;	10-K;	2003;	2008;	5-HT6 Antagonist Program;	;	5-HT6 antagonists;	40;	;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	S-1;	2004;	2004;	M-Enoxaparin;	Development;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	S-1;	2004;	2004;	M-Dalteparin;	Development;	Momenta Technology;	9;	21;	;		2009;	-1;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	S-1;	2004;	2004;	M118;	Preclinical;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	S-1;	2004;	2004;	Pulmonary Insulin;	Preclinical;	Momenta Technology;	24;	;	;		2006;	0.7143;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	S-1;	2004;	2004;	Pulmonary HGH;	Preclinical;	Momenta Technology;	24;	;	;		2006;	0.7143;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	S-1;	2004;	2004;	Pulmonary Interferon-beta;	Discovery;	Momenta Technology;	5;	;	;		2006;	0.7143;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	424;	2004;	2004;	M-Enoxaparin;	Development;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	424;	2004;	2004;	M-Dalteparin;	Development;	Momenta Technology;	9;	21;	;		2009;	-1;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	424;	2004;	2004;	M118;	Preclinical;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	424;	2004;	2004;	Pulmonary Insulin;	Preclinical;	Momenta Technology;	24;	;	;		2006;	0.7143;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	424;	2004;	2004;	Pulmonary HGH;	Preclinical;	Momenta Technology;	24;	;	;		2006;	0.7143;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	424;	2004;	2004;	Pulmonary Interferon-beta;	Discovery;	Momenta Technology;	5;	;	;		2006;	0.7143;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2005;	M-Enoxaparin;	 ANDA;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2005;	M-Dalteparin;	 ANDA;	Momenta Technology;	9;	21;	;		2009;	-1;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2005;	Glycoproteins;	Discovery ;	Momenta Technology;	24;	;	;		2011;	0.2;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2005;	Sugar Therapeutic;	Discovery;	Momenta Technology;	22;	;	;		2011;	-0.2727;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2005;	M118;	Preclinical;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2006;	M-Enoxaparin;	 ANDA;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2006;	M-Dalteparin;	 ANDA;	Momenta Technology;	9;	21;	;		2009;	-1;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2006;	Glycoproteins;	Discovery ;	Momenta Technology;	24;	;	;		2011;	0.2;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2006;	Sugar Therapeutic;	Discovery;	Momenta Technology;	22;	;	;		2011;	-0.2727;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2006;	M118;	Preclinical;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2007;	M-Enoxaparin;	NDA;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2007;	M-Dalteparin;	 ANDA;	Momenta Technology;	9;	21;	;		2009;	-1;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2007;	M356;	ANDA;	Momenta Technology;	40;	;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2007;	Sugar Therapeutic;	Discovery;	Momenta Technology;	22;	;	;		2011;	-0.2727;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2007;	M118;	IND;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2007;	M178;	Discovery;	Momenta Technology;	24;	;	;		2011;	0.2;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2007;	M249;	Discovery;	Momenta Technology;	24;	;	;		2010;	-0.25;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2008;	M-Enoxaparin;	NDA;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2008;	M118;	IND;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2008;	M356;	ANDA;	Momenta Technology;	40;	;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2008;	M178;	Discovery;	Momenta Technology;	24;	;	;		2011;	0.2;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2008;	M249;	Discovery;	Momenta Technology;	24;	;	;		2010;	-0.4;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2008;	Sugar Therapeutic;	Discovery;	Momenta Technology;	22;	;	;		2011;	-0.2727;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2009;	M-Enoxaparin;	NDA;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2009;	M118;	IND;	Momenta Technology;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2009;	M356;	ANDA;	Momenta Technology;	40;	;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2009;	M178;	Discovery;	Momenta Technology;	24;	;	;		2011;	-0.9016;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2009;	Glycoproteins;	Discovery;	Momenta Technology;	22;	;	;		2011;	-0.8689;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2010;	M-Enoxaparin;	NDA;	Heparan-Sulfate ProteoGlycan (HSPG) Based;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2010;	M118;	IND;	Heparan-Sulfate ProteoGlycan (HSPG) Based;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2010;	  M402;	preclinical studies ;	Heparan-Sulfate ProteoGlycan (HSPG) Based;	22;	;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2010;	M356;	ANDA;	Complex Polypeptide;	40;	;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2010;	Follow-On Biologics (FOBs) Program;	Discovery;	Therapeutic Protein;	;	;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2011;	M-Enoxaparin;	NDA;	Heparan-Sulfate ProteoGlycan (HSPG) Based;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2011;	M118;	IND;	Heparan-Sulfate ProteoGlycan (HSPG) Based;	9;	21;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2011;	  M402;	preclinical studies ;	Heparan-Sulfate ProteoGlycan (HSPG) Based;	22;	;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2011;	M356;	ANDA;	Complex Polypeptide;	40;	;	;		;	;		
wvcs20040001235010;	MOMENTA PHARMACEUTICALS INC;	10-K;	2004;	2011;	Follow-On Biologics (FOBs) Program;	Discovery;	Therapeutic Protein;	;	;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	S-1;	2004;	2004;	NRP104 ;	IND application;	Carrierwave technology ;	;	;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	S-1;	2004;	2004;	NRP369 ;	research phase;	Carrierwave technology ;	62;	;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	S-1;	2004;	2004;	NRP290;	IND application;	Carrierwave technology ;	62;	9;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	424;	2004;	2004;	NRP104 ;	IND application;	Carrierwave technology ;	;	;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	424;	2004;	2004;	NRP369 ;	research phase;	Carrierwave technology ;	62;	;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	424;	2004;	2004;	NRP290;	IND application;	Carrierwave technology ;	62;	9;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	10-K;	2004;	2005;	NRP104 ;	Phase 2;	Carrierwave technology ;	;	;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	10-K;	2004;	2005;	NRP369 ;	IND;	Carrierwave technology ;	62;	;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	10-K;	2004;	2005;	NRP290;	IND;	Carrierwave technology ;	62;	9;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	10-K;	2004;	2006;	NRP104 ;	Phase 2;	Carrierwave technology ;	;	;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	10-K;	2004;	2006;	NRP369 ;	IND;	Carrierwave technology ;	62;	;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	10-K;	2004;	2006;	NRP290;	IND;	Carrierwave technology ;	62;	9;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	10-K;	2004;	2007;	Vvyanse;	Marketed;	Carrierwave technology ;	;	;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	10-K;	2004;	2007;	NRP290;	Phase III;	Carrierwave technology ;	62;	9;	;		;	;		
wvcs20040001288379;	NEW RIVER PHARMACEUTICALS INC;	10-K;	2004;	2007;	NRP409;	Phase I;	Carrierwave technology ;	24;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	S-1;	2001;	2001;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	S-1;	2001;	2001;	DCVax;	Phase II;	dendritic cell-based;	22;	40;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	S-1;	2001;	2001;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	S-1;	2001;	2001;	DCVax;	Pre-clinical;	dendritic cell-based;	22;	28;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	S-1;	2001;	2001;	HuRx;	Phase I;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	S-1;	2001;	2001;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	S-1;	2001;	2001;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	S-1;	2001;	2001;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	424;	2001;	2001;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	424;	2001;	2001;	DCVax;	Phase II;	dendritic cell-based;	22;	40;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	424;	2001;	2001;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	424;	2001;	2001;	DCVax;	Pre-clinical;	dendritic cell-based;	22;	28;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	424;	2001;	2001;	HuRx;	Phase I;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	424;	2001;	2001;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	424;	2001;	2001;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	424;	2001;	2001;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	HuRx;	Phase I;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	CXCR4;	Pre-clinical;	Gene Therapy;	22;	;	;		2005;	-1;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2002;	CX43;	Pre-clinical;	Gene Therapy;	22;	;	;		2005;	-1;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	HuRx;	Phase I;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	CXCR4;	Pre-clinical;	Gene Therapy;	22;	;	;		2005;	-1;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2003;	CX43;	Pre-clinical;	Gene Therapy;	22;	;	;		2005;	-1;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2004;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2004;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2004;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2004;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2004;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2004;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2004;	HuRx;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2005;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2005;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2005;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2005;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2005;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2005;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2005;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2006;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2006;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2006;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2006;	CXCR4;	Pre-clinical;	Gene Therapy;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2006;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2006;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2006;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2007;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2007;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2007;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2007;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2007;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2007;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2007;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2007;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2007;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2008;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2008;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2008;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2008;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2008;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2008;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2008;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2008;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2008;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2008;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2009;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2009;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2009;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2009;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2009;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2009;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2009;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2009;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2009;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2009;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2010;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2010;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2010;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2010;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2010;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2010;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2010;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2010;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2010;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2010;	CXCR4;	Pre-clinical;	monoclonal antibody-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2011;	DCVax;	Phase III;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2011;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2011;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2011;	DCVax;	Phase II;	dendritic cell-based;	22;	;	;		;	;		
nvcs20010001072379;	NORTHWEST BIOTHERAPEUTICS INC;	10-K;	2001;	2011;	DCVax;	Phase I;	dendritic cell-based;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	S-1;	1996;	1996;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	S-1;	1996;	1996;	MGV;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2004;	-0.52;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	S-1;	1996;	1996;	MGV;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	S-1;	1996;	1996;	PRO  367;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	S-1;	1996;	1996;	PRO 5;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		2007;	-0.9167;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	424;	1996;	1997;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	424;	1996;	1997;	MGV;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2004;	-0.52;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	424;	1996;	1997;	MGV;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	424;	1996;	1997;	PRO  367;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	424;	1996;	1997;	PRO 5;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		2007;	-0.9167;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1998;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1998;	MGV;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2004;	-0.52;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1998;	PRO  367;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1998;	PRO 5;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		2007;	-0.9167;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1998;	 HIV Co-receptor/HIV therapy           ;	    Research   ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1998;	   ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		2001;	-0.9467;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1998;	HIV Attachment Drug;	 Research    ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1999;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1999;	MGV;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2004;	-0.52;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1999;	PRO 542     ;	Phase 1/2;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2007;	-0.9167;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1999;	PRO  367;	Phase 1/2;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1999;	  DHA   ;	 Preclinical;	dehydroascorbic acid;	40;	;	;		2001;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1999;	 HIV Co-receptor/HIV therapy           ;	    Research   ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1999;	   ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		2001;	3;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	1999;	HIV Attachment Drug;	 Research    ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2000;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2000;	MGV;	Phase II;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2004;	-0.52;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2000;	PRO 542     ;	Phase 1/2;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		2007;	-0.9167;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2000;	PRO  367;	Phase 1/2;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2000;	PRO 140 ;	 Preclinical;	 monoclonal antibody,;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2000;	  DHA   ;	 Preclinical;	dehydroascorbic acid;	40;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2000;	 HIV Co-receptor/HIV therapy           ;	    Research   ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2000;	HIV Attachment Drug;	 Research    ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2000;	ProVax  ;	 Research    ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2002;	4;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2001;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2001;	MGV;	Phase II;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2004;	-0.52;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2001;	PRO 542     ;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		2007;	-0.9167;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2001;	PRO  367;	Phase 1/2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2001;	PRO 140 ;	 Preclinical;	 monoclonal antibody,;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2001;	PRO 140 ;	 Preclinical;	 monoclonal antibody,;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2001;	 HIV Co-receptor/HIV therapy           ;	    Research   ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2001;	HIV Attachment Drug;	 Research    ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2001;	  DHA   ;	 Preclinical;	dehydroascorbic acid;	40;	;	;		2003;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	MGV;	Phase 3;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2004;	0.7143;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	PRO 542     ;	Phase 2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		2007;	-0.9167;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	PRO 542     ;	Phase 2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	PRO 140 ;	 Preclinical;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	PRO 140 ;	 Preclinical;	 monoclonal antibody,;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	HIV Attachment Drug;	 Research    ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	 HIV Co-receptor/HIV therapy           ;	    Research   ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	 HIV Co-receptor/HIV therapy           ;	    Research   ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	HIV Attachment Drug;	 Research    ;	HIV  co-receptor  technology CCR5 and CXCR4.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	Methylnaltrexone;	Phase II;	Joint Program;	61;	62;	;		2009;	-0.8294;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	Methylnaltrexone;	Phase II;	Joint Program;	61;	26;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2002;	DHA;	Preclinical;	licensed from Memorial Sloan-Kettering Cancer Center;	21;	40;	;		2004;	0.4;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2003;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2003;	PRO 542     ;	Phase 2;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		2007;	-0.9167;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2003;	PRO 140 ;	 Preclinical;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2003;	PRO 140 ;	 Preclinical;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2003;	CCR5 and gp41 fusion inhibition;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2003;	CCR5 and gp41 fusion inhibition;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2003;	Methylnaltrexone;	Phase III;	Joint Program;	61;	;	;		2009;	-0.8294;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2003;	Methylnaltrexone;	Phase I;	Joint Program;	61;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2003;	Methylnaltrexone;	Phase I;	Joint Program;	61;	26;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2003;	ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	PRO 542     ;	Phase 2;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		2007;	-0.9167;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	PRO 140 ;	 Preclinical;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	Monoclonal antibody;	Preclinical;	PSMA;	22;	;	;		2010;	-0.2727;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	Viral-vector vaccine;	Preclinical;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	Recombinant protein vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	CCR5 and gp41 fusion inhibition;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		2006;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	Methylnaltrexone;	Phase III;	Joint Program;	61;	;	;		2009;	-0.8294;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	Methylnaltrexone;	Phase II;	Joint Program;	61;	26;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	Methylnaltrexone;	Phase 1;	Joint Program;	61;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2004;	ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	Methylnaltrexone;	Phase III;	Joint Program;	61;	;	;		2009;	-0.8294;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	Methylnaltrexone;	Phase II;	Joint Program;	61;	26;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	Methylnaltrexone;	Phase 1;	Joint Program;	61;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	PRO 542     ;	Phase 2;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		2007;	-0.996;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	PRO 140 ;	 Preclinical;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	Monoclonal antibody;	 Preclinical;	PSMA;	22;	;	;		2010;	-0.2727;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	Viral-vector vaccine;	 Preclinical;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	Recombinant protein vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2005;	Hepatitis C therapeutic;	Research;	2.antiviral binding agent ("UnAB");	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2006;	Methylnaltrexone;	Phase III;	Joint Program;	61;	;	;		2009;	-0.8294;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2006;	Methylnaltrexone;	Phase III;	Joint Program;	61;	26;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2006;	PRO 140 ;	Phase I;	 monoclonal antibody,;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2006;	ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2006;	Monoclonal antibody;	 Preclinical;	PSMA;	22;	;	;		2010;	-0.2727;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2006;	Viral-vector vaccine;	 Preclinical;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2006;	Recombinant protein vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2006;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2006;	Hepatitis C therapeutic;	Research;	2.antiviral binding agent ("UnAB");	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2007;	Methylnaltrexone;	Phase III;	Joint Program;	26;	;	;		2009;	5.1429;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2007;	Methylnaltrexone;	Phase III;	Joint Program;	26;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2007;	PRO 140 ;	Phase I;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2007;	ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2007;	Hepatitis C therapeutic;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2007;	Monoclonal antibody;	 Preclinical;	PSMA;	22;	;	;		2010;	-0.2727;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2007;	Viral-vector vaccine;	 Preclinical;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2007;	Recombinant protein vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2007;	GMK.;	Phase III;	1.ganglioside conjugate vaccine technology, which the Company uses in its cancer program;	22;	;	;		2009;	-1;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2008;	RELISTOR-Subcutaneous;	Marketed;	mu-opioid-receptor antagonist ;	26;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2008;	RELISTOR-Subcutaneous;	Phase 3;	mu-opioid-receptor antagonist ;	62;	26;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2008;	RELISTOR-Subcutaneous;	Phase 2;	mu-opioid-receptor antagonist ;	26;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2008;	RELISTOR-Subcutaneous;	Phase III;	mu-opioid-receptor antagonist ;	26;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2008;	PRO 140 ;	Phase II;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2008;	ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2008;	Hepatitis C therapeutic;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2008;	Monoclonal antibody;	 Preclinical;	PSMA;	22;	;	;		2010;	0.1429;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2008;	Viral-vector vaccine;	 Preclinical;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2008;	Recombinant protein vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	RELISTOR-Subcutaneous;	Marketed;	mu-opioid-receptor antagonist ;	26;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	RELISTOR-Subcutaneous;	Phase 3;	mu-opioid-receptor antagonist ;	62;	26;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	RELISTOR-Subcutaneous;	Phase 2;	mu-opioid-receptor antagonist ;	26;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	RELISTOR-Oral;	Phase II;	mu-opioid-receptor antagonist ;	26;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	PRO 140 ;	Phase II;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	PRO 206;	Preclinical;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	Viral-vector vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	Viral-vector vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	Viral-vector vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	Recombinant protein vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	Recombinant protein vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2009;	PSMA ADC;	 Preclinical;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	RELISTOR-Subcutaneous;	Marketed;	mu-opioid-receptor antagonist ;	26;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	RELISTOR-Subcutaneous;	Phase 3;	mu-opioid-receptor antagonist ;	62;	26;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	RELISTOR-Oral;	Phase II;	mu-opioid-receptor antagonist ;	26;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	Viral-vector vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	Viral-vector vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	Viral-vector vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	Recombinant protein vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	Recombinant protein vaccine;	Phase I;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	PSMA ADC;	Phase 1;	PSMA;	22;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	PRO 140 ;	Phase II;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs19970000835887;	PROGENICS PHARMACEUTICALS INC;	10-K;	1996;	2010;	ProVax;	Research;	2.antiviral binding agent ("UnAB") technology, which the Company uses in its HIV program.;	23;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	S-1;	2003;	2003;	Rapinex powder-for- suspension;	NDA ;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	S-1;	2003;	2003;	Rapinex powder-for- suspension;	Phase III ;	immediate-release PPI;	26;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	S-1;	2003;	2003;	Rapinex capsule;	Preclinical;	immediate-release PPI;	21;	26;	;		2011;	-0.0967;		
wvcs20040001172480;	SANTARUS INC;	S-1;	2003;	2003;	Rapinex chewable tablet;	Preclinical;	immediate-release PPI;	21;	26;	;		2009;	0.458;		
wvcs20040001172480;	SANTARUS INC;	424;	2003;	2004;	Rapinex powder-for- suspension;	NDA ;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	424;	2003;	2004;	Rapinex powder-for- suspension;	Phase III ;	immediate-release PPI;	26;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	424;	2003;	2004;	Rapinex capsule;	Preclinical;	immediate-release PPI;	21;	26;	;		2011;	-0.0967;		
wvcs20040001172480;	SANTARUS INC;	424;	2003;	2004;	Rapinex chewable tablet;	Preclinical;	immediate-release PPI;	21;	26;	;		2009;	0.458;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2005;	Zegerid powder-for- suspension;	Marketed;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2005;	Zegerid  powder-for- suspension;	Marketed;	immediate-release PPI;	26;	;	;		2010;	-0.2393;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2005;	Zegerid capsule;	Clinical Trials;	immediate-release PPI;	21;	26;	;		2011;	-0.0967;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2005;	Zegerid  chewable tablet;	Clinical Trials;	immediate-release PPI;	21;	26;	;		2009;	0.458;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2006;	Zegerid powder-for- suspension;	Marketed;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2006;	Zegerid  powder-for- suspension;	Marketed;	immediate-release PPI;	26;	;	;		2010;	-0.2393;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2006;	Zegerid capsule;	Marketed;	immediate-release PPI;	21;	26;	;		2011;	-0.0967;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2006;	Zegerid  chewable tablet;	NDA;	immediate-release PPI;	21;	26;	;		2009;	0.458;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2007;	Zegerid powder-for- suspension;	Marketed;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2007;	Zegerid  powder-for- suspension;	Marketed;	immediate-release PPI;	26;	;	;		2010;	-0.2393;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2007;	Zegerid capsule;	Marketed;	immediate-release PPI;	21;	26;	;		2011;	-0.0967;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2007;	Zegerid  chewable tablet;	NDA;	immediate-release PPI;	21;	26;	;		2009;	0.29;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2008;	Zegerid powder-for- suspension;	Marketed;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2008;	Zegerid  powder-for- suspension;	Marketed;	immediate-release PPI;	26;	;	;		2010;	0.1897;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2008;	Zegerid capsule;	Marketed;	immediate-release PPI;	21;	26;	;		2011;	-0.0967;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2009;	Zegerid® Capsules and Powder for Oral Suspension ;	Marketed;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2009;	Glumetza® Extended Release Tablets ;	Marketed;	patented drug delivery technology;	24;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2009;	Zegerid® Tablet Formulation;	NDA;	immediate-release PPI;	21;	26;	;		2011;	0.5283;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2009;	OTC Zegerid;	NDA;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2009;	Budesonide MMX®;	 phase III;	 MMX technology;	26;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2009;	Rifamycin SV MMX®;	phase III ;	 MMX technology;	26;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2010;	Zegerid® Capsules and Powder for Oral Suspension ;	Marketed;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2010;	Glumetza® Extended Release Tablets ;	Marketed;	patented drug delivery technology;	24;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2010;	Immediate-release Omeprazole Tablets;	NDA;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2010;	OTC Zegerid;	NDA;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2010;	Budesonide MMX®;	 phase III;	 MMX technology;	26;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2010;	Rifamycin SV MMX®;	phase III ;	 MMX technology;	26;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2011;	Zegerid® Capsules and Powder for Oral Suspension ;	Marketed;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2011;	Glumetza® Extended Release Tablets ;	Marketed;	patented drug delivery technology;	24;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2011;	Cycloset® (bromocriptine mesylate) tablets;	Marketed ;	dopamine receptor;	24;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2011;	Rhucin® ;	phase III;	transgenic technology;	30;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2011;	Budesonide MMX®;	 phase III;	 MMX technology;	26;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2011;	Rifamycin SV MMX®;	phase III ;	 MMX technology;	26;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2011;	Merck Zegerid OTC®;	Marketed ;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2011;	GlaxoSmithKline Immediate-release Omeprazole products;	NDA;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2012;	Fenoglide® (fenofibrate) tablets;	Marketed ;	dopamine receptor;	24;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2012;	Zegerid® Capsules and Powder for Oral Suspension ;	Marketed;	immediate-release PPI;	21;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2012;	Glumetza® Extended Release Tablets ;	Marketed;	patented drug delivery technology;	24;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2012;	Cycloset® (bromocriptine mesylate) tablets;	Marketed ;	dopamine receptor;	24;	26;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2012;	Uceris™ (budesonide) tablets;	NDA;	 MMX technology;	26;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2012;	Rifamycin SV MMX®;	phase III ;	 MMX technology;	26;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2012;	Rhucin® ;	phase III;	transgenic technology;	30;	;	;		;	;		
wvcs20040001172480;	SANTARUS INC;	10-K;	2003;	2012;	SAN-300 (anti-VLA-1 mAb;	Phase I;	monoclonal antibody;	5;	20;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	S-1;	2000;	2000;	SGN-15 ;	Phase II;	mAb-drug conjugate;	22;	;	;		2007;	-0.6585;		
wvcs20010001060736;	SEATTLE GENETICS INC;	S-1;	2000;	2000;	SGN-10;	Phase I;	Single-chain immunotoxin;	22;	;	;		2004;	-0.9375;		
wvcs20010001060736;	SEATTLE GENETICS INC;	S-1;	2000;	2000;	SGN-14;	Preclinical;	Genetically-engineered mAb;	27;	;	;		2004;	-0.7143;		
wvcs20010001060736;	SEATTLE GENETICS INC;	424;	2000;	2001;	SGN-15 ;	Phase II;	mAb-drug conjugate;	22;	;	;		2007;	-0.6585;		
wvcs20010001060736;	SEATTLE GENETICS INC;	424;	2000;	2001;	SGN-10;	Phase I;	Single-chain immunotoxin;	22;	;	;		2004;	-0.9375;		
wvcs20010001060736;	SEATTLE GENETICS INC;	424;	2000;	2001;	SGN-14;	Preclinical;	Genetically engineered monoclonal antibody;	27;	;	;		2004;	-0.7143;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2002;	SGN-15 ;	Phase II;	mAb-drug conjugate;	22;	;	;		2007;	-0.6585;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2002;	SGN-10;	Phase I;	Single-chain immunotoxin;	22;	;	;		2004;	-0.9512;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2002;	SGN-30;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		2009;	-0.6316;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2002;	SGN-14;	Phase I;	Genetically-engineered mAb;	27;	;	;		2004;	-0.8947;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2003;	SGN-15 ;	Phase II;	mAb-drug conjugate;	22;	;	;		2007;	-0.6585;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2003;	SGN-30;	Phase I;	Genetically engineered monoclonal antibody;	;	;	;		2009;	-0.6316;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2003;	SGN-40;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2003;	SGN-15 ;	Phase II;	mAb-drug conjugate;	22;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2004;	SGN-15 ;	Phase II;	mAb-drug conjugate;	22;	;	;		2007;	-0.6585;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2004;	SGN-30;	Phase II;	Genetically engineered monoclonal antibody;	;	;	;		2009;	-0.6316;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2004;	SGN-40;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2004;	SGN-40;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2004;	SGN-30;	Phase II;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2004;	SGN-35;	Pre Clinical;	mAb-drug conjugate;	;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2005;	SGN-15 ;	Phase II;	mAb-drug conjugate;	22;	;	;		2007;	-0.906;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2005;	SGN-30;	Phase II;	Genetically engineered monoclonal antibody;	;	;	;		2009;	-0.6316;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2005;	SGN-40;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2005;	SGN-40;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2005;	SGN-30;	Phase II;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2005;	SGN-35;	Pre Clinical;	ADC;	;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2006;	SGN-33;	Phase I;	Genetically engineered monoclonal antibody;	9;	27;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2006;	SGN-30;	Phase II;	Genetically engineered monoclonal antibody;	;	;	;		2009;	-0.6316;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2006;	SGN-30;	Phase II;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2006;	SGN-30;	Phase II;	Genetically engineered monoclonal antibody;	;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2006;	SGN-40;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2006;	SGN-40;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2006;	SGN-33;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2006;	SGN-35;	Phase I;	ADC;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2007;	SGN-33;	Phase I;	Genetically engineered monoclonal antibody;	9;	27;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2007;	SGN-30;	Phase II;	Genetically engineered monoclonal antibody;	;	;	;		2009;	2.5;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2007;	SGN-30;	Phase II;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2007;	SGN-30;	Phase II;	Genetically engineered monoclonal antibody;	;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2007;	SGN-40;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2007;	SGN-40;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2007;	SGN-33;	Phase I;	Genetically engineered monoclonal antibody;	;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2007;	SGN-35;	Phase I;	ADC;	;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2008;	SGN-40;	Phase II;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2008;	SGN-40;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2008;	SGN-33;	Phase II;	Genetically engineered monoclonal antibody;	;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2008;	SGN-35;	Phase I;	ADC;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2008;	SGN-75;	Preclinical;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2009;	SGN-35;	Phase II;	ADC;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2009;	Dacetuzumab (SGN-40);	Phase III;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2009;	Lintuzumab (SGN-33);	Phase II;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2009;	Lintuzumab;	Phase II;	Genetically engineered monoclonal antibody;	27;	;	;		2011;	9;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2009;	SGN-75;	Preclinical;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2010;	Brentuximab vedotin;	Phase II;	Genetically engineered monoclonal antibody;	;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2010;	Brentuximab vedotin (SGN-35);	Phase II;	ADC;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2010;	Lintuzumab (SGN-33);	Phase II;	Genetically engineered monoclonal antibody;	;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2010;	Dacetuzumab (SGN-40);	Phase III;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2010;	SGN-75;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2011;	Brentuximab vedotin (SGN-35);	Marketed;	Genetically engineered monoclonal antibody;	;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2011;	Brentuximab vedotin (SGN-35);	Marketed;	ADC;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2011;	SGN-75;	Phase I;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2011;	Dacetuzumab (SGN-40);	Phase III;	Genetically engineered monoclonal antibody;	27;	;	;		;	;		
wvcs20010001060736;	SEATTLE GENETICS INC;	10-K;	2000;	2011;	ASG-5ME;	Phase I;	ADC;	22;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	S-1;	2004;	2004;	rhIGF-1;	Phase III ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	S-1;	2004;	2004;	rhIGF-1;	Phase III ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	S-1;	2004;	2004;	rhIGF-1;	Phase II ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	S-1;	2004;	2004;	rhIGF-1;	Phase II ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	S-1;	2004;	2004;	rhIGF-1;	Phase II ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	424;	2004;	2004;	rhIGF-1;	Phase III ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	424;	2004;	2004;	rhIGF-1;	Phase III ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	424;	2004;	2004;	rhIGF-1;	Phase II ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	424;	2004;	2004;	rhIGF-1;	Phase II ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	424;	2004;	2004;	rhIGF-1;	Phase II ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2005;	rhIGF-1;	Phase III ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2005;	rhIGF-1;	Phase III ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2005;	rhIGF-1;	Assessing potential development strategy;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2005;	rhIGF-1;	Assessing potential development strategy;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2006;	Increlex;	Marketed;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2006;	Increlex;	Phase III ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2006;	Increlex;	Assessing potential development strategy;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2006;	Increlex;	Assessing potential development strategy;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2007;	Increlex;	Marketed;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2007;	Increlex;	Phase III ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2007;	 Somatuline® Autogel®;	Marketed;	Somatostatin analogues;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2008;	Increlex;	Marketed;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2008;	Increlex;	Phase III ;	IGF-1;	24;	;	;		;	;		
wvcs20040001262175;	TERCICA INC;	10-K;	2004;	2008;	 Somatuline® Autogel®;	Marketed;	Somatostatin analogues;	;	;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	S-1;	2004;	2004;	GSK 159797;	Phase II;	Multivalency;	5;	29;	;		2007;	0;		
wvcs20040001080014;	THERAVANCE INC;	S-1;	2004;	2004;	 GSK 159901;	Phase II;	Multivalency;	5;	29;	;		2007;	0;		
wvcs20040001080014;	THERAVANCE INC;	S-1;	2004;	2004;	TD-5742;	Pre clinical;	Multivalency;	5;	29;	;		2008;	-0.5;		
wvcs20040001080014;	THERAVANCE INC;	S-1;	2004;	2004;	 telavancin;	Phase 2 ;	Multivalency;	23;	;	;		2007;	0.8409;		
wvcs20040001080014;	THERAVANCE INC;	S-1;	2004;	2004;	TD-6301;	Phase I;	Multivalency;	3;	;	;		2007;	-0.7273;		
wvcs20040001080014;	THERAVANCE INC;	S-1;	2004;	2004;	 TD-2749;	Phase I;	Multivalency;	26;	;	;		2009;	-1;		
wvcs20040001080014;	THERAVANCE INC;	S-1;	2004;	2004;	   TD-4756;	Pre clinical;	Multivalency;	61;	9;	25;		2007;	-1;		
wvcs20040001080014;	THERAVANCE INC;	424;	2004;	2004;	GSK 159797;	Phase II;	Multivalency;	5;	29;	;		2007;	0;		
wvcs20040001080014;	THERAVANCE INC;	424;	2004;	2004;	 GSK 159901;	Phase II;	Multivalency;	5;	29;	;		2007;	0;		
wvcs20040001080014;	THERAVANCE INC;	424;	2004;	2004;	TD-5742;	Pre clinical;	Multivalency;	5;	29;	;		2008;	-0.5;		
wvcs20040001080014;	THERAVANCE INC;	424;	2004;	2004;	 telavancin;	Phase 2 ;	Multivalency;	23;	;	;		2007;	0.8409;		
wvcs20040001080014;	THERAVANCE INC;	424;	2004;	2004;	TD-6301;	Phase I;	Multivalency;	3;	;	;		2007;	-0.7273;		
wvcs20040001080014;	THERAVANCE INC;	424;	2004;	2004;	 TD-2749;	Phase I;	Multivalency;	26;	;	;		2009;	-1;		
wvcs20040001080014;	THERAVANCE INC;	424;	2004;	2004;	   TD-4756;	Pre clinical;	Multivalency;	61;	9;	25;		2007;	-1;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2005;	GSK 159797;	Phase II;	Multivalency;	5;	29;	;		2007;	-0.6;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2005;	 GSK 159901;	Phase II;	Multivalency;	5;	29;	;		2007;	-0.6;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2005;	TD-5742;	Phase I;	Multivalency;	5;	29;	;		2008;	-0.5;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2005;	 telavancin;	Phase III;	Multivalency;	23;	;	;		2007;	39.5;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2005;	TD-6301;	Phase I;	Multivalency;	3;	;	;		2007;	0.5;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2005;	 TD-2749;	Phase I;	Multivalency;	26;	;	;		2009;	-1;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2005;	   TD-4756;	Pre clinical;	Multivalency;	61;	9;	25;		2007;	-1;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2005;	GSK 1578007;	Phase II;	Multivalency;	5;	29;	;		2007;	-1;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2006;	 telavancin cSSSI ;	Phase III;	Multivalency;	8;	23;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2006;	 telavancin HAP;	Phase III;	Multivalency;	23;	29;	;		2011;	-0.5638;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2006;	 Beyond Advair;	 Phase 2;	Multivalency;	5;	29;	;		2010;	-0.25;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2006;	TD-5742;	Phase I;	Multivalency;	5;	29;	;		2008;	-0.75;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2006;	 TD-5108;	Pre clinical;	Multivalency;	26;	;	;		2011;	0.2;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2006;	 TD-2749;	Phase I;	Multivalency;	26;	;	;		2009;	-1;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2007;	 telavancin cSSSI ;	NDA;	Multivalency;	8;	23;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2007;	 telavancin HAP;	Phase III;	Multivalency;	23;	29;	;		2011;	-0.5638;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2007;	TD-1792;	 Phase 2;	Multivalency;	23;	;	;		2010;	-0.8182;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2007;	 Beyond Advair;	 Phase 2;	Multivalency;	5;	29;	;		2010;	-0.25;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2007;	TD-5742 t (LAMA);	Phase I;	Multivalency;	5;	29;	;		2010;	0;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2007;	GSK961081  (MABA);	Phase I;	Multivalency;	5;	29;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2007;	 TD-5108;	Phase I;	Multivalency;	26;	;	;		2011;	0.2;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2007;	 TD-2749;	Phase I;	Multivalency;	26;	;	;		2009;	-1;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2008;	 telavancin cSSSI ;	NDA;	Multivalency;	8;	23;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2008;	 telavancin HAP;	Phase III;	Multivalency;	23;	29;	;		2011;	-0.5638;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2008;	TD-1792;	 Phase 2;	Multivalency;	23;	;	;		2010;	-0.9732;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2008;	 Beyond Advair;	 Phase 2;	Multivalency;	5;	29;	;		2010;	-0.9799;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2008;	TD-5742 t (LAMA);	Phase I;	Multivalency;	5;	29;	;		2010;	-0.9933;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2008;	Horizon ;	 Phase 2;	Multivalency;	5;	29;	;		2011;	-0.9574;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2008;	GSK961081  (MABA);	Phase II;	Multivalency;	5;	29;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2008;	 TD-5108;	Phase II;	Multivalency;	26;	;	;		2011;	0.2;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2009;	 telavancin cSSSI ;	NDA;	Multivalency;	8;	23;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2009;	 telavancin HAP;	NDA;	Multivalency;	23;	29;	;		2011;	15.25;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2009;	Horizon ;	 Phase 2;	Multivalency;	5;	29;	;		2011;	-0.5;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2009;	GSK961081  (MABA);	Phase II;	Multivalency;	5;	29;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2009;	 TD-5108;	Phase II;	Multivalency;	26;	;	;		2011;	0.5;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2010;	telavancin NP ;	NDA;	Multivalency;	8;	23;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2010;	TD-1792;	 Phase 2;	Multivalency;	23;	;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2010;	RELOVAIRTM ;	Phase III;	Multivalency;	29;	;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2010;	RELOVAIRTM ;	Phase II;	Multivalency;	5;	29;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2010;	GSK961081  (MABA);	Phase II;	Multivalency;	5;	29;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2011;	telavancin NP ;	NDA;	Multivalency;	8;	23;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2011;	TD-1792;	 Phase 2;	Multivalency;	23;	;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2011;	RELOVAIRTM ;	Phase III;	Multivalency;	29;	;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2011;	RELOVAIRTM ;	Phase III;	Multivalency;	5;	29;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2011;	LAMA GSK573719;	Phase III;	Multivalency;	29;	;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2011;	GSK961081  (MABA);	Phase II;	Multivalency;	5;	29;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2011;	TD-1211;	Phase II;	Multivalency;	40;	;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2011;	TD-9855;	Phase I;	Multivalency;	62;	42;	;		;	;		
wvcs20040001080014;	THERAVANCE INC;	10-K;	2004;	2011;	TD-5108;	Phase I;	Multivalency;	40;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	S-1;	2000;	2000;	Genotyping Product Catalog and Panels;	Preclinical;	Invader operating system;	30;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	S-1;	2000;	2000;	Gene Expression Product Catalog and Panels.;	Preclinical;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	S-1;	2000;	2000;	Genotyping Product Catalog and Panels;	Preclinical;	Invader operating system;	23;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	S-1;	2000;	2000;	Quantification Product Catalog and Panels.;	Preclinical;	Invader operating system;	23;	30;	;		2003;	0.8333;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	424;	2000;	2001;	Genotyping Product Catalog and Panels;	Preclinical;	Invader operating system;	30;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	424;	2000;	2001;	Gene Expression Product Catalog and Panels.;	Preclinical;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	424;	2000;	2001;	Genotyping Product Catalog and Panels;	Preclinical;	Invader operating system;	23;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	424;	2000;	2001;	Quantification Product Catalog and Panels.;	Preclinical;	Invader operating system;	23;	30;	;		2003;	10;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2002;	Genotyping Product Catalog and Panels;	Marketed;	Invader operating system;	30;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2002;	Gene Expression Product Catalog and Panels.;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2002;	Genotyping Product Catalog and Panels;	Marketed;	Invader operating system;	23;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2002;	Plant and Animal Agriculture Products;	Marketed;	Invader operating system;	30;	;	;		2005;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2003;	Genotyping Product Catalog and Panels;	Marketed;	Invader operating system;	30;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2003;	Gene Expression Product Catalog and Panels.;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2003;	Genotyping Product Catalog and Panels;	Marketed;	Invader operating system;	23;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2003;	Plant and Animal Agriculture Products;	Marketed;	Invader operating system;	30;	;	;		2005;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	Cystic Fibrosis Screen;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	Connexin 26;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	Factor V Leiden;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	Factor II;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	Factor VII;	Marketed;	Invader operating system;	30;	;	;		2006;	-0.8519;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	MTHFR;	Marketed;	Invader operating system;	21;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	ApoE;	Marketed;	Invader operating system;	21;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	PAI-1;	Marketed;	Invader operating system;	30;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	Tay-Sachs Disease (;	Marketed;	Invader operating system;	30;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	HCV Genotyping;	Development;	Invader operating system;	23;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	HCV Viral Load;	Development;	Invader operating system;	23;	;	;		2006;	-0.75;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	HBV Genotyping;	Development;	Invader operating system;	23;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	SNP Genotyping;	Marketed;	Invader operating system;	30;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	Gene Expression;	Marketed;	Invader operating system;	30;	;	;		2006;	0.25;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	miRNA;	Marketed;	Invader operating system;	30;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2004;	2D6 gene variation;	Marketed;	Invader operating system;	30;	;	;		2006;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	HCV;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	CFTR;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	CYP450 2D6;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	HPV;	Marketed;	Invader operating system;	23;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	Connexin 26;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	Factor V Leiden;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	Factor II;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	MTHFR;	Marketed;	Invader operating system;	21;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	ApoE;	Marketed;	Invader operating system;	21;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	Herpes Simplex Viruses 1 and 2;	Development;	Invader operating system;	23;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	CFTR with microfluidic format;	Development;	Invader operating system;	23;	;	;		2007;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2005;	Varicella-Zoster Virus;	Development;	Invader operating system;	23;	;	;		2007;	-1;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2006;	HCV;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2006;	CFTR;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2006;	CYP450 2D6;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2006;	HPV;	Marketed;	Invader operating system;	23;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2006;	Connexin 26;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2006;	Factor V Leiden;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2006;	Factor II;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2006;	MTHFR;	Marketed;	Invader operating system;	21;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2006;	ApoE;	Marketed;	Invader operating system;	21;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2006;	Herpes Simplex Viruses 1 and 2;	Development;	Invader operating system;	23;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	HCV;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	CFTR;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	CYP450 2D6;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	HPV;	Marketed;	Invader operating system;	23;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	Connexin 26;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	Factor V Leiden;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	Factor II;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	MTHFR;	Marketed;	Invader operating system;	21;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	ApoE;	Marketed;	Invader operating system;	21;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	Herpes Simplex Viruses 1 and 2;	Development;	Invader operating system;	23;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	Plasminogen Activator Inhibitor-1 (PAI-1) (4G/5G);	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	Warfarin;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	Platelet Glycoprotein IIIa;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2007;	Herpes Simplex Viruses 1 and 2;	Development;	Invader operating system;	23;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	HCV;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	CFTR;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	CYP450 2D6;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	HPV;	Marketed;	Invader operating system;	23;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	Connexin 26;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	Factor V Leiden;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	Factor II;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	MTHFR;	Marketed;	Invader operating system;	21;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	ApoE;	Marketed;	Invader operating system;	21;	30;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	Herpes Simplex Viruses 1 and 2;	Development;	Invader operating system;	23;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	Plasminogen Activator Inhibitor-1 (PAI-1) (4G/5G);	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	Warfarin;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	Platelet Glycoprotein IIIa;	Marketed;	Invader operating system;	30;	;	;		;	;		
wvcs20010001120438;	THIRD WAVE TECHNOLOGIE;	10-K;	2000;	2008;	Herpes Simplex Viruses 1 and 2;	Development;	Invader operating system;	23;	;	;		;	;		
wvcs19970001020910;	TRANSCEND THERAPEUTICS INC;	S-1;	1997;	1997;	Procysteine i.v;	Phase II;	intracellular glutathione-repleting agent;	9;	29;	;		;	;		
wvcs19970001020910;	TRANSCEND THERAPEUTICS INC;	S-1;	1997;	1997;	Procysteine i.v;	Phase II;	intracellular glutathione-repleting agent;	25;	;	;		;	;		
wvcs19970001020910;	TRANSCEND THERAPEUTICS INC;	S-1;	1997;	1997;	Procysteine (oral);	Phase I/II;	intracellular glutathione-repleting agent;	;	;	;		;	;		
wvcs19970001020910;	TRANSCEND THERAPEUTICS INC;	S-1;	1997;	1997;	TR-500 compounds;	Pre Clinical;	intracellular glutathione-repleting agent;	27;	;	;		;	;		
wvcs19970001020910;	TRANSCEND THERAPEUTICS INC;	S-1;	1997;	1997;	Procysteine i.v;	Phase II;	intracellular glutathione-repleting agent;	9;	29;	;		;	;		
wvcs19970001020910;	TRANSCEND THERAPEUTICS INC;	S-1;	1997;	1997;	Procysteine i.v;	Phase II;	intracellular glutathione-repleting agent;	25;	;	;		;	;		
wvcs19970001020910;	TRANSCEND THERAPEUTICS INC;	424;	1997;	1997;	Procysteine (oral);	Phase I/II;	intracellular glutathione-repleting agent;	;	;	;		;	;		
wvcs19970001020910;	TRANSCEND THERAPEUTICS INC;	424;	1997;	1997;	TR-500 compounds;	Pre Clinical;	intracellular glutathione-repleting agent;	27;	;	;		;	;		
wvcs19970001020910;	TRANSCEND THERAPEUTICS INC;	10-K;	1997;	1998;	Merged Non Existent;	;	;	;	;	;		;	;		
wvcs19970000932352;	MEGABIOS CORP;	S-1;	1997;	1997;	MB100 Series;	Phase II;	in vivo gene delivery systems;	29;	;	;		2002;	-0.7778;		
wvcs19970000932352;	MEGABIOS CORP;	S-1;	1997;	1997;	MB100 Series;	Pre Clinical;	in vivo gene delivery systems;	5;	29;	;		;	;		
wvcs19970000932352;	MEGABIOS CORP;	S-1;	1997;	1997;	MB200 Series;	Pre Clinical;	in vivo gene delivery systems;	22;	;	;		2001;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	S-1;	1997;	1997;	MB300 Series;	Pre Clinical;	in vivo gene delivery systems;	22;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	S-1;	1997;	1997;	MB400 Series;	Research;	in vivo gene delivery systems;	5;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	S-1;	1997;	1997;	MB400 Series;	Research;	in vivo gene delivery systems;	5;	;	;		;	;		
wvcs19970000932352;	MEGABIOS CORP;	S-1;	1997;	1997;	MB500 Series;	Research;	in vivo gene delivery systems;	23;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	S-1;	1997;	1997;	MB600 Series;	Research;	in vivo gene delivery systems;	40;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	S-1;	1997;	1997;	MB700 Series;	Research;	in vivo gene delivery systems;	22;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	424;	1997;	1997;	MB100 Series;	Phase II;	in vivo gene delivery systems;	29;	;	;		2002;	-0.7778;		
wvcs19970000932352;	MEGABIOS CORP;	424;	1997;	1997;	MB100 Series;	Pre Clinical;	in vivo gene delivery systems;	5;	29;	;		;	;		
wvcs19970000932352;	MEGABIOS CORP;	424;	1997;	1997;	MB200 Series;	Pre Clinical;	in vivo gene delivery systems;	22;	;	;		2001;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	424;	1997;	1997;	MB300 Series;	Pre Clinical;	in vivo gene delivery systems;	22;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	424;	1997;	1997;	MB400 Series;	Research;	in vivo gene delivery systems;	5;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	424;	1997;	1997;	MB400 Series;	Research;	in vivo gene delivery systems;	5;	;	;		;	;		
wvcs19970000932352;	MEGABIOS CORP;	424;	1997;	1997;	MB500 Series;	Research;	in vivo gene delivery systems;	23;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	424;	1997;	1997;	MB600 Series;	Research;	in vivo gene delivery systems;	40;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	424;	1997;	1997;	MB700 Series;	Research;	in vivo gene delivery systems;	22;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB100 Series;	Phase II;	in vivo gene delivery systems;	29;	;	;		2002;	-0.7778;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB100 Series;	Pre Clinical;	in vivo gene delivery systems;	5;	29;	;		;	;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB200 Series;	Pre Clinical;	in vivo gene delivery systems;	22;	;	;		2001;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB300 Series;	Phase II;	in vivo gene delivery systems;	22;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB400 Series;	Research;	in vivo gene delivery systems;	5;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB400 Series;	Research;	in vivo gene delivery systems;	5;	;	;		;	;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB500 Series;	Research;	in vivo gene delivery systems;	23;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB600 Series;	Research;	in vivo gene delivery systems;	40;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB700 Series;	Pre Clinical;	in vivo gene delivery systems;	22;	;	;		2000;	-1;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB800 Series;	Pre Clinical;	in vivo gene delivery systems;	5;	20;	;		2001;	0.1429;		
wvcs19970000932352;	MEGABIOS CORP;	10-K;	1997;	1998;	MB900 Series;	Pre Clinical;	in vivo gene delivery systems;	21;	20;	;		2000;	-1;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	1999;	Interleukin-2 ("IL-2");	Phase II;	plasmid-based gene delivery systems;	22;	;	;		2003;	-1;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	1999;	Interferon-alpha;	Phase II;	plasmid-based gene delivery systems;	22;	;	;		2002;	0;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	1999;	Interleukin-12;	Phase II;	plasmid-based gene delivery systems;	22;	;	;		2002;	1;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	1999;	IL-2/superantigen B;	Phase II;	plasmid-based gene delivery systems;	22;	;	;		2001;	-0.5;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	1999;	BRCA-1;	Pre Clinical;	plasmid-based gene delivery systems;	22;	;	;		2002;	-0.75;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	1999;	dnDel-1 (anti-angiogenesis);	Pre Clinical;	plasmid-based gene delivery systems;	22;	;	;		2001;	-1;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	1999;	VEGF;	Phase II;	plasmid-based gene delivery systems;	21;	;	;		2003;	-0.56;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	1999;	CFTR;	Phase II;	plasmid-based gene delivery systems;	29;	;	;		2002;	-0.7778;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	1999;	RHEUMATOLOGY;	Pre Clinical;	plasmid-based gene delivery systems;	5;	20;	;		2001;	0.7778;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	VEGF;	Phase II;	plasmid-based gene delivery systems;	21;	;	;		2003;	-0.56;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	VEGF;	Phase II;	plasmid-based gene delivery systems;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	VEGF;	Phase II;	plasmid-based gene delivery systems;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	Del-1;	Pre Clinical;	plasmid-based gene delivery systems;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	Del-1;	Pre Clinical;	plasmid-based gene delivery systems;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	Interleukin-2 ("IL-2");	Phase II;	plasmid-based gene delivery systems;	22;	2;	;		2003;	-1;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	Interferon-alpha;	Phase II;	plasmid-based gene delivery systems;	22;	2;	;		2002;	0;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	Interleukin-12;	Phase II;	plasmid-based gene delivery systems;	22;	2;	;		2002;	0;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	Interleukin-2 ("IL-2");	Phase II;	plasmid-based gene delivery systems;	22;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	Interleukin-12;	Phase II;	plasmid-based gene delivery systems;	22;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	CFTR;	Research;	plasmid-based gene delivery systems;	30;	;	;		2002;	-0.5;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	PEGylated ONYX-015;	Pre Clinical;	PEGYLATION TECHNOLOGY;	22;	;	;		2002;	6.75;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	BRCA-1;	Pre Clinical;	plasmid-based gene delivery systems;	22;	;	;		2002;	-0.25;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2000;	PEGylated Factor VIII;	Feasibility   ;	PEGYLATION TECHNOLOGY;	27;	30;	;		2002;	6.75;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	VEGF;	Phase II;	plasmid-based gene delivery systems;	21;	;	;		2003;	1.75;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	VEGF;	Phase II;	plasmid-based gene delivery systems;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	VEGF;	Phase II;	plasmid-based gene delivery systems;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	Del-1;	Pre Clinical;	plasmid-based gene delivery systems;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	Del-1;	Phase I;	plasmid-based gene delivery systems;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	Interleukin-2 ("IL-2");	Phase II;	plasmid-based gene delivery systems;	22;	2;	;		2003;	-1;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	Interleukin-2 ("IL-2");	Phase II;	plasmid-based gene delivery systems;	22;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	Intravenous IL-2;	Phase I;	plasmid-based gene delivery systems;	22;	;	;		2003;	-0.8261;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	IL-2 + superantigen B;	Phase I;	plasmid-based gene delivery systems;	22;	;	;		2003;	-0.9783;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	PEGylated Omniferon™ (IFN-a);	Pre Clinical;	PEGYLATION TECHNOLOGY;	23;	;	;		2003;	-0.6304;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	PEGylated CI-1042;	Pre Clinical;	PEGYLATION TECHNOLOGY;	22;	;	;		2003;	-0.6304;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2001;	EpoSwitch™;	Pre Clinical;	plasmid-based gene delivery systems;	27;	20;	;		2004;	-0.4;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2002;	Del-1;	Pre Clinical;	PINC™ (Polymeric, non-condensing) polymers ;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2002;	Del-1;	Phase I;	PINC™ (Polymeric, non-condensing) polymers ;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2002;	EpoSwitch™;	Pre Clinical;	GeneSwitch®;	27;	20;	;		2004;	-0.8696;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2002;	PEDF;	Research;	PINC™ (Polymeric, non-condensing) polymers ;	22;	;	;		2004;	-1;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2003;	Del-1;	Pre Clinical;	PINC™ (Polymeric, non-condensing) polymers ;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2003;	Del-1;	Phase II;	PINC™ (Polymeric, non-condensing) polymers ;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2003;	Del-1;	Research;	PINC™ (Polymeric, non-condensing) polymers ;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2003;	DNA Vaccine;	Phase I ;	PINC™ gene delivery technology;	23;	;	;		2006;	0.6667;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2004;	Deltavasc;	Pre Clinical;	PINC™ (Polymeric, non-condensing) polymers ;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2004;	Deltavasc;	Phase II;	PINC™ (Polymeric, non-condensing) polymers ;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2004;	DNA Vaccine;	Phase I ;	PINC™ gene delivery technology;	23;	;	;		2006;	-0.8913;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2005;	VLTS 934;	Phase II;	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology;	21;	;	;		2009;	0;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2005;	Deltavasc;	Pre Clinical;	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2005;	DEL-1 Antibody Product;	Phase I;	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology;	22;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2005;	DEL-1 Protein Product;	Phase I;	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2006;	VLTS 934;	Phase II;	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology;	21;	;	;		2009;	0;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2006;	Deltavasc;	Phase II;	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2006;	DEL-1 Antibody Product;	Phase I;	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology;	22;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2006;	DEL-1 Protein Product;	Phase I;	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology;	21;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2007;	URG301/URG 302;	 IND ;	;	3;	;	;		2009;	-0.413;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2007;	URG101;	Phase III;	;	62;	3;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2007;	URG101;	Phase II;	;	22;	70;	3;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2007;	URG101;	Pre Clinical;	;	3;	;	;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2007;	URG301;	Phase II;	;	9;	70;	3;		;	;		
wvcs19970000932352;	VALENTIS INC;	10-K;	1997;	2007;	URG301;	Phase II;	;	3;	;	;		;	;		
wvcs19970000932352;	Urigen Pharmaceuticals, Inc;	10-K;	1997;	2008;	URG101;	Phase II;	;	62;	3;	;		;	;		
wvcs19970000932352;	Urigen Pharmaceuticals, Inc;	10-K;	1997;	2008;	URG301;	 IND;	urethral suppository;	70;	3;	;		;	;		
wvcs19970000932352;	Urigen Pharmaceuticals, Inc;	10-K;	1997;	2008;	URG301;	 IND;	intraurethral suppository;	9;	3;	;		;	;		
wvcs19970000932352;	Urigen Pharmaceuticals, Inc;	10-K;	1997;	2009;	URG101;	Phase II;	bladder instillation;	62;	3;	;		;	;		
wvcs19970000932352;	Urigen Pharmaceuticals, Inc;	10-K;	1997;	2009;	URG301;	 IND;	urethral suppository;	70;	3;	;		;	;		
wvcs19970000932352;	Urigen Pharmaceuticals, Inc;	10-K;	1997;	2009;	URG301;	 IND;	intraurethral suppository;	9;	3;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	S-1;	1997;	1997;	ZstatFlu;	Phase III;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	S-1;	1997;	1997;	VIRAZYME CULTURE SCREEN.;	marketed;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	S-1;	1997;	1997;	VIRASTAT PARAINFLUENZA 1, 2 AND 3;	marketed;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	S-1;	1997;	1997;	VIRAZYME INFLUENZA ID A/B.;	clinical studies;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	S-1;	1997;	1997;	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES;	clinical studies;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	424;	1997;	1997;	ZstatFlu;	Phase III;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	424;	1997;	1997;	VIRAZYME CULTURE SCREEN.;	marketed;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	424;	1997;	1997;	VIRASTAT PARAINFLUENZA 1, 2 AND 3;	marketed;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	424;	1997;	1997;	VIRAZYME INFLUENZA ID A/B.;	clinical studies;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	424;	1997;	1997;	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES;	clinical studies;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	1998;	ZstatFlu;	Marketed;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	1998;	VIRAZYME CULTURE SCREEN.;	marketed;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	1998;	VIRASTAT PARAINFLUENZA 1, 2 AND 3;	marketed;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	1998;	VIRAZYME INFLUENZA ID A/B.;	clinical studies;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	1998;	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES;	clinical studies;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	1999;	ZstatFlu;	Marketed;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	1999;	VIRAZYME CULTURE SCREEN.;	marketed;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	1999;	VIRASTAT PARAINFLUENZA 1, 2 AND 3;	marketed;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	1999;	VIRAZYME INFLUENZA ID A/B.;	clinical studies;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	1999;	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES;	clinical studies;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2000;	ZstatFlu;	Marketed;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2000;	VIRAZYME CULTURE SCREEN.;	marketed;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2000;	VIRASTAT PARAINFLUENZA 1, 2 AND 3;	marketed;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2000;	VIRAZYME INFLUENZA ID A/B.;	marketed;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2000;	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES;	clinical studies;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2001;	ZstatFlu;	Marketed;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2001;	VIRAZYME CULTURE SCREEN.;	marketed;	ViraZyme technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2001;	VIRASTAT PARAINFLUENZA 1, 2 AND 3;	marketed;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2001;	VIRAZYME INFLUENZA ID A/B.;	marketed;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2001;	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES;	clinical studies;	MAb technology;	;	;	;		;	;		
wvcs19970000921439;	ZYMETX INC;	10-K;	1997;	2001;	ADVANCED VIRAL TESTING PLATFORM TECHNOLOGY.;	Development;	MAb technology;	;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	S-1;	2003;	2003;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	S-1;	2003;	2003;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	S-1;	2003;	2003;	 Thalomid® ;	Phase II;	 S.T.E.P.S.® program ;	22;	28;	20;		;	;		
wvcs20030001203866;	PHARMION CORP;	S-1;	2003;	2003;	 Thalomid® ;	Phase II;	 S.T.E.P.S.® program ;	22;	28;	20;		;	;		
wvcs20030001203866;	PHARMION CORP;	S-1;	2003;	2003;	 Thalomid® ;	Phase II;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	S-1;	2003;	2003;	 Thalomid® ;	Phase II;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	S-1;	2003;	2003;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	S-1;	2003;	2003;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	S-1;	2003;	2003;	Vidaza;	Phase III;	;	27;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	S-1;	2003;	2003;	Refludan®;	Marketed;	;	21;	27;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	424;	2003;	2003;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	424;	2003;	2003;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	424;	2003;	2003;	 Thalomid® ;	Phase II;	 S.T.E.P.S.® program ;	22;	28;	20;		;	;		
wvcs20030001203866;	PHARMION CORP;	424;	2003;	2003;	 Thalomid® ;	Phase II;	 S.T.E.P.S.® program ;	22;	28;	20;		;	;		
wvcs20030001203866;	PHARMION CORP;	424;	2003;	2003;	 Thalomid® ;	Phase II;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	424;	2003;	2003;	 Thalomid® ;	Phase II;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	424;	2003;	2003;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	424;	2003;	2003;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	424;	2003;	2003;	Vidaza;	Phase III;	;	27;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	424;	2003;	2003;	Refludan®;	Marketed;	;	21;	27;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2004;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2004;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2004;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2004;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2004;	Vidaza;	NDA;	;	27;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2004;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2004;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2004;	Refludan®;	Marketed;	;	21;	27;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	 Thalomid® ;	Phase III;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	Vidaza;	MArketed;	;	27;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	Vidaza;	Phase II;	;	27;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	Vidaza;	Phase II;	;	22;	27;	20;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	Satraplatin;	Phase III;	;	22;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	Satraplatin;	Phase III;	;	22;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	MGCD0103;	Phase II;	 HDAC inhibitor program;	22;	27;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2005;	Refludan®;	Marketed;	;	21;	27;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	 Thalomid® ;	Marketed;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	 Thalomid® ;	marketed;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	Vidaza;	MArketed;	;	27;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	Vidaza;	Phase II;	;	27;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	Vidaza;	Phase II;	;	22;	27;	20;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	Satraplatin;	Phase III;	;	22;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	Satraplatin;	Phase III;	;	22;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	MGCD0103;	Phase II;	 HDAC inhibitor program;	22;	27;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	Amrubicin;	Phase II;	;	22;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	Amrubicin;	Phase II;	;	22;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2006;	Refludan®;	Marketed;	;	21;	27;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	 Thalomid® ;	Marketed;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	 Thalomid® ;	marketed;	 S.T.E.P.S.® program ;	22;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	Vidaza;	MArketed;	;	27;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	Vidaza;	Phase II;	;	27;	20;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	Vidaza;	Phase II;	;	22;	27;	20;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	Satraplatin;	Phase III;	;	22;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	Satraplatin;	Phase III;	;	22;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	MGCD0103;	Phase II;	 HDAC inhibitor program;	22;	27;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	Amrubicin;	Phase II;	;	22;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	Amrubicin;	Phase II;	;	22,;	;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	Innohep®;	Marketed;	;	21;	22;	;		;	;		
wvcs20030001203866;	PHARMION CORP;	10-K;	2003;	2007;	Refludan®;	Marketed;	;	21;	27;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	S-1;	2004;	2004;	CS-917;	Phase II;	NuMimetic technology;	24;	;	;		2008;	-0.0909;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	S-1;	2004;	2004;	CS-917;	Phase II;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	S-1;	2004;	2004;	Hepavir B™;	Phase II;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	S-1;	2004;	2004;	Hepavir B™;	Phase II;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	S-1;	2004;	2004;	MB07133;	Phase II;	 HepDirect technology;	22;	26;	27;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	S-1;	2004;	2004;	MB07811;	Research;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	S-1;	2004;	2004;	Unnamed;	Research;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	424;	2004;	2004;	CS-917;	Phase II;	NuMimetic technology;	24;	;	;		2008;	-0.0909;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	424;	2004;	2004;	CS-917;	Phase II;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	424;	2004;	2004;	Hepavir B™;	Phase II;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	424;	2004;	2004;	Hepavir B™;	Phase II;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	424;	2004;	2004;	MB07133;	Phase II;	 HepDirect technology;	22;	26;	27;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	424;	2004;	2004;	MB07811;	Research;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	424;	2004;	2004;	;	;	;	;	;	;		2008;	-0.0909;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2004;	CS-917;	Phase II;	NuMimetic technology;	24;	;	;		2008;	-0.0909;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2004;	CS-917;	Phase II;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2004;	Pradefovir mesylate;	Phase II;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2004;	Pradefovir mesylate;	Phase II;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2004;	MB07133;	Phase II;	 HepDirect technology;	22;	26;	27;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2004;	MB07811;	Pre Clinical;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2004;	Unnamed;	Research;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2004;	 MB07100;	Research;	 HepDirect technology;	26;	28;	;		2007;	-1;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2005;	CS-917;	Phase II;	NuMimetic technology;	24;	;	;		2008;	-0.0909;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2005;	CS-917;	Phase II;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2005;	Pradefovir mesylate;	Phase III;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2005;	Pradefovir mesylate;	Phase III;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2005;	MB07133;	Phase II;	 HepDirect technology;	22;	26;	27;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2005;	MB07803;	Phase I;	NuMimetic technology;	24;	26;	28;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2005;	MB07811;	Pre Clinical;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2005;	Unnamed;	Research;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2005;	 MB07100;	Research;	 HepDirect technology;	26;	28;	;		2007;	-1;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2005;	AMPK;	Discovery;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2006;	CS-917;	Phase II;	NuMimetic technology;	24;	;	;		2008;	9;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2006;	CS-917;	Phase II;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2006;	Pradefovir mesylate;	Phase III;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2006;	Pradefovir mesylate;	Phase III;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2006;	MB07133;	Phase II;	 HepDirect technology;	22;	26;	27;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2006;	MB07803;	Phase I;	NuMimetic technology;	24;	26;	28;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2006;	MB07811;	Phase I;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2006;	Unnamed;	Research;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2006;	Unnamed;	Research;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2006;	AMPK;	Discovery;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2007;	Pradefovir mesylate;	Phase III;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2007;	Pradefovir mesylate;	Phase III;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2007;	MB07133;	Phase II;	 HepDirect technology;	22;	26;	27;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2007;	MB07803;	Phase IIA;	NuMimetic technology;	24;	26;	28;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2007;	MB07811;	Phase IB;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2007;	Unnamed;	Lead Optimization;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2007;	Unnamed;	Lead Optimization;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2007;	AMPK;	Lead Optimization;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2008;	Pradefovir mesylate;	Phase III;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2008;	Pradefovir mesylate;	Phase III;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2008;	MB07133;	Phase II;	 HepDirect technology;	22;	26;	27;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2008;	MB07803;	Phase IIA;	NuMimetic technology;	24;	26;	28;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2008;	MB07811;	Phase II;	NuMimetic technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2008;	Unnamed;	Lead Optimization;	 HepDirect technology;	26;	28;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2008;	AMPK;	Lead Optimization;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2008;	Glucagon Antagonist;	Lead Optimization;	NuMimetic technology;	24;	;	;		;	;		
wvcs20040001053221;	METABASIS THERAPEUTICS INC;	10-K;	2004;	2008;	TRß Agonist;	Lead Optimization;	NuMimetic technology;	24;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	S-1;	2002;	2002;	 NBI-34060;	Phase III;	non-BDZ/GABA (A) Receptors;	46;	;	;		2004;	-1;		
newx20021066833;	Euthymics Bioscience Inc;	S-1;	2002;	2002;	OCINAPLON;	Phase II;	non-BDZ/GABA (A) Receptors;	30;	40;	;		2006;	-0.0909;		
newx20021066833;	Euthymics Bioscience Inc;	S-1;	2002;	2002;	BICIFADINE;	Phase II;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	S-1;	2002;	2002;	DOV 216,303;	Phase IB;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	S-1;	2002;	2002;	DOV DILTIAZEM;	Phase II;	formulation of diltiazem;	21;	;	;		2007;	-0.1765;		
newx20021066833;	Euthymics Bioscience Inc;	S-1;	2002;	2002;	DOV 21,947;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	S-1;	2002;	2002;	DOV 22,047;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	S-1;	2002;	2002;	DOV 102,677 ;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	S-1;	2002;	2002;	DOV 102,177;	Pre Clinical;	neurochemical profile of bicifadine,;	3;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	424;	2002;	2002;	 NBI-34060;	Phase III;	non-BDZ/GABA (A) Receptors;	46;	;	;		2004;	-1;		
newx20021066833;	Euthymics Bioscience Inc;	424;	2002;	2002;	OCINAPLON;	Phase II;	non-BDZ/GABA (A) Receptors;	30;	40;	;		2006;	-0.0909;		
newx20021066833;	Euthymics Bioscience Inc;	424;	2002;	2002;	BICIFADINE;	Phase II;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	424;	2002;	2002;	DOV 216,303;	Phase IB;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	424;	2002;	2002;	DOV DILTIAZEM;	Phase II;	formulation of diltiazem;	21;	;	;		2007;	-0.1765;		
newx20021066833;	Euthymics Bioscience Inc;	424;	2002;	2002;	DOV 21,947;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	424;	2002;	2002;	DOV 22,047;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	424;	2002;	2002;	DOV 102,677 ;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	424;	2002;	2002;	DOV 102,177;	Pre Clinical;	neurochemical profile of bicifadine,;	3;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2002;	Indiplon;	Phase III;	non-BDZ/GABA (A) Receptors;	46;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2002;	Indiplon;	Phase III;	non-BDZ/GABA (A) Receptors;	46;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2002;	OCINAPLON;	Phase III;	non-BDZ/GABA (A) Receptors;	30;	40;	;		2006;	-0.0909;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2002;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2002;	DOV 216,303;	Phase II;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2002;	DOV 21,947;	Phase I;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2002;	DOV DILTIAZEM;	Phase II;	formulation of diltiazem;	21;	;	;		2007;	-0.1765;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2002;	DOV 22,047;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2002;	DOV 102,677 ;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2002;	DOV 102,177;	Pre Clinical;	neurochemical profile of bicifadine,;	3;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2003;	Indiplon;	Phase III;	non-BDZ/GABA (A) Receptors;	46;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2003;	OCINAPLON;	Phase III;	non-BDZ/GABA (A) Receptors;	30;	40;	;		2006;	-0.0909;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2003;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2003;	DOV 216,303;	Phase II;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2003;	DOV 21,947;	Phase I;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2003;	DOV DILTIAZEM;	Phase II;	formulation of diltiazem;	21;	;	;		2007;	-0.1765;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2003;	DOV 102,677 ;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2003;	DOV 51,892;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2004;	Indiplon;	NDA;	non-BDZ/GABA (A) Receptors;	46;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2004;	OCINAPLON;	Phase III;	non-BDZ/GABA (A) Receptors;	30;	40;	;		2006;	0.1111;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2004;	DOV 216,303;	Phase II;	Dual uptake inhibitors, referred to as SNRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2004;	DOV 21,947;	Phase I;	Dual uptake inhibitors, referred to as SNRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2004;	DOV 102,677 ;	Phase I;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2004;	DOV DILTIAZEM;	Phase II;	formulation of diltiazem;	21;	;	;		2007;	-0.1765;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2004;	DOV 51,892;	Pre Clinical;	non-BDZ/GABA (A) Receptors;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2004;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2005;	Indiplon;	NDA;	non-BDZ/GABA (A) Receptors;	46;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2005;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2005;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2005;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2005;	BICIFADINE;	Phase II;	controlled-release formulation of bicifadine;	62;	9;	20;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2005;	DOV 21,947;	Phase I;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2005;	DOV 102,677 ;	Phase I;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2005;	DOV 216,303;	Phase II;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2005;	DOV 216,303;	Pre Clinical;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2005;	DOV DILTIAZEM;	Phase II;	formulation of diltiazem;	21;	;	;		2007;	-0.0667;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2006;	Indiplon;	NDA;	non-BDZ/GABA (A) Receptors;	46;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2006;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2006;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2006;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2006;	BICIFADINE;	Phase II;	controlled-release formulation of bicifadine;	62;	9;	20;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2006;	DOV 21,947;	Phase I;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2006;	DOV 21,947;	Pre Clinical;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2006;	DOV 102,677 ;	Phase I;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2006;	Triple reuptake inhibitor;	PRE-IND;	triple reuptake inhibitor, or TRI;	42;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	DOV 21,947;	Phase II;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	DOV 21,947;	Phase I;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	9;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	BICIFADINE;	Phase III;	controlled-release formulation of bicifadine;	62;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	BICIFADINE;	Phase II;	controlled-release formulation of bicifadine;	62;	9;	20;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	Indiplon;	NDA;	non-BDZ/GABA (A) Receptors;	46;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	DOV 102,677 ;	Phase I;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	DOV 216,419;	Discovery;	triple reuptake inhibitor, or TRI;	62;	42;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	Uptake Inhibitors;	Discovery;	triple reuptake inhibitor, or TRI;	42;	;	;		;	;		
newx20021066833;	Euthymics Bioscience Inc;	10-K;	2002;	2007;	GABA modulators;	Discovery;	triple reuptake inhibitor, or TRI;	40;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	S-1;	2002;	2002;	TACI-Ig;	Pre-IND;	 bioinformatics-based;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	S-1;	2002;	2002;	TACI-Ig;	PRE-IND;	 bioinformatics-based;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	S-1;	2002;	2002;	IL-21;	Pre-development;	 bioinformatics-based;	22;	27;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	S-1;	2002;	2002;	Zsig37;	Pre-development;	 bioinformatics-based;	21;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	S-1;	2002;	2002;	rh Factor XIII;	PRE-IND;	 bioinformatics-based;	25;	9;	30;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	S-1;	2002;	2002;	rh Thrombin;	PRE-IND;	 bioinformatics-based;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	424;	2002;	2002;	TACI-Ig;	Pre-IND;	 bioinformatics-based;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	424;	2002;	2002;	TACI-Ig;	PRE-IND;	 bioinformatics-based;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	424;	2002;	2002;	IL-21;	Pre-development;	 bioinformatics-based;	22;	27;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	424;	2002;	2002;	Zsig37;	Pre-development;	 bioinformatics-based;	21;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	424;	2002;	2002;	rh Factor XIII;	PRE-IND;	 bioinformatics-based;	25;	9;	30;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	424;	2002;	2002;	rh Thrombin;	PRE-IND;	 bioinformatics-based;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2002;	TACI-Ig;	Pre-IND;	 bioinformatics-based;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2002;	TACI-Ig;	PRE-IND;	 bioinformatics-based;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2002;	IL-21;	Pre-development;	 bioinformatics-based;	22;	27;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2002;	Zsig37;	Pre-development;	 bioinformatics-based;	21;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2002;	rh Factor XIII;	PRE-IND;	 bioinformatics-based;	25;	9;	30;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2002;	rh Thrombin;	PRE-IND;	 bioinformatics-based;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2003;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2003;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2003;	IL-21;	Pre -IND;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2003;	rh Factor XIII;	Phase I;	 bioinformatics-based;	25;	9;	30;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2003;	rh Thrombin;	Phase II;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2004;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2004;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	20;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2004;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	27;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2004;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2004;	IL-21;	Phase I;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2004;	IL-21;	Pre-clinical;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2004;	rh Thrombin;	Phase II;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2004;	rh Thrombin;	Preclinical;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2004;	IL-29;	Preclinical;	 bioinformatics-based;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2004;	IL-31;	Preclinical;	 bioinformatics-based;	5;	29;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	20;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	27;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	TACI-Ig;	Research;	 patent portfolio for TACI-Ig;	5;	22;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	TACI-Ig;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	27;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	IL-21;	Phase I;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	IL-21;	IND;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	IL-29;	Preclinical;	 bioinformatics-based;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	IL-31;	Preclinical;	 bioinformatics-based;	5;	8;	29;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	rh Thrombin;	Phase III;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2005;	rh Thrombin;	Preclinical;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	Atacicept;	Phase I;	 patent portfolio for TACI-Ig;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	Atacicept;	Phase II;	 patent portfolio for TACI-Ig;	5;	20;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	Atacicept;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	27;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	Atacicept;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	Atacicept;	Pre Clinical;	 patent portfolio for TACI-Ig;	5;	22;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	Atacicept;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	27;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	IL-21;	Phase I;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	IL-21;	Phase II;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	IL-21;	Phase I;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	27;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	PEG-IFN-l;	Phase I;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	PEG-IFN-l;	Preclinical;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	22;	23;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	PEG-IFN-l;	Preclinical;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	IL-31;	Preclinical;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	5;	8;	29;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	rh Thrombin;	BLA ;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	rh Thrombin;	Phase II;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2006;	IL-17RC;	Preclinical;	 bioinformatics-based;	5;	20;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	Atacicept;	Phase III;	 patent portfolio for TACI-Ig;	5;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	Atacicept;	Phase II;	 patent portfolio for TACI-Ig;	5;	20;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	Atacicept;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	27;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	Atacicept;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	Atacicept;	Phase II;	 patent portfolio for TACI-Ig;	5;	22;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	Atacicept;	Phase I;	 patent portfolio for TACI-Ig;	5;	22;	27;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	IL-21;	Phase II;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	IL-21;	Phase II;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	IL-21;	Phase I;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	27;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	IL-21;	Phase I;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	IL-21;	Phase II;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	RECOTHROM;	Marketed;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	RECOTHROM;	Marketed;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	PEG-IFN-l;	Phase I;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	PEG-IFN-l;	Preclinical;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	IL-17RC;	Preclinical;	 bioinformatics-based;	5;	20;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2007;	IL-31 MAB;	Preclinical;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	5;	8;	29;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2008;	IL-21;	Phase II;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2008;	IL-21;	Phase II;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2008;	RECOTHROM;	Marketed;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2008;	PEG-IFN-l;	Phase I;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2008;	PEG-IFN-l;	Preclinical;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2008;	PEG-IFN-l;	Phase I;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2008;	PEG-IFN-l;	Preclinical;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2008;	IL-21 mAb;	PRE-IND;	anti-IL-21 monoclonal antibodies and their use in disease, including autoimmune and inflammatory diseases.;	5;	20;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2008;	IL-31 MAB;	Preclinical;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	5;	8;	29;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2009;	IL-21;	Phase II;	 IL-21 polypeptides, polynucleotides and methods of using IL-21;	22;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2009;	RECOTHROM;	Marketed;	 recombinant human thrombin, methods of producing recombinant human thrombin;	25;	9;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2009;	PEG-IFN-l;	Phase II;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2009;	PEG-IFN-l;	Phase I;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2009;	PEG-IFN-l;	Phase II;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2009;	PEG-IFN-l;	Phase I;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	23;	;	;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2009;	IL-31 MAB;	Pre -IND;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	5;	8;	29;		;	;		
wvcs20020001129425;	ZYMOGENETICS INC;	10-K;	2002;	2009;	IL-31 MAB;	Research;	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1;	5;	62;	29;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	S-1;	2003;	2003;	AI-700;	Phase III;	Porous Microparticle Technology;	21;	20;	60;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	S-1;	2003;	2003;	AI-850;	Phase I;	Porous Microparticle Technology;	22;	;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	S-1;	2003;	2003;	AI-128;	Phase I;	Porous Microparticle Technology;	5;	29;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	424;	2003;	2003;	AI-700;	Phase III;	Porous Microparticle Technology;	21;	20;	60;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	424;	2003;	2003;	AI-850;	Phase I;	Porous Microparticle Technology;	22;	;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	424;	2003;	2003;	AI-128;	Phase I;	Porous Microparticle Technology;	5;	29;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2003;	AI-700;	Phase III;	Porous Microparticle Technology;	21;	20;	60;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2003;	AI-850;	Phase I;	Porous Microparticle Technology;	22;	;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2003;	AI-128;	Phase I;	Porous Microparticle Technology;	5;	29;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2004;	AI-700;	Phase III;	Porous Microparticle Technology;	21;	20;	60;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2004;	AI-850;	Phase I;	Porous Microparticle Technology;	22;	;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2004;	AI-128;	Phase I;	Porous Microparticle Technology;	5;	29;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2005;	AI-700;	Phase III;	Porous Microparticle Technology;	21;	20;	60;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2005;	AI-850;	Phase I;	Porous Microparticle Technology;	22;	;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2005;	AI-128;	Phase I;	Porous Microparticle Technology;	5;	29;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2006;	Imagify;	Phase III;	Porous Microparticle Technology;	21;	20;	60;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2006;	Hydrophobic Drug Delivery System™, HDDS.  ;	Phase I;	Porous Microparticle Technology;	22;	;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2006;	       Pulmonary Drug Delivery System™, PDDS. ;	Phase I;	Porous Microparticle Technology;	5;	29;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2007;	Imagify;	Phase III;	Porous Microparticle Technology;	21;	20;	60;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2007;	Hydrophobic Drug Delivery System™, HDDS.  ;	Phase I;	Porous Microparticle Technology;	22;	;	;		;	;		
wvcs20030001115143;	ACUSPHERE INC;	10-K;	2003;	2007;	       Pulmonary Drug Delivery System™, PDDS. ;	Phase I;	Porous Microparticle Technology;	5;	29;	;		;	;		
wvcu19970001016518;	APOLLON INC;	S-1;	1997;	1997;	GENEVAX vaccine product;	Phase I;	proprietary facilitated DNA;	23;	;	;		;	;		
wvcu19970001016518;	APOLLON INC;	S-1;	1997;	1997;	GENEVAX vaccine product;	Phase I;	proprietary facilitated DNA;	23;	;	;		;	;		
wvcu19970001016518;	APOLLON INC;	S-1;	1997;	1997;	GENEVAX vaccine product;	Phase II;	proprietary facilitated DNA;	23;	;	;		;	;		
wvcu19970001016518;	APOLLON INC;	S-1;	1997;	1997;	GENEVAX vaccine product;	Phase II;	proprietary facilitated DNA;	5;	27;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	S-1;	1997;	1997;	FGN-1(TM);	Phase III;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	S-1;	1997;	1997;	FGN-1(TM);	Phase III;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	S-1;	1997;	1997;	FGN-1(TM);	Phase III;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	S-1;	1997;	1997;	FGN-1(TM);	Phase III;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	S-1;	1997;	1997;	FGN-1(TM);	Phase III;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	S-1;	1997;	1997;	FGN-1(TM);	Phase II;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	1999;	PREVATAC(TM);	IND;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	1999;	PREVATAC(TM);	Phase III;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	1999;	PREVATAC(TM);	Phase II;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	1999;	PREVATAC(TM);	Phase II;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	1999;	PREVATAC(TM);	Phase I;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	1999;	PREVATAC(TM);	Phase III;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	1999;	PREVATAC(TM);	Phase II;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	1999;	PREVATAC(TM);	Phase III;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	1999;	CP 461;	IND;	Proprietary;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2000;	Aptosyn(TM);	Terminated;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2000;	Aptosyn(TM);	Have NO Plans;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2000;	Aptosyn(TM);	Phase II;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2000;	Aptosyn(TM);	Have NO Plans;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2000;	Aptosyn(TM);	Have NO Plans;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2000;	Aptosyn(TM);	Phase II;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2000;	Aptosyn(TM);	Phase II;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2000;	Aptosyn(TM);	Phase II;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2000;	Aptosyn(TM);	Phase II;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2000;	CP 461;	IND;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2001;	Aptosyn(TM);	Have NO Plans;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2001;	Aptosyn(TM);	Phase II;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2001;	Aptosyn(TM);	Phase III;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2001;	Aptosyn(TM);	Phase III;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2001;	Aptosyn(TM);	Phase II;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2001;	CP 461;	Phase II;	selective apoptotic anti-neoplastic drugs;	22;	27;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2001;	CP 461;	Phase II;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2001;	CP 461;	Phase II;	selective apoptotic anti-neoplastic drugs;	22;	28;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2002;	CP 461;	Phase II;	selective apoptotic anti-neoplastic drugs;	26;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2002;	Aptosyn(TM);	No Plans;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2002;	Aptosyn(TM);	No Plans;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2002;	Aptosyn(TM);	No Plans;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2002;	Aptosyn(TM);	No Plans;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2002;	CP 461;	No Plans;	selective apoptotic anti-neoplastic drugs;	22;	27;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2002;	CP 461;	No Plans;	selective apoptotic anti-neoplastic drugs;	22;	;	;		;	;		
wvcu19970000925732;	CELL PATHWAYS INC;	10-K;	1997;	2002;	CP 461;	No Plans;	selective apoptotic anti-neoplastic drugs;	22;	28;	;		;	;		
wvcu19970000944753;	SCRIPTGEN PHARMACEUTICALS INC;	S-1;	1997;	1997;	ST61769;	Pre Clinical;	GATE  ATLAS (Any Target Ligand Affinity Screen)	23;	;	;		;	;		
wvcu19970000944753;	SCRIPTGEN PHARMACEUTICALS INC;	S-1;	1997;	1997;	ST61219;	Pre Clinical;	GATE  ATLAS (Any Target Ligand Affinity Screen)	23;	;	;		;	;		
wvcu19970000944753;	SCRIPTGEN PHARMACEUTICALS INC;	S-1;	1997;	1997;	ST61219;	Pre Clinical;	GATE  ATLAS (Any Target Ligand Affinity Screen)	23;	;	;		;	;		
wvcu19970000944753;	SCRIPTGEN PHARMACEUTICALS INC;	S-1;	1997;	1997;	 ST41590;	Pre Clinical;	GATE  ATLAS (Any Target Ligand Affinity Screen)	23;	;	;		;	;		
wvcu19970000944753;	SCRIPTGEN PHARMACEUTICALS INC;	S-1;	1997;	1997;	ST135647;	Pre Clinical;	GATE  ATLAS (Any Target Ligand Affinity Screen)	23;	;	;		;	;		
wvcs20000000934473;	GENVEC INC;	S-1;	1998;	1998;	BIOBYPASS angiogen;	Phase II;	VEGF/121/ gene;	21;	;	;		;	;		
wvcs20000000934473;	GENVEC INC;	S-1;	1998;	1998;	BIOBYPASS angiogen;	Phase II;	VEGF/121/ gene;	21;	;	;		;	;		
wvcs20000000934473;	GENVEC INC;	S-1;	1998;	1998;	Ad.TNF(alpha);	Preclinical;	TNF(alpha);	22;	;	;		;	;		
wvcs20000000934473;	GENVEC INC;	S-1;	1998;	1998;	 Ad.iNOS;	Preclinical;	iNOS;	21;	;	;		;	;		
wvcs20000000934473;	GENVEC INC;	S-1;	1998;	1998;	 Ad.CD.;	Phase II;	 CD  ;	22;	;	;		;	;		
wvcs20000000934473;	GENVEC INC;	S-1;	1998;	1998;	Immunotherapy Program;	Research;	None;	22;	;	;		;	;		
wvcs20000000934473;	GENVEC INC;	S-1;	1998;	1998;	Neurology Program;	Research;	None;	45;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	 OncoVAX(CL);	Phase III;	Active Specific Immunotherapy;	22;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	HumaSPECT;	Phase III;	 Antibody-Based Diagnosis;	22;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	KLH ;	Phase III;	Active Non-Specfic Immunotherapy;	22;	3;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	ASI(BCL;	Phase III;	Active Specfic Immunotherapy;	22;	27;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	HumaRAD(16.88);	Phase I;	Antibody-Based Diagnosis  ;	22;	2;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	HumaRAD(88BV59)      ;	Phase I;	Antibody-Based Diagnosis  ;	22;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	HumaSPECT;	Phase II;	Antibody-Based Diagnosis  ;	22;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	MONOGENE(INT) ;	Phase I;	Antibody-Based gene therapy;	22;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	Confirmatory diagnostic Products;	Marketed;	;	23;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	 ZYMMUNE CD4/CD8;	Marketed;	;	23;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	Accu-D(x);	Marketed;	;	22;	3;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	S-1;	1999;	1999;	 Apo-Tek Lp(a);	Marketed;	;	21;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	 OncoVAX(CL);	Phase III;	Active Specific Immunotherapy;	22;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	KLH ;	Phase III;	Active Non-Specfic Immunotherapy;	22;	3;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	ASI(BCL;	Phase III;	Active Specfic Immunotherapy;	22;	27;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	HumaRAD(16.88);	Phase I;	Antibody-Based Diagnosis  ;	22;	2;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	HumaRAD(88BV59)      ;	Phase I;	Antibody-Based Diagnosis  ;	22;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	MONOGENE(INT) ;	Phase I;	Antibody-Based gene therapy;	22;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	Confirmatory diagnostic Products;	Marketed;	;	23;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	 ZYMMUNE CD4/CD8;	Marketed;	;	23;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	Accu-D(x);	Marketed;	;	22;	3;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	 Apo-Tek Lp(a);	Marketed;	;	21;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	HumaSPECT ;	BLA;	;	22;	;	;		;	;		
wvcu19980001001557;	INTRACEL CORP;	424B;	1999;	1999;	HumaSPECT ;	Phase II;	;	22;	;	;		;	;		
wvcu19980000949175;	SENSUS DRUG DEVELOPMENT CORP;	S-1;	1998;	1998;	Trovert (B2036PEG);	Phase III;	growth hormone antagonists ("GHAs");	24;	;	;		;	;		
wvcu19980000949175;	SENSUS DRUG DEVELOPMENT CORP;	S-1;	1998;	1998;	Trovert (B2036PEG);	Phase III;	growth hormone antagonists ("GHAs");	24;	;	;		;	;		
wvcu19980000949175;	SENSUS DRUG DEVELOPMENT CORP;	S-1;	1998;	1998;	Trovert (B2036PEG);	Phase II;	growth hormone antagonists ("GHAs");	24;	;	;		;	;		
wvcu19980000949175;	SENSUS DRUG DEVELOPMENT CORP;	S-1;	1998;	1998;	Trovert (B2036PEG);	Phase II;	growth hormone antagonists ("GHAs");	24;	;	;		;	;		
wvcu19980000949175;	SENSUS DRUG DEVELOPMENT CORP;	S-1;	1998;	1998;	Trovert (B2036PEG);	Research;	growth hormone antagonists ("GHAs");	24;	;	;		;	;		
wvcu19980000949175;	SENSUS DRUG DEVELOPMENT CORP;	S-1;	1998;	1998;	Trovert (B2036PEG);	Research;	growth hormone antagonists ("GHAs");	24;	;	;		;	;		
wvcu20000001123959;	CONTROL DELIVERY SYSTEM;	S-1;	2000;	2000;	Vitrasert;	Marketed;	Aeon Platform Technology;	1;	;	;		;	;		
wvcu20000001123959;	CONTROL DELIVERY SYSTEM;	S-1;	2000;	2000;	Aeon Platform Technology;	Pre Clinical;	Aeon Platform Technology;	1;	;	;		;	;		
wvcu20000001123959;	CONTROL DELIVERY SYSTEM;	S-1;	2000;	2000;	Aeon Platform Technology;	Phase II;	Aeon Platform Technology;	1;	;	;		;	;		
wvcu20000001123959;	CONTROL DELIVERY SYSTEM;	S-1;	2000;	2000;	Aeon Platform Technology;	Phase II;	Aeon Platform Technology;	1;	;	;		;	;		
wvcu20000001123959;	CONTROL DELIVERY SYSTEM;	S-1;	2000;	2000;	Aeon Platform Technology;	Research;	Aeon Platform Technology;	20;	;	;		;	;		
wvcu20000001123959;	CONTROL DELIVERY SYSTEM;	S-1;	2000;	2000;	Ceredur;	Phase II;	Aeon Platform Technology;	22;	40;	;		;	;		
wvcu20000001123959;	CONTROL DELIVERY SYSTEM;	S-1;	2000;	2000;	Codrug Platform Technology;	Research;	Codrug Platform Technology;	62;	;	;		;	;		
wvcu20000001123959;	CONTROL DELIVERY SYSTEM;	S-1;	2000;	2000;	Codrug Platform Technology;	Research;	Codrug Platform Technology;	22;	;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Phase I;	Xcellerate Technology;	22;	;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	22;	27;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	22;	;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	22;	;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	22;	;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	22;	;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	22;	;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	27;	20;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	27;	20;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	27;	20;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	27;	20;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	23;	;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	23;	;	;		;	;		
wvcu20000001130166;	Cyclacel Pharmaceuticals, Inc.;	S-1;	2000;	2000;	Xcellerate Therapy;	Research;	Xcellerate Technology;	23;	;	;		;	;		
wvcu20000001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2000;	2000;	AIC;	Phase II;	 immunostimulatory sequences, or ISS;	5;	;	;		;	;		
wvcu20000001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2000;	2000;	 Lol p 1;	Pre Clinical;	 immunostimulatory sequences, or ISS;	5;	;	;		;	;		
wvcu20000001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2000;	2000;	ISS linked to peanut Allergy;	Pre Clinical;	 immunostimulatory sequences, or ISS;	5;	;	;		;	;		
wvcu20000001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2000;	2000;	ISS linked or combined with;	Phase I ;	 immunostimulatory sequences, or ISS;	23;	;	;		;	;		
wvcu20000001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2000;	2000;	ISS linked or combined with HIV antigens;	Pre Clinical;	 immunostimulatory sequences, or ISS;	23;	;	;		;	;		
wvcu20000001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2000;	2000;	ISS alone in various  formulations ;	Pre Clinical;	 immunostimulatory sequences, or ISS;	5;	;	;		;	;		
wvcu20000001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2000;	2000;	TZP I-153 ;	Pre Clinical;	thiazolopyrimidine, or TZP, class;	5;	20;	;		;	;		
wvcu20010001115143;	ACUSPHERE INC;	S-1;	2001;	2001;	 AI-700;	Phase II;	POROUS MICROPARTICLE TECHNOLOGY;	21;	60;	;		;	;		
wvcu20010001115143;	ACUSPHERE INC;	S-1;	2001;	2001;	AI-850 ;	Pre Clinical;	POROUS MICROPARTICLE TECHNOLOGY;	22;	;	;		;	;		
wvcu20010001115143;	ACUSPHERE INC;	S-1;	2001;	2001;	 Pulmonary Drug Delivery System;	Pre Clinical;	POROUS MICROPARTICLE TECHNOLOGY;	5;	29;	;		;	;		
wvcu20010001014455;	AGRAQUEST INC;	S-1;	2001;	2001;	Serenade;	Registration EPA;	microorganism database;	;	;	;		;	;		
wvcu20010001014455;	AGRAQUEST INC;	S-1;	2001;	2001;	Sonata;	Registration EPA;	microorganism database;	70;	;	;		;	;		
wvcu20010001014455;	AGRAQUEST INC;	S-1;	2001;	2001;	Virtuoso;	Registration EPA;	microorganism database;	;	;	;		;	;		
wvcu20010001014455;	AGRAQUEST INC;	S-1;	2001;	2001;	Vivace;	Registration EPA;	microorganism database;	;	;	;		;	;		
wvcu20010001088856;	CORCEPT THERAPEUTICS INC;	S-1;	2001;	2001;	C-1073;	Phase III;	GR-II Antagonist Platform;	40;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	 Taxoprexin®;	Phase II;	 Targaceutical® platform technology;	22;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	 Taxoprexin®;	Phase II;	 Targaceutical® platform technology;	22;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	 Taxoprexin®;	Phase II;	 Targaceutical® platform technology;	22;	26;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	 Taxoprexin®;	Phase II;	 Targaceutical® platform technology;	22;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	 Taxoprexin®;	Phase II;	 Targaceutical® platform technology;	22;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	 Taxoprexin®;	Phase II;	 Targaceutical® platform technology;	22;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	 Taxoprexin®;	Phase II;	 Targaceutical® platform technology;	22;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	 Taxoprexin®;	Phase II;	 Targaceutical® platform technology;	22;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	P-232;	Pre Clinical;	 Targaceutical® platform technology;	22;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	P-274;	Pre Clinical;	 Targaceutical® platform technology;	22;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	P-309;	Pre Clinical;	 Targaceutical® platform technology;	22;	;	;		;	;		
wvcu20010001115616;	PROTARGA INC;	S-1;	2001;	2001;	Clozaprexin™;	Pre Clinical;	 Targaceutical® platform technology;	40;	;	;		;	;		
wvcu20020001164722;	ADERIS PHARMACEUTICALS INC;	S-1;	2002;	2002;	Rotigotine-CDS;	Phase III;	Agonist;	40;	;	;		;	;		
wvcu20020001164722;	ADERIS PHARMACEUTICALS INC;	S-1;	2002;	2002;	Rotigotine-CDS;	Phase II;	Agonist;	40;	;	;		;	;		
wvcu20020001164722;	ADERIS PHARMACEUTICALS INC;	S-1;	2002;	2002;	 MRE-470;	Phase II;	Agonist;	21;	60;	;		;	;		
wvcu20020001164722;	ADERIS PHARMACEUTICALS INC;	S-1;	2002;	2002;	DTI-0009;	Phase II;	(antagonists) ;	21;	;	;		;	;		
wvcu20020001164722;	ADERIS PHARMACEUTICALS INC;	S-1;	2002;	2002;	DTI-0017 ;	Phase I;	(antagonists) ;	21;	;	;		;	;		
wvcu20030001008848;	ACORDA THERAPEUTICS INC;	S-1;	2003;	2003;	Fampridine-SR;	Phase III;	core technologies;	25;	40;	70;		;	;		
wvcu20030001008848;	ACORDA THERAPEUTICS INC;	S-1;	2003;	2003;	Fampridine-SR;	Phase II;	core technologies;	25;	40;	70;		;	;		
wvcu20030001008848;	ACORDA THERAPEUTICS INC;	S-1;	2003;	2003;	Valrocemide;	Phase II;	core technologies;	43;	;	;		;	;		
wvcu20030001008848;	ACORDA THERAPEUTICS INC;	S-1;	2003;	2003;	Valrocemide;	Phase II;	core technologies;	43;	;	;		;	;		
wvcu20030001008848;	ACORDA THERAPEUTICS INC;	S-1;	2003;	2003;	GGF-2;	Pre Clinical;	 remyelinating antibodies;	40;	;	;		;	;		
wvcu20030001008848;	ACORDA THERAPEUTICS INC;	S-1;	2003;	2003;	Remyelinating Antibodies;	Pre Clinical;	 remyelinating antibodies;	40;	;	;		;	;		
wvcu20030001008848;	ACORDA THERAPEUTICS INC;	S-1;	2003;	2003;	Chondroitinase;	research;	 Scar Matrix Modification;	45;	;	;		;	;		
wvcu20030001008848;	ACORDA THERAPEUTICS INC;	S-1;	2003;	2003;	Regenerative Antibodies;	research;	 Scar Matrix Modification;	40;	;	;		;	;		
wvcu20030001164722;	ADERIS PHARMACEUTICALS INC;	S-1;	2003;	2003;	Rotigotine-CDS;	Phase III;	Agonist;	40;	;	;		;	;		
wvcu20030001164722;	ADERIS PHARMACEUTICALS INC;	S-1;	2003;	2003;	Rotigotine-CDS;	Phase II;	Agonist;	40;	;	;		;	;		
wvcu20030001164722;	ADERIS PHARMACEUTICALS INC;	S-1;	2003;	2003;	Binodenoson     ;	Phase II;	Agonist;	21;	60;	;		;	;		
wvcu20030001164722;	ADERIS PHARMACEUTICALS INC;	S-1;	2003;	2003;	Selodenoson  ;	Phase II;	Agonist;	21;	;	;		;	;		
wvcu20030001164722;	ADERIS PHARMACEUTICALS INC;	S-1;	2003;	2003;	MRE-0094  ;	IND;	Agonist;	5;	;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	S-1;	2004;	2004;	E2F Decoy;	Phase III;	TF decoy technology.;	21;	;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	S-1;	2004;	2004;	E2F Decoy;	Phase I;	TF decoy technology.;	28;	;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	S-1;	2004;	2004;	NF-kB Decoy;	Pre Clinical;	TF decoy technology.;	5;	20;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	S-1;	2004;	2004;	Cancer Decoys;	Pre Clinical;	TF decoy technology.;	22;	;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	424B;	2004;	2004;	E2F Decoy;	Phase III;	TF decoy technology.;	21;	;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	424B;	2004;	2004;	E2F Decoy;	Phase I;	TF decoy technology.;	28;	;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	424B;	2004;	2004;	NF-kB Decoy;	Pre Clinical;	TF decoy technology.;	5;	20;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	424B;	2004;	2004;	Cancer Decoys;	Pre Clinical;	TF decoy technology.;	22;	;	;		2007;	-1;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2004;	E2F Decoy;	Phase III;	TF decoy technology.;	21;	;	;		2007;	-1;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2004;	E2F Decoy;	Phase I;	TF decoy technology.;	28;	;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2004;	NF-kB Decoy;	Pre Clinical;	TF decoy technology.;	5;	20;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2004;	Cancer Decoys;	Pre Clinical;	TF decoy technology.;	22;	;	;		2007;	-1;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2005;	E2F Decoy;	Phase III;	TF decoy technology.;	21;	;	;		2007;	-1;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2005;	E2F Decoy;	Phase I;	TF decoy technology.;	28;	;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2005;	NF-kB Decoy;	Phase II;	TF decoy technology.;	5;	8;	20;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2005;	 HIF Decoy;	Pre Clinical;	TF decoy technology.;	22;	;	;		2007;	0;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2005;	 HIF Decoy;	Pre Clinical;	TF decoy technology.;	22;	;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2005;	 HIF Decoy;	Pre Clinical;	TF decoy technology.;	22;	;	;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2006;	3268;	Phase III;	TARGETED SPECIFITY;	62;	9;	25;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2006;	4975;	Phase II;	TARGETED SPECIFITY;	62;	9;	25;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2006;	Avrina (NF-KB Decoy);	Phase II;	TF decoy technology.;	5;	8;	20;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2006;	1207;	Phase I;	TARGETED SPECIFITY;	62;	9;	42;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2007;	Zingo;	NDA;	TARGETED SPECIFITY;	62;	9;	25;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2007;	4975;	Phase II;	TARGETED SPECIFITY;	62;	9;	25;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2008;	Zingo;	NDA;	TARGETED SPECIFITY;	62;	9;	25;		;	;		
nvcs20040001131517;	ANESIVA, INC.;	10-K;	2004;	2008;	Adlea™;	Phase II;	TARGETED SPECIFITY;	62;	9;	25;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2004;	2004;	AIC;	Phase II;	ISS;	5;	;	;		2010;	-0.8605;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2004;	2004;	 HBV vaccine;	Phase II;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2004;	2004;	Asthma Vaccine;	Phase II;	ISS;	5;	29;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2004;	2004;	1018 ISS;	Pre Clinical;	ISS;	22;	27;	;		2009;	0.7778;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2004;	2004;	 rheumatoid arthritis;	Pre Clinical;	 TZPs;	5;	20;	;		2007;	-0.6667;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2004;	2004;	Crohn's Disease;	Pre Clinical;	 TZPs;	5;	20;	;		2007;	0;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	S-1;	2004;	2004;	Human viral influenza;	Pre Clinical;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	424B;	2004;	2004;	AIC;	Phase II;	ISS;	5;	;	;		2010;	-0.8605;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	424B;	2004;	2004;	 HBV vaccine;	Phase II;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	424B;	2004;	2004;	Asthma Vaccine;	Phase II;	ISS;	5;	29;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	424B;	2004;	2004;	1018 ISS;	Pre Clinical;	ISS;	22;	27;	;		2009;	0.7778;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	424B;	2004;	2004;	 rheumatoid arthritis;	Pre Clinical;	 TZPs;	5;	20;	;		2007;	-0.6667;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	424B;	2004;	2004;	Crohn's Disease;	Pre Clinical;	 TZPs;	5;	20;	;		2007;	0;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	424B;	2004;	2004;	Human viral influenza;	Pre Clinical;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2005;	AIC;	Phase II;	ISS;	5;	;	;		2010;	-0.8605;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2005;	 HBV vaccine;	Phase II;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2005;	Asthma Vaccine;	Phase IIA;	ISS;	5;	29;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2005;	1018 ISS;	Pre Clinical;	ISS;	22;	27;	;		2009;	0.7778;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2005;	 rheumatoid arthritis;	Pre Clinical;	 TZPs;	5;	20;	;		2007;	-0.8889;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2005;	Crohn's Disease;	Pre Clinical;	 TZPs;	5;	20;	;		2007;	-1;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2005;	Human viral influenza;	Pre Clinical;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2006;	TOLAMBAtm;	Phase II;	ISS;	5;	;	;		2010;	-0.8605;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2006;	Hepatitis B Therapy;	Pre Clinical;	ISS;	23;	;	;		2010;	1.2;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2006;	 HEPLISAVtm;	Phase III;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2006;	Asthma Vaccine;	Phase IIA;	ISS/TLR9 agonists;	5;	29;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2006;	1018 ISS;	Phase I;	ISS;	22;	27;	;		2009;	0.7778;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2006;	Human viral influenza;	Pre Clinical;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2007;	TOLAMBAtm;	Phase II;	ISS;	5;	;	;		2010;	-0.8605;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2007;	Hepatitis B Therapy;	Phase I;	ISS;	23;	;	;		2010;	1.2;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2007;	 HEPLISAVtm;	Phase III;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2007;	(COPD) program;	Pre Clinical;	ISS/TLR9 agonists;	5;	29;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2007;	1018 ISS;	Phase I;	ISS;	22;	27;	;		2009;	1.6667;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2007;	Human viral influenza;	Pre Clinical;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2007;	metastatic colorectal ;	Phase I;	ISS;	22;	;	;		2011;	0;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2007;	hepatitis B virus (HBV) ;	Phase I;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2008;	TOLAMBAtm;	Phase II;	ISS;	5;	;	;		2010;	-0.3333;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2008;	Hepatitis B Therapy;	Phase I;	ISS;	23;	;	;		2010;	0.2222;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2008;	 HEPLISAVtm;	Phase III;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2008;	(COPD) program;	Pre Clinical;	ISS/TLR9 agonists;	5;	29;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2008;	metastatic colorectal ;	Phase I;	ISS;	22;	;	;		2011;	0;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2008;	hepatitis B virus (HBV) ;	Phase I;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2008;	Human viral influenza;	Pre Clinical;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2009;	 HEPLISAVtm;	Phase III;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2009;	DV-601;	PhaseIB;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2009;	SD-101;	PhaseIB;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2009;	AZD1419;	Pre Clinical;	ISS/TLR9 agonists;	5;	29;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2009;	metastatic colorectal ;	Phase I;	ISS;	22;	;	;		2011;	-1;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2009;	DV1079;	Pre Clinical;	ISS;	5;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2009;	Human viral influenza;	Pre Clinical;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2010;	 HEPLISAVtm;	Phase III;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2010;	DV-601;	PhaseIB;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2010;	SD-101;	PhaseIB;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2010;	AZD1419;	Pre Clinical;	ISS/TLR9 agonists;	5;	29;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2010;	Human viral influenza;	Pre Clinical;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2010;	DV1079;	Pre Clinical;	ISS;	5;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2011;	 HEPLISAVtm;	Phase III;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2011;	DV-601;	PhaseIB;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2011;	SD-101;	PhaseIB;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2011;	AZD1419;	Pre Clinical;	ISS/TLR9 agonists;	5;	29;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2011;	Human viral influenza;	Pre Clinical;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2011;	DV1079;	Pre Clinical;	ISS;	5;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2012;	 HEPLISAVtm;	Phase III;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2012;	DV-601;	PhaseIB;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2012;	AZD1419;	Pre Clinical;	ISS/TLR9 agonists;	5;	29;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2012;	Human viral influenza;	Phase IB;	ISS;	23;	;	;		;	;		
wvcs20040001029142;	DYNAVAX TECHNOLOGIES CORP;	10-K;	2004;	2012;	DV1079;	Phase I;	ISS;	5;	;	;		;	;		
nvcs20040001118361;	RENOVIS INC;	S-1;	2003;	2003;	Cerovive ;	Phase III;	neuroprotectant( nitrones);	9;	45;	;		2008;	-0.8045;		
nvcs20040001118361;	RENOVIS INC;	S-1;	2003;	2003;	REN-1654;	Phase II;	 TNFa inhibition;	62;	9;	42;		2007;	-0.7667;		
nvcs20040001118361;	RENOVIS INC;	S-1;	2003;	2003;	REN-213;	Phase I;	 nalbuphine, a kappa-opiate, with naloxone, an opiate antagonist ;	62;	9;	29;		2006;	-0.7949;		
nvcs20040001118361;	RENOVIS INC;	S-1;	2003;	2003;	VR1 Antagonist;	research;	(VR1) Blocker;	5;	62;	29;		;	;		
nvcs20040001118361;	RENOVIS INC;	S-1;	2003;	2003;	Nitrone Analgesic;	research;	neuroprotectant( nitrones);	62;	;	;		2007;	0;		
nvcs20040001118361;	RENOVIS INC;	S-1;	2003;	2003;	Leukocyte Trafficking Inhibitor;	research;	 inhibitor of leukocyte trafficking;	40;	;	;		2007;	-0.825;		
nvcs20040001118361;	RENOVIS INC;	424B;	2003;	2004;	Cerovive ;	Phase III;	neuroprotectant( nitrones);	9;	45;	;		2008;	-0.8045;		
nvcs20040001118361;	RENOVIS INC;	424B;	2003;	2004;	REN-1654;	Phase II;	 TNFa inhibition;	62;	9;	42;		2007;	-0.7667;		
nvcs20040001118361;	RENOVIS INC;	424B;	2003;	2004;	REN-213;	Phase II;	 nalbuphine, a kappa-opiate, with naloxone, an opiate antagonist ;	62;	9;	29;		2006;	-0.7333;		
nvcs20040001118361;	RENOVIS INC;	424B;	2003;	2004;	VR1 Antagonist;	research;	(VR1) Blocker;	5;	62;	29;		;	;		
nvcs20040001118361;	RENOVIS INC;	424B;	2003;	2004;	Nitrone Analgesic;	research;	neuroprotectant( nitrones);	62;	;	;		2007;	0;		
nvcs20040001118361;	RENOVIS INC;	424B;	2003;	2004;	Leukocyte Trafficking Inhibitor;	research;	 inhibitor of leukocyte trafficking;	40;	;	;		2007;	-0.825;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2005;	Cerovive ;	Phase III;	neuroprotectant( nitrones);	9;	45;	;		2008;	-0.8045;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2005;	REN-1654;	Phase II;	 TNFa inhibition;	62;	9;	42;		2007;	-0.8947;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2005;	REN-850;	Phase I;	 inhibitor of leukocyte trafficking;	5;	;	;		2007;	-0.9474;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2005;	VR1 Antagonist;	research;	(VR1) Blocker;	5;	62;	29;		;	;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2005;	Nerve Growth/Angiogenesis;	research;	neuroprotectant( nitrones);	25;	45;	;		2008;	-0.1111;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2005;	Oral Cytoprotectant;	research;	neuroprotectant( nitrones);	9;	42;	;		2007;	-1;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2006;	NXY-059 ;	Phase III;	neuroprotectant( nitrones);	9;	25;	45;		2008;	1.8889;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2006;	VR1 Antagonist;	research;	(VR1) Blocker;	5;	62;	9;		;	;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2006;	Nerve Growth/Angiogenesis;	research;	neuroprotectant( nitrones);	25;	45;	;		2008;	-0.2;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2007;	VR1 Antagonist;	Pre Clinical;	(VR1) Blocker;	5;	62;	29;		;	;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2007;	P2X7 Antagonist Program;	Pre Clinical;	receptor antagonists ;	5;	26;	20;		;	;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2007;	P2X3, P2X2/3;	Pre Clinical;	receptor antagonists ;	62;	9;	42;		;	;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2007;	TRPV4;	research;	receptor antagonists ;	62;	;	;		;	;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2008;	VR1 Antagonist;	Phase I;	(VR1) Blocker;	5;	62;	29;		;	;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2008;	P2X7 Antagonist Program;	Pre Clinical;	receptor antagonists ;	5;	26;	20;		;	;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2008;	P2X3, P2X2/3;	Pre Clinical;	receptor antagonists ;	62;	9;	42;		;	;		
nvcs20040001118361;	RENOVIS INC;	10-K;	2003;	2008;	TRPV4;	research;	receptor antagonists ;	62;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	S-1;	1997;	1997;	   Dexamethasone;	Marketed;	iontophoretic    technology;	9;	;	;		1999;	-0.5;		
wvcs19980001041652;	IOMED LLC;	S-1;	1997;	1997;	Iontocaine;	NDA;	iontophoretic    technology ;	61;	8;	9;		2001;	-0.4091;		
wvcs19980001041652;	IOMED LLC;	S-1;	1997;	1997;	iontophoretic  drug  delivery  systems;	Phase I;	iontophoretic    technology ;	70;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	S-1;	1997;	1997;	iontophoretic  drug  delivery  systems;	Pre Clinical;	iontophoretic    technology ;	62;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	S-1;	1997;	1997;	iontophoretic  drug  delivery  systems;	Phase II;	iontophoretic    technology ;	62;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	S-1;	1997;	1997;	iontophoretic  drug  delivery  systems;	Pre Clinical;	iontophoretic    technology ;	20;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	424;	1997;	1997;	iontophoretic  drug  delivery  systems;	Marketed;	iontophoretic    technology;	9;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	424;	1997;	1997;	Numby Stuff;	MArketed;	iontophoretic    technology ;	61;	8;	9;		;	;		
wvcs19980001041652;	IOMED LLC;	424;	1997;	1997;	iontophoretic  drug  delivery  systems;	Phase I;	iontophoretic    technology ;	70;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	424;	1997;	1997;	iontophoretic  drug  delivery  systems;	Phase I;	iontophoretic    technology ;	62;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	424;	1997;	1997;	iontophoretic  drug  delivery  systems;	Phase II;	iontophoretic    technology ;	62;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	424;	1997;	1997;	iontophoretic  drug  delivery  systems;	Pre Clinical;	iontophoretic    technology ;	20;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	424;	1997;	1997;	Iontocaine;	Pre Clinical;	iontophoretic    technology ;	61;	9;	;		2001;	-0.4091;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1998;	iontophoretic  drug  delivery  systems;	Marketed;	iontophoretic    technology;	9;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1998;	Numby Stuff;	MArketed;	iontophoretic    technology ;	61;	8;	9;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1998;	iontophoretic  drug  delivery  systems;	Phase I;	iontophoretic    technology ;	70;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1998;	iontophoretic  drug  delivery  systems;	Phase I;	iontophoretic    technology ;	62;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1998;	iontophoretic  drug  delivery  systems;	Phase II;	iontophoretic    technology ;	62;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1998;	Iontocaine;	Pre Clinical;	iontophoretic    technology ;	61;	9;	;		2001;	-0.4091;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1999;	iontophoretic  drug  delivery  systems;	Marketed;	iontophoretic    technology;	9;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1999;	Numby Stuff;	MArketed;	iontophoretic    technology ;	61;	8;	9;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1999;	 OcuPhor(TM) System;	Pre Clinical;	iontophoretic    technology ;	1;	;	;		2005;	-0.1111;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1999;	iontophoretic  drug  delivery  systems;	Phase I;	iontophoretic    technology ;	62;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1999;	iontophoretic  drug  delivery  systems;	Phase II;	iontophoretic    technology ;	62;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	1999;	Iontocaine;	Pre Clinical;	iontophoretic    technology ;	61;	9;	;		2001;	12;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2000;	iontophoretic  drug  delivery  systems;	Marketed;	iontophoretic    technology;	9;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2000;	Numby Stuff;	MArketed;	iontophoretic    technology ;	61;	8;	9;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2000;	 OcuPhor(TM) System;	Pre Clinical;	iontophoretic    technology ;	1;	;	;		2005;	-0.1111;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2000;	 OcuPhor(TM) System;	Pre Clinical;	iontophoretic    technology ;	1;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2001;	IontoDex™ ;	Marketed;	iontophoretic    technology;	9;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2001;	Numby Stuff;	MArketed;	iontophoretic    technology ;	61;	8;	9;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2001;	 OcuPhor(TM) System;	Pre Clinical;	iontophoretic    technology ;	1;	;	;		2005;	-0.1111;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2001;	 OcuPhor(TM) System;	Pre Clinical;	iontophoretic    technology ;	1;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2002;	IontoDex™ ;	Marketed;	iontophoretic    technology;	9;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2002;	Numby Stuff;	MArketed;	iontophoretic    technology ;	61;	8;	9;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2002;	 OcuPhor(TM) System;	Pre Clinical;	iontophoretic    technology ;	1;	;	;		2005;	-0.1111;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2002;	 OcuPhor(TM) System;	Pre Clinical;	iontophoretic    technology ;	1;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2003;	IontoDex™ ;	Marketed;	iontophoretic    technology;	9;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2003;	Numby Stuff;	MArketed;	iontophoretic    technology ;	61;	8;	9;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2003;	 OcuPhor(TM) System;	Pre Clinical;	iontophoretic    technology ;	1;	;	;		2005;	0;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2003;	 OcuPhor(TM) System;	Pre Clinical;	iontophoretic    technology ;	1;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2004;	IontoDex™ ;	Marketed;	iontophoretic    technology;	9;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2004;	Numby Stuff;	MArketed;	iontophoretic    technology ;	61;	8;	9;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2005;	IontoDex™ ;	Marketed;	iontophoretic    technology;	9;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2005;	Numby Stuff;	MArketed;	iontophoretic    technology ;	61;	8;	9;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2006;	IontoDex™ ;	Marketed;	iontophoretic    technology;	9;	;	;		;	;		
wvcs19980001041652;	IOMED LLC;	10-K;	1997;	2006;	Numby Stuff;	MArketed;	iontophoretic    technology ;	61;	8;	9;		;	;		
wvcs19980001025573;	NATROL INC;	S-1;	1998;	1998;	ESTER-C;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	S-1;	1998;	1998;	HERBALS.  ;	Marketed;	proprietary formulations;	;	;	;		2000;	-0.2;		
wvcs19980001025573;	NATROL INC;	S-1;	1998;	1998;	LIFESTYLE PRODUCTS.;	Marketed;	proprietary formulations;	;	;	;		2000;	-1;		
wvcs19980001025573;	NATROL INC;	S-1;	1998;	1998;	 NATROL PREMIUM.;	Marketed;	proprietary formulations;	;	;	;		2002;	0.119;		
wvcs19980001025573;	NATROL INC;	S-1;	1998;	1998;	GARLIC.;	Marketed;	proprietary formulations;	;	;	;		2002;	0.1875;		
wvcs19980001025573;	NATROL INC;	S-1;	1998;	1998;	 SPECIALTY DIETARY SUPPLEMENTS;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	S-1;	1998;	1998;	 NATURAL DIET CONTROL.;	Marketed;	proprietary formulations;	;	;	;		2000;	15;		
wvcs19980001025573;	NATROL INC;	424;	1998;	1998;	ESTER-C;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	424;	1998;	1998;	HERBALS.  ;	Marketed;	proprietary formulations;	;	;	;		2000;	-0.2;		
wvcs19980001025573;	NATROL INC;	424;	1998;	1998;	LIFESTYLE PRODUCTS.;	Marketed;	proprietary formulations;	;	;	;		2000;	-1;		
wvcs19980001025573;	NATROL INC;	424;	1998;	1998;	 NATROL PREMIUM.;	Marketed;	proprietary formulations;	;	;	;		2002;	0.119;		
wvcs19980001025573;	NATROL INC;	424;	1998;	1998;	GARLIC.;	Marketed;	proprietary formulations;	;	;	;		2002;	0.1875;		
wvcs19980001025573;	NATROL INC;	424;	1998;	1998;	 SPECIALTY DIETARY SUPPLEMENTS;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	424;	1998;	1998;	 NATURAL DIET CONTROL.;	Marketed;	proprietary formulations;	;	;	;		2000;	15;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	1999;	ESTER-C;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	1999;	herbal teas;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	1999;	 NATROL PREMIUM.;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	1999;	GARLIC.;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	1999;	Melatonin;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2000;	ESTER-C;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2000;	herbal teas;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2000;	 NATROL PREMIUM.;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2000;	GARLIC.;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2000;	Melatonin;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2001;	 Dietary supplements;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2001;	nutraceutical grade ingredients;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2001;	herbal teas;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2001;	sports nutrition line of products;	Marketed;	proprietary formulations;	20;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2002;	 Dietary supplements;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2002;	nutraceutical grade ingredients;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2002;	herbal teas;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2002;	sports nutrition line of products;	Marketed;	proprietary formulations;	20;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2003;	 Dietary supplements;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2003;	nutraceutical grade ingredients;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2003;	herbal teas;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2003;	sports nutrition line of products;	Marketed;	proprietary formulations;	20;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2004;	 Dietary supplements;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2004;	nutraceutical grade ingredients;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2004;	herbal teas;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2004;	sports nutrition line of products;	Marketed;	proprietary formulations;	20;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2005;	 Dietary supplements;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2005;	Essentially Pure Ingredients® (EPI);	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2005;	herbal teas;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2005;	sports nutrition line of products;	Marketed;	proprietary formulations;	20;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2006;	 Dietary supplements;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2006;	Essentially Pure Ingredients® (EPI);	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2006;	herbal teas;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2006;	sports nutrition line of products;	Marketed;	proprietary formulations;	20;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2007;	 Dietary supplements;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2007;	Essentially Pure Ingredients® (EPI);	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2007;	herbal teas;	Marketed;	proprietary formulations;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2007;	sports nutrition line of products;	Marketed;	proprietary formulations;	20;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2007;	  Nu Hair® and Shen Min®;	Marketed;	Acquired;	;	;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2007;	 Promensil® ;	Marketed;	Acquired;	21;	20;	;		;	;		
wvcs19980001025573;	NATROL INC;	10K;	1998;	2007;	     Trinovin®;	Marketed;	Acquired;	21;	20;	3;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	s-1;	1999;	1999;	BM101;	BLA;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	s-1;	1999;	1999;	BM102;	Preclinical;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	s-1;	1999;	1999;	BM201;	Preclinical;	Carbohydrate-active Enzymes;	8;	;	;		2008;	-1;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	s-1;	1999;	1999;	BM202.;	Preclinical;	Carbohydrate-active Enzymes;	8;	;	;		2002;	-1;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	s-1;	1999;	1999;	BM301 and BM302;	Preclinical;	Carbohydrate-active Enzymes;	23;	;	;		2002;	-1;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	s-1;	1999;	1999;	carbohydrate-active enzyme;	Development;	Carbohydrate-active Enzymes;	5;	;	;		2001;	1;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	s-1;	1999;	1999;	 FACE Imaging System;	Marketed;	FACE(R);	60;	2;	;		2001;	-0.75;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	424B;	1999;	1999;	BM101;	BLA;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	424B;	1999;	1999;	BM102;	Preclinical;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	424B;	1999;	1999;	BM201;	Preclinical;	Carbohydrate-active Enzymes;	8;	;	;		2008;	-1;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	424B;	1999;	1999;	BM202.;	Preclinical;	Carbohydrate-active Enzymes;	8;	;	;		2002;	-1;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	424B;	1999;	1999;	BM301 and BM302;	Preclinical;	Carbohydrate-active Enzymes;	23;	;	;		2002;	-1;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	424B;	1999;	1999;	carbohydrate-active enzyme;	Development;	Carbohydrate-active Enzymes;	5;	;	;		2001;	1;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	424B;	1999;	1999;	 FACE Imaging System;	Marketed;	FACE(R);	60;	2;	;		2001;	-0.75;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2000;	2000;	AldurazymeTM;	Phase II;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2000;	2000;	BM102;	orphan  drug  designation;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2000;	2000;	BM201;	Preclinical;	Carbohydrate-active Enzymes;	8;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2000;	2000;	BM202.;	Preclinical;	Carbohydrate-active Enzymes;	8;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2000;	2000;	BM301 and BM302;	Preclinical;	Carbohydrate-active Enzymes;	23;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2001;	2001;	AldurazymeTM;	Phase II;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2001;	2001;	RhASB ;	Phase I;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2001;	2001;	Vibriolysin ;	Preclinical;	Carbohydrate-active Enzymes;	8;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2002;	2002;	AldurazymeTM;	Phase III;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2002;	2002;	 AryplaseTM;	Phase I;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2002;	2002;	Vibriolysin ;	Phase I;	Carbohydrate-active Enzymes;	8;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2002;	2002;	 Neutralase(TM);	Phase II;	Carbohydrate-active Enzymes;	;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2002;	2002;	Phenylase;	PreClincal;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2003;	2003;	AldurazymeTM;	Pre-Market;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2003;	2003;	 AryplaseTM;	Phase II;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2003;	2003;	Vibrilase;	Phase I;	Carbohydrate-active Enzymes;	8;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2003;	2003;	 Neutralase(TM);	Phase III;	Carbohydrate-active Enzymes;	;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2003;	2003;	Phenylase;	PreClincal;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2004;	2004;	AldurazymeTM;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2004;	2004;	 AryplaseTM;	Phase III;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2004;	2004;	Vibrilase;	Phase IB;	Carbohydrate-active Enzymes;	8;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2004;	2004;	 Neutralase(TM);	Phase III;	Carbohydrate-active Enzymes;	;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2004;	2004;	Phenoptin and Phenylase™;	PreClincal;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2004;	2004;	NeuroTrans;	Development;	NeuroTrans;	27;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2004;	2004;	Immune Tolerance Technology;	Development;	Immune Tolerance Technology;	27;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2005;	2005;	AldurazymeTM;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2005;	2005;	rhASB;	Phase III;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2005;	2005;	Vibrilase;	Phase IB;	Carbohydrate-active Enzymes;	8;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2005;	2005;	Phenylase;	PreClincal;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2005;	2005;	Phenoptin;	Phase II;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2005;	2005;	NeuroTrans;	Development;	NeuroTrans;	27;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2005;	2005;	Immune Tolerance Technology;	Preclinical;	Immune Tolerance Technology;	27;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2005;	2005;	Orapred;	Marketed;	Orapred intellectual property;	5;	29;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2006;	2006;	AldurazymeTM;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2006;	2006;	Naglazyme;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2006;	2006;	Vibrilase;	Phase IB;	Carbohydrate-active Enzymes;	8;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2006;	2006;	Phenylase;	PreClincal;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2006;	2006;	Phenoptin;	Phase III;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2006;	2006;	Immune Tolerance Technology;	Preclinical;	Immune Tolerance Technology;	27;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2006;	2006;	Orapred;	Marketed;	Orapred intellectual property;	5;	29;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2007;	2007;	AldurazymeTM;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2007;	2007;	Naglazyme;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2007;	2007;	6R-BH4;	Phase II;	Carbohydrate-active Enzymes;	21;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2007;	2007;	Phenylase;	PreClincal;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2007;	2007;	Kuvan;	Phase III;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2007;	2007;	Immune Tolerance Technology;	Preclinical;	Immune Tolerance Technology;	27;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2008;	2008;	AldurazymeTM;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2008;	2008;	Naglazyme;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2008;	2008;	6R-BH4;	Phase II;	Carbohydrate-active Enzymes;	21;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2008;	2008;	PEG-PAL;	PreClincal;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2008;	2008;	Kuvan;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2008;	2008;	Immune Tolerance Technology;	Preclinical;	Immune Tolerance Technology;	27;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2009;	2009;	AldurazymeTM;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2009;	2009;	Naglazyme;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2009;	2009;	6R-BH4;	Phase II;	Carbohydrate-active Enzymes;	21;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2009;	2009;	PEG-PAL;	PreClincal;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2009;	2009;	Kuvan;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2009;	2009;	GALNS for Morquio Syndrome Type A;	PreClincal;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2010;	2010;	AldurazymeTM;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2010;	2010;	Naglazyme;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2010;	2010;	PEG-PAL;	Phase I;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2010;	2010;	Kuvan;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2010;	2010;	GALNS for Morquio Syndrome Type A;	Phase II;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2010;	2010;	Firdapse ;	Marketed;	;	5;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2010;	2010;	BMN-195 ;	Phase I;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2011;	2011;	AldurazymeTM;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2011;	2011;	Naglazyme;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2011;	2011;	PEG-PAL;	Phase II;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2011;	2011;	Kuvan;	Marketed;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2011;	2011;	GALNS for Morquio Syndrome Type A;	Phase II;	Carbohydrate-active Enzymes;	30;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2011;	2011;	Firdapse ;	Marketed;	;	5;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2011;	2011;	BMN-701;	Phase I;	;	;	;	;		;	;		
wvcs19990001048477;	BIOMARIN PHARMACEUTICAL INC;	10K;	2011;	2011;	BMN-673;	Phase I;	 (PARP) inhibitor;	22;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	S-1;	1999;	1999;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	S-1;	1999;	1999;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	S-1;	1999;	1999;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	S-1;	1999;	1999;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	22;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	S-1;	1999;	1999;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	S-1;	1999;	1999;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	S-1;	1999;	1999;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	S-1;	1999;	1999;	Oxyglobin;	Marketed;	OXYGENATION TECHNOLOGY;	27;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	424B;	1999;	1999;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	424B;	1999;	1999;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	424B;	1999;	1999;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	424B;	1999;	1999;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	22;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	424B;	1999;	1999;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	424B;	1999;	1999;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	424B;	1999;	1999;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	424B;	1999;	1999;	Oxyglobin;	Marketed;	OXYGENATION TECHNOLOGY;	27;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2000;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2000;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2000;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2000;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2000;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	22;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2000;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2000;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2000;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2000;	Oxyglobin;	Marketed;	OXYGENATION TECHNOLOGY;	27;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2001;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2001;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2001;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2001;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2001;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	22;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2001;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2001;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2001;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2001;	Oxyglobin;	Marketed;	OXYGENATION TECHNOLOGY;	27;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2002;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2002;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2002;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2002;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2002;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	22;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2002;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2002;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2002;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2002;	Oxyglobin;	Marketed;	OXYGENATION TECHNOLOGY;	27;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2003;	 Hemopure;	Post Clinical;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2003;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2003;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2003;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2003;	 Hemopure;	Phase I;	OXYGENATION TECHNOLOGY;	22;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2003;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2003;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2003;	Oxyglobin;	Marketed;	OXYGENATION TECHNOLOGY;	27;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2004;	 Hemopure;	Post Clinical;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2004;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2004;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2004;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2004;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2004;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2004;	Oxyglobin;	Marketed;	OXYGENATION TECHNOLOGY;	27;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2005;	 Hemopure;	Post Clinical;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2005;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2005;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2005;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2005;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2005;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2005;	Oxyglobin;	Marketed;	OXYGENATION TECHNOLOGY;	27;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2006;	 Hemopure;	Post Clinical;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2006;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2006;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2006;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2006;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2006;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2006;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2006;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2006;	Oxyglobin;	Marketed;	OXYGENATION TECHNOLOGY;	27;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2007;	 Hemopure;	Post Clinical;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2007;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2007;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2007;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2007;	 Hemopure;	Phase III;	OXYGENATION TECHNOLOGY;	25;	27;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2007;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2007;	 Hemopure;	Preclinical;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2007;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2007;	Oxyglobin;	Marketed;	OXYGENATION TECHNOLOGY;	27;	;	;		;	;		
wvcs19990000815508;	BIOPURE CORP;	10K;	1999;	2007;	 Hemopure;	Phase II;	OXYGENATION TECHNOLOGY;	21;	25;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	S-1;	1999;	1999;	AIDSVAX;	Phase III;	;	23;	;	;		2004;	-0.3301;		
wvcs19990001036968;	diaDexus, Inc.;	424B;	1999;	1999;	AIDSVAX;	Phase III;	;	23;	;	;		2004;	-0.3301;		
wvcs19990001036968;	diaDexus, Inc.;	424B;	1999;	1999;	AIDSVAX B ;	Phase II;	;	23;	;	;		2004;	2.1667;		
wvcs19990001036968;	diaDexus, Inc.;	424B;	1999;	1999;	AIDSVAX B/B';	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	424B;	1999;	1999;	AIDSVAX B/E;	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2000;	AIDSVAX;	Phase III;	;	23;	;	;		2004;	-0.3301;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2000;	AIDSVAX B ;	Phase II;	;	23;	;	;		2004;	2.1667;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2000;	AIDSVAX B/B';	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2000;	AIDSVAX B/E;	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2001;	AIDSVAX;	Phase III;	;	23;	;	;		2004;	-0.3301;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2001;	AIDSVAX B ;	Phase II;	;	23;	;	;		2004;	2.1667;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2001;	AIDSVAX B/B';	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2001;	AIDSVAX B/E;	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2002;	AIDSVAX;	Phase III;	;	23;	;	;		2004;	27;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2002;	AIDSVAX B ;	Phase II;	;	23;	;	;		2004;	2.8;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2002;	AIDSVAX B/B';	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2002;	AIDSVAX B/E;	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2003;	rPA102 vaccine;	Phase I;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2003;	rPA102 vaccine;	Phase I;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2003;	LC16-Kaketsuken;	Preclinical;	;	23;	;	;		2005;	-0.8667;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2003;	AIDSVAX B/B';	Phase III;	Genentech version of the gp120 protein;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2003;	AIDSVAX B/E;	Phase III;	Genentech version of the gp120 protein;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2004;	rPA102 vaccine;	Phase I;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2004;	rPA102 vaccine;	Phase I;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2004;	LC16m8 ;	Preclinical;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2004;	Anthrax Monoclonal Antibody;	Preclinical;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2004;	AIDSVAX B/B';	Phase III;	Genentech version of the gp120 protein;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2004;	AIDSVAX B/E;	Phase III;	Genentech version of the gp120 protein;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2005;	rPA102 vaccine;	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2005;	LC16m8 ;	Phase I;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2006;	rPA102 vaccine;	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2006;	LC16m8 ;	Phase II;	;	23;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2006;	MERGER;	;	;	;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2006;	MERGER;	;	;	;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2006;	MERGER;	;	;	;	;	;		;	;		
wvcs19990001036968;	diaDexus, Inc.;	10-K;	1999;	2006;	MERGER;	;	;	;	;	;		;	;	
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	FastTrack Kit;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	Micro-FastTrack Kit;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	TA Cloning Kit ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-0.1429;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	Zero Blunt PCR Cloning ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	 TOPO TA Cloning Kit ;	Marketed;	TOPO TA Cloning technology;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	Expression Vectors ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-0.6154;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	MaxBac Baculovirus;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	Ecdysone-Inducible Mammalian Expression ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	 GeneStorm Expression- Ready Clones   ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	Hybrid Hunter Systems;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-0.75;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	One Shot INVALPHAF;	Marketed;	gene cloning and gene expression technologies.;	;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	Zeocin Antibiotic ;	Marketed;	gene cloning and gene expression technologies.;	;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	S-1;	1998;	1998;	Invitrogenomics;	Marketed;	TOPO TA Cloning technology;	;	;	;		2002;	8.7778;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	FastTrack Kit;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	Micro-FastTrack Kit;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	TA Cloning Kit ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-0.1429;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	Zero Blunt PCR Cloning ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	 TOPO TA Cloning Kit ;	Marketed;	TOPO TA Cloning technology;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	Expression Vectors ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-0.6154;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	MaxBac Baculovirus;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	Ecdysone-Inducible Mammalian Expression ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	 GeneStorm Expression- Ready Clones   ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	8.8;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	Hybrid Hunter Systems;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-0.75;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	One Shot INVALPHAF;	Marketed;	gene cloning and gene expression technologies.;	;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	Zeocin Antibiotic ;	Marketed;	gene cloning and gene expression technologies.;	;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	424;	1998;	1999;	Invitrogenomics;	Marketed;	TOPO TA Cloning technology;	;	;	;		2002;	8.7778;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	FastTrack Kit;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Micro-FastTrack Kit;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	TA Cloning Kit ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-0.7778;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Zero Blunt PCR Cloning ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	 TOPO TA Cloning Kit ;	Marketed;	TOPO TA Cloning technology;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Expression Vectors ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	-0.8148;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	MaxBac Baculovirus;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Ecdysone-Inducible Mammalian Expression ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	 GeneStorm Expression- Ready Clones   ;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Hybrid Hunter Systems;	Marketed;	gene cloning and gene expression technologies.;	30;	;	;		2002;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Pre-Cast NuPAGE Gels;	Marketed;	re-cast gel electrophoresis system;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Pre-Cast Tris Glycine Gels ;	Marketed;	re-cast gel electrophoresis system;	30;	;	;		2002;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Pre-Cast Isoelectric Focusing Gels;	Marketed;	re-cast gel electrophoresis system;	30;	;	;		2002;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Pre-Cast TBE Polyacrylamide Gels;	Marketed;	re-cast gel electrophoresis system;	30;	;	;		2002;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	WesternBreeze;	Marketed;	re-cast gel electrophoresis system;	30;	;	;		2002;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	XCell II Mini-Cell and Blotting Apparatus;	Marketed;	re-cast gel electrophoresis system;	30;	;	;		2002;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	One Shot INVALPHAF;	Marketed;	gene cloning and gene expression technologies.;	;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Zeocin Antibiotic ;	Marketed;	gene cloning and gene expression technologies.;	;	;	;		2002;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2000;	Invitrogenomics;	Marketed;	TOPO TA Cloning technology;	;	;	;		2002;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	TOPO(R) Cloning Systems;	Marketed;	TOPO TA Cloning technology;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	GATEWAY(3) Cloning Technology;	Marketed;	GATEWAY(3) Cloning Technology;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	Mammalian Expression System;	Marketed;	Mammalian Expression System;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	Baculovirus Expression Systems;	Marketed;	Bac-To-Bac System;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	PICHIA PASTORIS Expression Systems;	Marketed;	PICHIA System;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	NuPAGE(R) Precast PAGE Gels;	Marketed;	NuPAGE gel formulations;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	E-Gel(R) Precast Agarose Gels;	Marketed;	re-cast gel electrophoresis system;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	CUSTOM OLIGONUCLEOTIDE SYNTHESIS;	Marketed;	 Parallel Array Synthesis technology;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	COMPETENT BACTERIAL STRAINS;	Marketed;	N/A;	;	;	;		2005;	0.1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	ResGen(TM);	Marketed;	ResGen(TM);	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	PLATINUM(R) Taq DNA Polymerase;	Marketed;	PLATINUM(R) Taq DNA Polymerase;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	PLATINUM(R) Pfx DNA Polymerase;	Marketed;	PLATINUM(R) Pfx DNA Polymerase;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	Fetal Bovine Serum;	Marketed;	N/A;	;	;	;		2005;	-0.2;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2001;	 Liquid and Powdered Culture Media:;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	;	;	;		2005;	1.4286;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	TOPO(R) Cloning Systems;	Marketed;	TOPO TA Cloning technology;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	GATEWAY(3) Cloning Technology;	Marketed;	GATEWAY(3) Cloning Technology;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	Mammalian Expression System;	Marketed;	Mammalian Expression System;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	Baculovirus Expression Systems;	Marketed;	Bac-To-Bac System;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	PICHIA PASTORIS Expression Systems;	Marketed;	PICHIA System;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	NuPAGE(R) Precast PAGE Gels;	Marketed;	NuPAGE gel formulations;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	E-Gel(R) Precast Agarose Gels;	Marketed;	re-cast gel electrophoresis system;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	CUSTOM OLIGONUCLEOTIDE SYNTHESIS;	Marketed;	 Parallel Array Synthesis technology;	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	COMPETENT BACTERIAL STRAINS;	Marketed;	N/A;	;	;	;		2005;	0.1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	ResGen(TM);	Marketed;	ResGen(TM);	30;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	PLATINUM(R) Taq DNA Polymerase;	Marketed;	PLATINUM(R) Taq DNA Polymerase;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	PLATINUM(R) Pfx DNA Polymerase;	Marketed;	PLATINUM(R) Pfx DNA Polymerase;	;	;	;		2005;	0;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	Fetal Bovine Serum;	Marketed;	N/A;	;	;	;		2005;	-0.2;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2002;	 Liquid and Powdered Culture Media:;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	;	;	;		2005;	1.4286;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	TOPO(R) Cloning Systems;	Marketed;	TOPO TA Cloning technology;	;	;	;		2005;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	GATEWAY(3) Cloning Technology;	Marketed;	GATEWAY(3) Cloning Technology;	;	;	;		2005;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	Mammalian Expression System;	Marketed;	Mammalian Expression System;	30;	;	;		2005;	-0.8571;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	Baculovirus Expression Systems;	Marketed;	Bac-To-Bac System;	30;	;	;		2005;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	PICHIA PASTORIS Expression Systems;	Marketed;	PICHIA System;	30;	;	;		2005;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	NuPAGE(R) Precast PAGE Gels;	Marketed;	NuPAGE gel formulations;	;	;	;		2005;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	E-Gel(R) Precast Agarose Gels;	Marketed;	re-cast gel electrophoresis system;	;	;	;		2005;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	CUSTOM OLIGONUCLEOTIDE SYNTHESIS;	Marketed;	 Parallel Array Synthesis technology;	30;	;	;		2005;	-0.2857;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	COMPETENT BACTERIAL STRAINS;	Marketed;	N/A;	;	;	;		2005;	0.5714;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	ResGen(TM);	Marketed;	ResGen(TM);	30;	;	;		2005;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	PLATINUM(R) Taq DNA Polymerase;	Marketed;	PLATINUM(R) Taq DNA Polymerase;	;	;	;		2005;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	PLATINUM(R) Pfx DNA Polymerase;	Marketed;	PLATINUM(R) Pfx DNA Polymerase;	;	;	;		2005;	-1;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	Fetal Bovine Serum;	Marketed;	N/A;	;	;	;		2005;	-0.4286;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2003;	 Liquid and Powdered Culture Media:;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	;	;	;		2005;	1.4286;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2004;	, BioDiscovery products;	Marketed;	Prop. Cloning Technology;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2004;	, BioDiscovery products;	Marketed;	Expression System;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2004;	, BioDiscovery products;	Marketed;	Gel Formulations;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2004;	 BioProduction products;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2004;	 BioProduction products;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2005;	, BioDiscovery products;	Marketed;	Prop. Cloning Technology;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2005;	, BioDiscovery products;	Marketed;	Expression System;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2005;	, BioDiscovery products;	Marketed;	Gel Formulations;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2005;	 BioProduction products;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2005;	 BioProduction products;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2006;	, BioDiscovery products;	Marketed;	Prop. Cloning Technology;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2006;	, BioDiscovery products;	Marketed;	Expression System;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2006;	, BioDiscovery products;	Marketed;	Gel Formulations;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2006;	 BioProduction products;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2006;	 BioProduction products;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2007;	, BioDiscovery products;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2007;	, BioDiscovery products;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2007;	, BioDiscovery products;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2007;	 BioProduction products;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2007;	 BioProduction products;	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2008;	, BioDiscovery products;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2008;	, BioDiscovery products;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2008;	, BioDiscovery products;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2008;	Cell Systems (CS);	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	INVITROGEN CORP;	10-K;	1998;	2008;	Cell Systems (CS);	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2009;	, BioDiscovery products;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2009;	, BioDiscovery products;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2009;	, BioDiscovery products;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2009;	Cell Systems (CS);	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2009;	Cell Systems (CS);	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2009;	Applied Biosystems (AB;	Marketed;	Applied Biosystems;	;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2009;	Applied Biosystems (AB;	Marketed;	Applied Biosystems;	;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2010;	 Molecular Biology Systems;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2010;	 Molecular Biology Systems;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2010;	 Molecular Biology Systems;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2010;	Cell Systems (CS);	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2010;	Cell Systems (CS);	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2010;	 Genetic Systems;	Marketed;	 Genetic Systems;	;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2010;	 Genetic Systems;	Marketed;	 Genetic Systems;	;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2010;	Applied Biosystems (AB;	Marketed;	Applied Biosystems;	;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2010;	Cell Systems (CS);	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2011;	 Molecular Biology Systems;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2011;	 Molecular Biology Systems;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2011;	 Molecular Biology Systems;	Marketed;	 Molecular Biology Systems;	30;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2011;	Cell Systems (CS);	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2011;	Cell Systems (CS);	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2011;	 Genetic Systems;	Marketed;	 Genetic Systems;	;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2011;	 Genetic Systems;	Marketed;	 Genetic Systems;	;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2011;	Applied Biosystems (AB;	Marketed;	Applied Biosystems;	;	;	;		;	;		
wvcs19990001073431;	Life Technologies Corp;	10-K;	1998;	2011;	Cell Systems (CS);	Marketed;	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ;	70;	;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	DiscoverWorks Technology Platform;	Marketed;	DiscoverWorks Technology Platform;	;	;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	 GPCR Technology Program;	Marketed;	 GPCR Technology Program;	5;	29;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	3DP-4815;	Phase I;	 DiscoverWorks;	21;	;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	AvB3/AvB5;	Preclinical;	 DiscoverWorks;	22;	20;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	AvB3/AvB5;	Preclinical;	 DiscoverWorks;	20;	;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	AvB3/AvB5;	Preclinical;	 DiscoverWorks;	21;	20;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	  C1s-1;	Preclinical;	 GPCR Technology Program;	5;	;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	  C1s-1;	Preclinical;	 DiscoverWorks;	29;	;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	 FXa;	Discovery;	 DiscoverWorks;	21;	;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	PAI-1;	Discovery;	 DiscoverWorks;	21;	;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	PAI-1;	Discovery;	 DiscoverWorks;	22;	;	;		;	;		
wvcs20000000914201;	3 DIMENSIONAL PHARMACEUTICALS INC;	S-1;	2000;	2000;	hdm2 (mdm);	Discovery;	 DiscoverWorks;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	S-1;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	22;	40;	;		2009;	-0.76;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	S-1;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	S-1;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	S-1;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	S-1;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	S-1;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	21;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	S-1;	2000;	2000;	RSR13;	Preclinical;	allosteric modification;	21;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	S-1;	2000;	2000;	RSR46   ;	Preclinical;	allosteric modification;	9;	21;	;		2004;	-1;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	S-1;	2000;	2000;	JP7 ;	Preclinical;	allosteric modification;	9;	21;	;		2004;	-1;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	424B;	2000;	2000;	RSR13;	Phase III;	allosteric modification;	22;	40;	;		2009;	-0.76;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	424B;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	424B;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	424B;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	424B;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	424B;	2000;	2000;	RSR13;	Phase II;	allosteric modification;	21;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	424B;	2000;	2000;	RSR13;	Preclinical;	allosteric modification;	21;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	424B;	2000;	2000;	RSR46   ;	Preclinical;	allosteric modification;	9;	21;	;		2004;	-1;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	424B;	2000;	2000;	JP7 ;	Preclinical;	allosteric modification;	9;	21;	;		2004;	-1;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2001;	RSR13;	Phase III;	allosteric modification;	22;	40;	;		2009;	-0.76;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2001;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2001;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2001;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2001;	RSR13;	Phase II;	allosteric modification;	;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2001;	RSR13;	Phase II;	allosteric modification;	21;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2001;	RSR13;	Preclinical;	allosteric modification;	21;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2001;	RSR46   ;	Preclinical;	allosteric modification;	9;	21;	;		2004;	-1;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2001;	JP7 ;	Preclinical;	allosteric modification;	9;	21;	;		2004;	-1;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2002;	RSR13;	Phase III;	allosteric modification;	22;	40;	;		2009;	-0.76;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2002;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2002;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2002;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2002;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2002;	RSR13;	Phase II;	allosteric modification;	;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2002;	RSR13;	Phase II;	allosteric modification;	21;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2002;	RSR13;	Preclinical;	allosteric modification;	21;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2002;	RSR46   ;	Preclinical;	allosteric modification;	9;	21;	;		2004;	-1;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2002;	JP7 ;	Preclinical;	allosteric modification;	9;	21;	;		2004;	-1;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	RSR13;	Phase III;	allosteric modification;	22;	40;	;		2009;	-0.76;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	RSR13;	Phase III;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	RSR13;	Phase II;	allosteric modification;	;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	RSR13;	Phase II;	allosteric modification;	21;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	RSR13;	Preclinical;	allosteric modification;	21;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	PDX;	Phase I;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2003;	BGP-15;	Preclinical;	 license from N-Gene Research Laboratories to intellectual property covering BGP-15, ;	22;	70;	;		2005;	-0.9878;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2004;	RSR13;	Phase III;	allosteric modification;	22;	40;	;		2009;	-0.76;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2004;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2004;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2004;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2004;	RSR13;	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2004;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2004;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2004;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2005;	EFAPROXYN (efaproxiral);	Phase III;	allosteric modification;	22;	40;	;		2009;	-0.76;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2005;	EFAPROXYN (efaproxiral);	Phase I;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2005;	EFAPROXYN (efaproxiral);	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2005;	EFAPROXYN (efaproxiral);	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2005;	EFAPROXYN (efaproxiral);	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2005;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2005;	PDX;	Phase I;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2005;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2005;	RH1;	Phase I;	 license from the University of Colorado Health Sciences Center, the University of Salford and Cancer Research Technology to certain intellectual property surrounding a proprietary molecule known as RH1;	22;	;	;		2010;	-0.0714;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2006;	EFAPROXYN (efaproxiral);	Phase III;	allosteric modification;	22;	40;	;		2009;	-0.76;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2006;	EFAPROXYN (efaproxiral);	Phase I;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2006;	EFAPROXYN (efaproxiral);	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2006;	PDX;	Phase I;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2006;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2006;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2006;	RH1;	Phase I;	 license from the University of Colorado Health Sciences Center, the University of Salford and Cancer Research Technology to certain intellectual property surrounding a proprietary molecule known as RH1;	22;	;	;		2010;	-0.0714;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2007;	EFAPROXYN (efaproxiral);	Phase III;	allosteric modification;	22;	40;	;		2009;	-0.4286;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2007;	EFAPROXYN (efaproxiral);	Phase I;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2007;	EFAPROXYN (efaproxiral);	Phase II;	allosteric modification;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2007;	PDX;	Phase I;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2007;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2007;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2007;	RH1;	Phase I;	 license from the University of Colorado Health Sciences Center, the University of Salford and Cancer Research Technology to certain intellectual property surrounding a proprietary molecule known as RH1;	22;	;	;		2010;	-0.0714;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2008;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2008;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2008;	PDX;	Phase I;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2008;	PDX;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2008;	RH1;	Phase I;	 license from the University of Colorado Health Sciences Center, the University of Salford and Cancer Research Technology to certain intellectual property surrounding a proprietary molecule known as RH1;	22;	;	;		2010;	-0.9206;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2009;	Pralatrexate (PDX);	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2009;	Pralatrexate (PDX);	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2009;	Pralatrexate (PDX);	Phase I;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2009;	Pralatrexate (PDX);	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2009;	Pralatrexate (PDX);	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	3;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2010;	FOLOTYNTM ;	Marketed;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2010;	FOLOTYNTM ;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2010;	FOLOTYNTM ;	Phase I;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	27;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2010;	FOLOTYNTM ;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	;	;		;	;		
wvcs20000001097264;	ALLOS THERAPEUTICS INC;	10-K;	2000;	2010;	FOLOTYNTM ;	Phase II;	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX;	22;	3;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	S-1;	2000;	2000;	Ramoplanin Oral;	Phase II;	in-licensed five antibiotic technologies;	23;	;	;		2003;	-0.8621;		
wvcs20000001103390;	Ardea Bioscience;	S-1;	2000;	2000;	Protegrin IB-367 Rinse;	Phase II;	in-licensed five antibiotic technologies;	22;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	S-1;	2000;	2000;	Protegrin IB-367 Gel ;	Phase I;	in-licensed five antibiotic technologies;	23;	29;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	S-1;	2000;	2000;	IB-880 SERIES;	Preclinical;	in-licensed five antibiotic technologies;	23;	;	;		2003;	-0.4;		
wvcs20000001103390;	Ardea Bioscience;	S-1;	2000;	2000;	IB-863 SERIES;	Preclinical;	in-licensed five antibiotic technologies;	23;	;	;		2003;	-0.25;		
wvcs20000001103390;	Ardea Bioscience;	S-1;	2000;	2000;	IB-974 SERIES;	Preclinical;	in-licensed five antibiotic technologies;	23;	70;	;		2002;	-1;		
wvcs20000001103390;	Ardea Bioscience;	424B;	2000;	2000;	Ramoplanin Oral;	Phase II;	in-licensed five antibiotic technologies;	23;	;	;		2003;	-0.8621;		
wvcs20000001103390;	Ardea Bioscience;	424B;	2000;	2000;	Protegrin IB-367 Rinse;	Phase II;	in-licensed five antibiotic technologies;	22;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	424B;	2000;	2000;	Protegrin IB-367 Gel ;	Phase I;	in-licensed five antibiotic technologies;	23;	29;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	424B;	2000;	2000;	IB-880 SERIES;	Preclinical;	in-licensed five antibiotic technologies;	23;	;	;		2003;	-0.4;		
wvcs20000001103390;	Ardea Bioscience;	424B;	2000;	2000;	IB-863 SERIES;	Preclinical;	in-licensed five antibiotic technologies;	23;	;	;		2003;	-0.25;		
wvcs20000001103390;	Ardea Bioscience;	424B;	2000;	2000;	IB-974 SERIES;	Preclinical;	in-licensed five antibiotic technologies;	23;	70;	;		2002;	-1;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2001;	Ramoplanin Oral;	Phase III;	in-licensed five antibiotic technologies;	23;	;	;		2003;	-0.3333;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2001;	Iseganan HCl oral solution;	Phase III;	in-licensed five antibiotic technologies;	22;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2001;	Iseganan HCl oral solution;	Phase II;	in-licensed five antibiotic technologies;	23;	29;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2001;	Ramoplanin ointment;	Phase I;	in-licensed five antibiotic technologies;	23;	70;	;		2004;	-0.3333;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2001;	Ramoplanin Oral;	IND;	in-licensed five antibiotic technologies;	23;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2001;	IB-880 SERIES;	Preclinical;	in-licensed five antibiotic technologies;	23;	;	;		2003;	-0.5;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2001;	IB-863 SERIES;	Preclinical;	in-licensed five antibiotic technologies;	23;	;	;		2003;	-0.5;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2002;	Iseganan HCl oral solution;	Phase III;	in-licensed five antibiotic technologies;	22;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2002;	Iseganan HCl oral solution;	Phase II;	in-licensed five antibiotic technologies;	23;	29;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2002;	Iseganan HCl Solution;	Phase I;	in-licensed five antibiotic technologies;	23;	29;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2002;	Ramoplanin ointment;	Phase I;	in-licensed five antibiotic technologies;	23;	70;	;		2004;	-0.954;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2003;	Iseganan HCl oral solution;	Phase III;	in-licensed five antibiotic technologies;	23;	29;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2003;	Iseganan HCl Solution;	Phase I;	in-licensed five antibiotic technologies;	23;	29;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2004;	Iseganan HCl oral solution;	Phase III;	in-licensed five antibiotic technologies;	23;	29;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2004;	Iseganan HCl Solution;	Phase I;	in-licensed five antibiotic technologies;	23;	29;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2005;	terminated	;	in-licensed five antibiotic technologies;	;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2005;	terminated	;	in-licensed five antibiotic technologies;	;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2006;	terminated	;	in-licensed five antibiotic technologies;	;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2006;	terminated	;	in-licensed five antibiotic technologies;	;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2007;	800 Series Program;	Phase I;	 intellectual propertyValeant Research & Development, Inc.;	23;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2007;	900 Series Program,;	Preclinical;	 intellectual propertyValeant Research & Development, Inc.;	23;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2007;	100 Series Program;	Preclinical;	 intellectual propertyValeant Research & Development, Inc.;	5;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2007;	100 Series Program;	Preclinical;	 intellectual propertyValeant Research & Development, Inc.;	22;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2008;	RDEA806 ;	Phase II;	(NNRTI;	23;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2008;	2nd generation NNRTI;	Preclinical;	(NNRTI;	23;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2008;	RDEA806;	Phase II;	(NNRTI;	5;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2008;	RDEA119 ;	Phase I;	 intellectual propertyValeant Research & Development, Inc.;	22;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2008;	RDEA119;	Phase I;	MEK Inhibitor Program;	5;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2008;	2nd Generation MEK Inhibitor Program;	Preclinical;	MEK Inhibitor Program;	22;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2009;	RDEA806 ;	Phase II;	(NNRTI;	23;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2009;	RDEA119 ;	Phase II;	 intellectual propertyValeant Research & Development, Inc.;	22;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2009;	RDEA119;	Phase I;	 intellectual propertyValeant Research & Development, Inc.;	5;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2009;	RDEA436;	Preclinical;	MEK inhibitor program;	5;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2009;	RDEA594;	Phase I;	(NNRTI;	5;	;	;		;	;		
wvcs20000001103390;	Ardea Bioscience;	10-K;	2000;	2009;	RDEA427;	Preclinical;	(NNRTI;	23;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	S-1;	2000;	2000;	AGI-1067;	Phase II;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	S-1;	2000;	2000;	AGI-series;	Preclinical;	 v-protectant;	5;	29;	;		2006;	-0.6207;		
wvcs20000001107601;	ATHEROGENICS INC;	S-1;	2000;	2000;	AGI-series, oral ;	Preclinical;	 v-protectant;	5;	20;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	S-1;	2000;	2000;	AGI-series, oral ;	Preclinical;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	S-1;	2000;	2000;	Oral product;	Research;	 v-protectant;	5;	29;	;		2006;	-1;		
wvcs20000001107601;	ATHEROGENICS INC;	S-1;	2000;	2000;	Oxykine diagnostic ;	Preclinical;	 v-protectant;	5;	;	;		2004;	-0.6667;		
wvcs20000001107601;	ATHEROGENICS INC;	424B;	2000;	2000;	AGI-1067;	Phase II;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	424B;	2000;	2000;	AGI-series;	Preclinical;	 v-protectant;	5;	29;	;		2006;	-0.6207;		
wvcs20000001107601;	ATHEROGENICS INC;	424B;	2000;	2000;	AGI-series, oral ;	Preclinical;	 v-protectant;	5;	20;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	424B;	2000;	2000;	AGI-series, oral ;	Preclinical;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	424B;	2000;	2000;	Oral product;	Research;	 v-protectant;	5;	29;	;		2006;	-1;		
wvcs20000001107601;	ATHEROGENICS INC;	424B;	2000;	2000;	Oxykine diagnostic ;	Preclinical;	 v-protectant;	5;	;	;		2004;	-0.6667;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2001;	AGI-1067;	Phase II;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2001;	AGIX-4207 ;	 IND filed     ;	 v-protectant;	5;	20;	;		2006;	-0.6207;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2001;	AGI-series;	Preclinical;	 v-protectant;	5;	29;	20;		2004;	0;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2001;	AGI-series, oral ;	Preclinical;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2001;	Oral product;	Research;	 v-protectant;	5;	29;	;		2006;	-1;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2001;	 OXYKINE® assay;	Preclinical;	 v-protectant;	5;	;	;		2004;	-0.6667;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2002;	AGI-1067;	Phase IIB;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2002;	AGIX-4207 ;	Phase I;	 v-protectant;	5;	20;	;		2006;	-0.6207;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2002;	AGI-series;	Preclinical;	 v-protectant;	5;	29;	20;		2004;	-0.9655;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2002;	AGI-1096;	Phase I;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2002;	Oral product;	Research;	 v-protectant;	5;	29;	;		2006;	-1;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2002;	 OXYKINE® assay;	Preclinical;	 v-protectant;	5;	;	;		2004;	0;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2002;	diagnostics and therapeutic;	Disovery;	MEKK Technology;	5;	29;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2003;	AGI-1067;	Phase III;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2003;	AGIX-4207 ;	Phase II;	 v-protectant;	5;	20;	;		2006;	-0.6207;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2003;	AGI-1096;	Phase I;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2003;	Oral product;	Pre IND;	 v-protectant;	5;	29;	;		2006;	-1;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2003;	diagnostics and therapeutic;	Disovery;	MEKK Technology;	5;	29;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2004;	AGI-1067;	Phase III;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2004;	AGIX-4207 ;	Phase II;	 v-protectant;	5;	20;	;		2006;	-0.89;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2004;	AGI-1096;	Phase I;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2004;	Oral product;	Pre IND;	 v-protectant;	5;	29;	;		2006;	-1;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2004;	diagnostics and therapeutic;	Disovery;	MEKK Technology;	5;	29;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2005;	AGI-1067;	Phase III;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2005;	AGI-1096;	Phase I;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2005;	AGI Series;	Pre IND;	 v-protectant;	5;	29;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2005;	diagnostics and therapeutic;	Disovery;	MEKK Technology;	5;	29;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2005;	AGI Series;	Pre IND;	 v-protectant;	5;	20;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2006;	AGI-1067;	Phase III;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2006;	AGI-1096;	Phase I;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2006;	AGI Series;	Pre IND;	 v-protectant;	5;	29;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2006;	diagnostics and therapeutic;	Disovery;	MEKK Technology;	5;	29;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2006;	AGI Series;	Pre IND;	 v-protectant;	5;	20;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2007;	AGI-1067;	Phase III;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2007;	AGI-1096;	Phase I;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2007;	AGI Series;	Research;	 v-protectant;	5;	29;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2007;	diagnostics and therapeutic;	Disovery;	MEKK Technology;	5;	29;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2007;	AGI Series;	Research;	 v-protectant;	5;	20;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2008;	AGI-1067;	Phase III;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2008;	AGI-1067;	Phase III;	 v-protectant;	5;	24;	;		;	;		
wvcs20000001107601;	ATHEROGENICS INC;	10-K;	2000;	2008;	AGI-1096;	Phase I;	 v-protectant;	5;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	 Provenge(TM)     ;	Phase III;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	APC8020    ;	Phase II;	Antigen Delivery Cassette technology;	22;	;	;		2002;	-0.9589;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	APC8020    ;	Phase II;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	APC80NY   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2003;	-0.6667;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	APC80NY   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	APC80NY   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	 APC80TR;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2003;	1;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	 APC80TR;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	 APC80TR;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	 Danton(TM);	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	 Danton(TM);	Preclinical;	Antigen Delivery Cassette technology;	5;	22;	27;		;	;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	Dantes(TM);	Preclinical;	Antigen Delivery Cassette technology;	5;	20;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	S-1;	2000;	2000;	DACS(R)SC Kit ;	FDA Approved;	cell separation technology;	27;	;	;		2005;	0;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	 Provenge(TM)     ;	Phase III;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	 Mylovenge(TM);	Phase II;	Antigen Delivery Cassette technology;	22;	;	;		2005;	-0.7692;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	 Mylovenge(TM);	Phase II;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	APC80NY   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2003;	-0.6667;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	APC80NY   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	APC80NY   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	 APC80TR;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2003;	1;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	 APC80TR;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	 APC80TR;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	 Danton(TM);	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	 Danton(TM);	Preclinical;	Antigen Delivery Cassette technology;	5;	22;	27;		;	;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	Dantes(TM);	Preclinical;	Antigen Delivery Cassette technology;	5;	20;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	424B;	2000;	2000;	DACS(R)SC Kit ;	FDA Approved;	cell separation technology;	27;	;	;		2005;	0;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	 Provenge(TM)     ;	Phase III;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	 Mylovenge(TM);	Phase II;	Antigen Delivery Cassette technology;	22;	;	;		2005;	-0.7692;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	 Mylovenge(TM);	Phase II;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	APC80NY   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2003;	-0.5;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	APC80NY   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	APC80NY   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	 APC80TR;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2003;	3;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	 APC80TR;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	 APC80TR;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	 Danton(TM);	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	 Danton(TM);	Preclinical;	Antigen Delivery Cassette technology;	5;	22;	27;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	Dantes(TM);	Preclinical;	Antigen Delivery Cassette technology;	5;	20;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	DACS(R)SC Kit ;	FDA Approved;	cell separation technology;	27;	;	;		2005;	0;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2001;	PRI-Immunotherapy (2) ;	Preclinical;	R.W. Johnson technology;	22;	;	;		2004;	-0.6;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	 Provenge(TM)     ;	Phase III;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	 Mylovenge(TM);	Phase II;	Antigen Delivery Cassette technology;	22;	;	;		2005;	-0.7692;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	 Mylovenge(TM);	Phase II;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	CTL8004;	Phase I;	R.W. Johnson technology;	22;	;	;		2004;	0;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	3;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2007;	0;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	CEA ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	MN   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	MN   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	 DN1924  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	 DN1924  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	 DN1921  ;	Preclinical;	Antigen Delivery Cassette technology;	5;	20;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2002;	DACS(R)SC Kit ;	FDA Approved;	cell separation technology;	27;	;	;		2005;	0;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	 Provenge(TM)     ;	Phase III;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	 Mylovenge(TM);	Phase II;	Antigen Delivery Cassette technology;	22;	;	;		2005;	-0.9863;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	 Mylovenge(TM);	Phase II;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2007;	0;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	3;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	CEA ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	MN   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	MN   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	 DN1924  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	 DN1924  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	 DN1921  ;	Preclinical;	Antigen Delivery Cassette technology;	5;	20;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	DACS(R)SC Kit ;	FDA Approved;	cell separation technology;	27;	;	;		2005;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2003;	Telomerase;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	 Provenge(TM)     ;	Phase III;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	APC8024;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2007;	0;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	3;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	CEA ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	MN   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	MN   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	Telomerase;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	PACT;	Preclinical;	proteases that are present on the surface of tumor cells;	22;	;	;		2006;	13;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	Anti-Endotheliase;	Preclinical;	 human antibody technologies ;	22;	;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	Anti-Matriptase;	Preclinical;	 human antibody technologies ;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	 DN1924  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	 DN1924  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2004;	 DN1921  ;	Preclinical;	Antigen Delivery Cassette technology;	5;	20;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	 Provenge(TM)     ;	Phase III;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	APC8024 (Neuvenge);	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	APC8024 (Neuvenge);	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	APC8024 (Neuvenge);	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2007;	8;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	Trp-p8  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	3;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	NY-ESO ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	CEA ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	MN   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	MN   ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	Telomerase;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	Anti-Endotheliase;	Preclinical;	 human antibody technologies ;	22;	;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	Anti-Matriptase;	Preclinical;	 human antibody technologies ;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	 DN1924  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	 DN1924  ;	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2005;	 DN1921  ;	Preclinical;	Antigen Delivery Cassette technology;	5;	20;	;		2007;	-1;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2006;	 Provenge(TM)     ;	Phase III;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2006;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2006;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2006;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2006;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2006;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2006;	CEA ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2006;	CA-9;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2006;	CA-9;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2006;	Anti-Serine Protease;	Preclinical;	 human antibody technologies ;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2007;	 Provenge(TM)     ;	BLA;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2007;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2007;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2007;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2007;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2007;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2007;	CEA ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2007;	CA-9;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2007;	CA-9;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2007;	Anti-Serine Protease;	Preclinical;	 human antibody technologies ;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2008;	 Provenge(TM)     ;	BLA;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2008;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2008;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2008;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2008;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2008;	Trp-p8;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2008;	CEA ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2008;	CA-9;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2008;	CA-9;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2008;	Anti-Serine Protease;	Preclinical;	 human antibody technologies ;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2009;	 Provenge(TM)     ;	BLA;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2009;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2009;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2009;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2009;	D3263;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2009;	CEA ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2009;	CA-9;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2009;	CA-9;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2009;	Anti-Serine Protease;	Preclinical;	 human antibody technologies ;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2009;	Anti-HLA-DR;	Preclinical;	Antigen Delivery Cassette technology;	22;	27;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2010;	 Provenge(TM)     ;	BLA;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2010;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2010;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2010;	Neuvenge (lapuleucel-T;	Phase I;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2010;	D3263;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2010;	CEA ;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2010;	CA-9;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001107332;	DENDREON CORP;	10-K;	2000;	2010;	CA-9;	Preclinical;	Antigen Delivery Cassette technology;	22;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	S-1;	2000;	2000;	Sufentanil  ;	Phase I;	proprietary formulations of traditional small molecule drugs;	62;	;	;		2011;	-0.1;		
wvcs20000001082038;	DURECT CORP;	S-1;	2000;	2000;	Hydromorphone;	Preclinical;	proprietary formulations of traditional small molecule drugs;	62;	22;	42;		2003;	-1;		
wvcs20000001082038;	DURECT CORP;	S-1;	2000;	2000;	Gentamycin   ;	Preclinical;	proprietary formulations of traditional small molecule drugs;	2;	;	;		2003;	-1;		
wvcs20000001082038;	DURECT CORP;	S-1;	2000;	2000;	Cardiovascular Diseases;	Research;	proprietary formulations of traditional small molecule drugs;	21;	;	;		2003;	1.75;		
wvcs20000001082038;	DURECT CORP;	S-1;	2000;	2000;	Vascular Graft;	Research;	proprietary formulations of traditional small molecule drugs;	21;	;	;		2003;	0.8889;		
wvcs20000001082038;	DURECT CORP;	S-1;	2000;	2000;	 Cancer Immunotherapy;	Research;	proprietary formulations of traditional small molecule drugs;	22;	;	;		2003;	-0.3333;		
wvcs20000001082038;	DURECT CORP;	424B4;	2000;	2000;	Sufentanil  ;	Phase I;	proprietary formulations of traditional small molecule drugs;	62;	;	;		2011;	-0.1;		
wvcs20000001082038;	DURECT CORP;	424B4;	2000;	2000;	Hydromorphone;	Preclinical;	proprietary formulations of traditional small molecule drugs;	62;	22;	42;		2003;	-1;		
wvcs20000001082038;	DURECT CORP;	424B4;	2000;	2000;	Gentamycin   ;	Preclinical;	proprietary formulations of traditional small molecule drugs;	2;	;	;		2003;	-1;		
wvcs20000001082038;	DURECT CORP;	424B4;	2000;	2000;	Cardiovascular Diseases;	Research;	proprietary formulations of traditional small molecule drugs;	21;	;	;		2003;	1.75;		
wvcs20000001082038;	DURECT CORP;	424B4;	2000;	2000;	Vascular Graft;	Research;	proprietary formulations of traditional small molecule drugs;	21;	;	;		2003;	0.8889;		
wvcs20000001082038;	DURECT CORP;	424B4;	2000;	2000;	 Cancer Immunotherapy;	Research;	proprietary formulations of traditional small molecule drugs;	22;	;	;		2003;	-0.3333;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2001;	Sufentanil  ;	Phase II;	proprietary formulations of traditional small molecule drugs;	62;	;	;		2011;	-0.1;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2001;	Hydromorphone;	Preclinical;	proprietary formulations of traditional small molecule drugs;	62;	22;	42;		2003;	-1;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2001;	Gentamycin   ;	Preclinical;	proprietary formulations of traditional small molecule drugs;	2;	;	;		2003;	-1;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2001;	Cardiovascular Diseases;	Research;	proprietary formulations of traditional small molecule drugs;	21;	;	;		2003;	-0.45;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2001;	Vascular Graft;	Research;	proprietary formulations of traditional small molecule drugs;	21;	;	;		2003;	-0.15;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2001;	 Cancer Immunotherapy;	Research;	proprietary formulations of traditional small molecule drugs;	22;	;	;		2003;	-0.5;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2002;	CHRONOGESIC;	Phase II;	proprietary formulations of traditional small molecule drugs;	62;	;	;		2011;	-0.1;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2002;	SABER Injection;	Research;	 SABER;	62;	9;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2002;	Spinal Delivery;	Preclinical;	proprietary formulations of traditional small molecule drugs;	62;	;	;		2004;	-0.9237;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2002;	Antipsychotic;	Research;	 SABER;	40;	;	;		2004;	-0.9924;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2002;	Brain Tumor Local Delivery;	Preclinical;	proprietary formulations of traditional small molecule drugs;	22;	40;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2002;	Pericardial;	Preclinical;	proprietary formulations of traditional small molecule drugs;	21;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2002;	ALZET®;	Marketed;	 DUROS technology (Alzet Technology);	70;	;	;		2008;	0.1429;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2002;	IntraEAR®;	Marketed;	proprietary formulations of traditional small molecule drugs;	2;	;	;		2005;	-0.3;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2002;	SABER delivery system;	Marketed;	 SABER;	;	;	;		2004;	-0.5;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2002;	 DURIN bioerodable implant;	Marketed;	DURIN technology;	;	;	;		2004;	0.2;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2003;	CHRONOGESIC;	Phase II;	proprietary formulations of traditional small molecule drugs;	62;	;	;		2011;	-0.1;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2003;	SABER Injection;	Research;	 SABER;	62;	9;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2003;	Central Nervous System Disorders;	Preclinical;	proprietary formulations of traditional small molecule drugs;	22;	45;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2003;	Pericardial;	Preclinical;	proprietary formulations of traditional small molecule drugs;	21;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2003;	Controlled Release Injection;	Preclinical;	Saber;	23;	;	;		2005;	0;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2003;	Controlled Release Injection of Cromolyn Sodium;	Preclinical;	 SABER/DURIN;	5;	29;	;		2006;	-0.4286;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2003;	Various;	Research;	DURIN technology;	40;	;	;		2011;	-0.625;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2003;	ALZET®;	Marketed;	 DUROS technology (Alzet Technology);	70;	;	;		2008;	0.1429;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2003;	IntraEAR®;	Marketed;	proprietary formulations of traditional small molecule drugs;	2;	;	;		2005;	-0.6667;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2004;	CHRONOGESIC;	Phase III;	 DUROS technology;	62;	;	;		2011;	-0.1;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2004;	Post Operative Pain;	Phase I;	 SABER;	62;	9;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2004;	Remoxy™;	Phase I;	  ORADUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2004;	Central Nervous System Disorders;	Preclinical;	 DUROS technology;	22;	45;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2004;	Pericardial;	Preclinical;	 DUROS technology;	21;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2004;	Controlled Release Injection of Cromolyn Sodium;	Preclinical;	 SABER/DURIN;	5;	29;	;		2006;	0;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2004;	Controlled Release Implant;	Research;	DURIN technology;	40;	;	;		2011;	-0.625;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2004;	ALZET®;	Marketed;	 DUROS technology (Alzet Technology);	70;	;	;		2008;	0.1429;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2005;	CHRONOGESIC;	Phase III;	 DUROS technology;	62;	;	;		2011;	-0.1;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2005;	Post Operative Pain;	Phase II;	 SABER;	62;	9;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2005;	Remoxy™;	Phase III;	  ORADUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2005;	Central Nervous System Disorders;	Preclinical;	 DUROS technology;	22;	45;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2005;	Pericardial;	Preclinical;	 DUROS technology;	21;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2005;	Transdermal sufentanil;	Phase II;	TRANSDUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2005;	Controlled Release Implant;	Phase I;	DURIN technology;	40;	;	;		2011;	-0.625;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2005;	LACTEL® brand;	Marketed;	N/A;	;	;	;		2008;	1.8;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2005;	ALZET®;	Marketed;	 DUROS technology (Alzet Technology);	70;	;	;		2008;	0.1429;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2006;	CHRONOGESIC;	Phase III;	 DUROS technology;	62;	;	;		2011;	-0.1;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2006;	SABER-Bupivacaine;	Phase II;	 SABER;	62;	9;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2006;	Remoxy™;	Phase III;	  ORADUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2006;	Central Nervous System Disorders;	Preclinical;	 DUROS technology;	22;	45;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2006;	Pericardial;	Preclinical;	 DUROS technology;	21;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2006;	TRANSDUR-Sufentanil;	Phase II;	TRANSDUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2006;	Memryte;	Phase III;	DURIN technology;	40;	;	;		2011;	-0.625;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2006;	ALZET®;	Marketed;	 DUROS technology (Alzet Technology);	70;	;	;		2008;	-0.4;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2006;	LACTEL® brand;	Marketed;	N/A;	;	;	;		2008;	-0.65;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2007;	POSIDUR;	Phase II;	 SABER;	62;	9;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2007;	TRANSDUR-Sufentanil;	Phase II;	TRANSDUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2007;	Remoxy™;	Phase III;	  ORADUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2007;	Memryte;	Phase III;	DURIN technology;	40;	;	;		2011;	-0.625;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2007;	Central Nervous System Disorders;	Preclinical;	 DUROS technology;	22;	45;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2007;	Pericardial;	Preclinical;	 DUROS technology;	21;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2007;	CHRONOGESIC;	Phase III;	 DUROS technology;	62;	;	;		2011;	-0.1;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2007;	TRANSDUR-Bupivacaine;	Phase II;	TRANSDUR;	62;	9;	42;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2008;	POSIDUR;	Phase II;	 SABER;	62;	9;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2008;	TRANSDUR-Sufentanil;	Phase II;	TRANSDUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2008;	Remoxy™;	NDA;	  ORADUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2008;	Memryte;	Phase III;	DURIN technology;	40;	;	;		2011;	-0.625;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2008;	Central Nervous System Disorders;	Preclinical;	 DUROS technology;	22;	45;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2008;	Pericardial;	Preclinical;	 DUROS technology;	21;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2008;	ELADUR;	Phase II;	TRANSDUR;	62;	9;	42;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2008;	CHRONOGESIC;	System Redesign;	 DUROS technology;	62;	;	;		2011;	-0.1;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2009;	POSIDUR;	Phase II;	 SABER;	62;	9;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2009;	TRANSDUR-Sufentanil;	Phase II;	TRANSDUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2009;	Remoxy™;	NDA;	  ORADUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2009;	Memryte;	Phase III;	DURIN technology;	40;	;	;		2011;	-0.8421;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2009;	Central Nervous System Disorders;	Preclinical;	 DUROS technology;	22;	45;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2009;	Pericardial;	Preclinical;	 DUROS technology;	21;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2009;	ELADUR;	Phase II;	TRANSDUR;	62;	9;	42;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2009;	CHRONOGESIC;	System Redesign;	 DUROS technology;	62;	;	;		2011;	-0.6727;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2009;	Oral controlled release opioid;	Phase I;	ORADUR-;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2010;	POSIDUR;	Phase III;	 SABER;	62;	9;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2010;	TRANSDUR-Sufentanil;	Phase II;	TRANSDUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2010;	Remoxy™;	NDA;	  ORADUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2010;	Central Nervous System Disorders;	Preclinical;	 DUROS technology;	22;	45;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2010;	Pericardial;	Preclinical;	 DUROS technology;	21;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2010;	ELADUR;	Phase II;	TRANSDUR;	62;	9;	42;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2010;	Oral controlled release opioid;	Phase I;	ORADUR-;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2010;	ORADUR-ADHD;	Preclinical;	ORADUR-;	40;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2011;	POSIDUR;	Phase III;	 SABER;	62;	9;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2011;	TRANSDUR-Sufentanil;	Phase II;	TRANSDUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2011;	Remoxy™;	NDA;	  ORADUR;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2011;	Central Nervous System Disorders;	Preclinical;	 DUROS technology;	22;	45;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2011;	Pericardial;	Preclinical;	 DUROS technology;	21;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2011;	ELADUR;	Phase II;	TRANSDUR;	62;	9;	42;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2011;	Oral controlled release opioid;	Phase I;	ORADUR-;	62;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2011;	ORADUR-ADHD;	Preclinical;	ORADUR-;	40;	;	;		;	;		
wvcs20000001082038;	DURECT CORP;	10-K;	2000;	2011;	•ORADUR-based opioid (oxymorphone);	Phase I;	ORADUR-;	62;	;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	S-1;	2000;	2000;	ProApoA-I;	Preclinical;	recombinant DNA sequence for ProApoA-1,;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	S-1;	2000;	2000;	A-I Milano, or AIM,;	Preclinical;	worldwide rights to AIM ;	21;	;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	S-1;	2000;	2000;	RLT Peptide;	Preclinical;	RLT peptide technology;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	S-1;	2000;	2000;	HDL Elevators;	Preclinical;	HDL Therapy;	21;	;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	S-1;	2000;	2000;	LUVs;	Preclinical;	LUV technology;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	424B4;	2000;	2000;	ProApoA-I;	Phase I;	recombinant DNA sequence for ProApoA-1,;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	424B4;	2000;	2000;	A-I Milano, or AIM,;	Preclinical;	worldwide rights to AIM ;	21;	;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	424B4;	2000;	2000;	RLT Peptide;	Preclinical;	RLT peptide technology;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	424B4;	2000;	2000;	HDL Elevators;	Preclinical;	HDL Therapy;	21;	;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	424B4;	2000;	2000;	LUVs;	Preclinical;	LUV technology;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2001;	ETC-276;	Phase I;	recombinant DNA sequence for ProApoA-1,;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2001;	ETC-216;	Phase I;	worldwide rights to AIM ;	21;	;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2001;	ETC-642;	Preclinical;	RLT peptide technology;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2001;	HDL Elevators;	Preclinical;	HDL Therapy;	21;	;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2001;	ETC-588;	Phase II;	LUV technology;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2002;	ETC-276;	Phase I;	recombinant DNA sequence for ProApoA-1,;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2002;	ETC-216;	Phase II;	worldwide rights to AIM ;	21;	;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2002;	ETC-642;	Phase I;	RLT peptide technology;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2002;	ESP 31015;	IND;	HDL Therapy;	21;	;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2002;	ETC-588;	Phase IIA;	LUV technology;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2003;	ETC-588;	Phase IIA;	LUV technology;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2003;	ETC-216;	Phase II;	worldwide rights to AIM ;	21;	;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2003;	ETC-642;	Phase I;	RLT peptide technology;	9;	21;	;		;	;		
wvcs20000001066745;	ESPERION THERAPEUTICS;	10-K;	2000;	2003;	 ETC-1001;	IND;	HDL Therapy;	21;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	S-1;	2000;	2000;	INS365 Respiratory ;	Phase IIA;	P2Y receptor technology platform.;	29;	;	;		2004;	-0.5;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	S-1;	2000;	2000;	INS365 Respiratory ;	Phase IIA;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	S-1;	2000;	2000;	 INS365 Ophthalmic;	Phase IIB;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	S-1;	2000;	2000;	 INS316 Diagnostic;	Phase III;	P2Y receptor technology platform.;	9;	29;	;		2006;	-0.6111;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	S-1;	2000;	2000;	INS37217 Respiratory;	Phase I;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	S-1;	2000;	2000;	 INS37217 Ophthalmic;	Phase I;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	S-1;	2000;	2000;	P2Y\\2\\ Agonist ;	Preclinical;	P2Y receptor technology platform.;	29;	2;	;		2003;	0.3871;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	424B1;	2000;	2000;	INS365 Respiratory ;	Phase II;	P2Y receptor technology platform.;	29;	;	;		2004;	-0.5;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	424B1;	2000;	2000;	INS365 Respiratory ;	Phase II;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	424B1;	2000;	2000;	 INS365 Ophthalmic;	Phase III;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	424B1;	2000;	2000;	 INS316 Diagnostic;	Phase III;	P2Y receptor technology platform.;	9;	29;	;		2006;	-0.6111;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	424B1;	2000;	2000;	INS37217 Respiratory;	Phase I;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	424B1;	2000;	2000;	 INS37217 Ophthalmic;	Phase I;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	424B1;	2000;	2000;	P2Y\\2\\ Agonist ;	Preclinical;	P2Y receptor technology platform.;	29;	2;	;		2003;	0.3871;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2001;	INS365 Respiratory ;	Phase II;	P2Y receptor technology platform.;	29;	;	;		2004;	-0.5;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2001;	INS365 Respiratory ;	Phase II;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2001;	INS37217 Respiratory;	Phase I;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2001;	 INS37217  Respiratory ;	Preclinical;	P2Y receptor technology platform.;	29;	2;	;		2003;	2.9091;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2001;	 INS365 Ophthalmic;	Phase III;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2001;	 INS316 Diagnostic;	Phase III;	P2Y receptor technology platform.;	9;	29;	;		2006;	-0.6111;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2001;	 INS37217 Ophthalmic;	Phase I;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2002;	 INS365 Ophthalmic;	Phase III;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2002;	 INS365 Ophthalmic;	Phase III;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2002;	 INS37217 Ophthalmic;	Phase II;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2002;	 INS316 Diagnostic;	Phase III;	P2Y receptor technology platform.;	9;	29;	;		2006;	-0.6111;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2002;	INS37217 Respiratory;	Phase I;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2002;	INS365 Respiratory ;	Phase II;	P2Y receptor technology platform.;	29;	;	;		2004;	0.0909;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2002;	 INS37217   Intranasal;	Phase II;	P2Y receptor technology platform.;	29;	2;	;		2006;	0.4074;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2003;	Diquafosol tetrasodium;	Phase II;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2003;	Diquafosol tetrasodium;	Phase II;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2003;	 INS37217   Intranasal;	Phase III;	P2Y receptor technology platform.;	29;	2;	;		2006;	0.4074;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2003;	INS37217 Respiratory;	Phase II;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2003;	 INS316 Diagnostic;	Phase III;	P2Y receptor technology platform.;	9;	29;	;		2006;	-0.6111;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2003;	Denufosol tetrasodium ;	Phase II;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2004;	Elestat™;	Marketed;	N/A;	5;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2004;	Restasis®;	Marketed;	N/A;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2004;	Diquafosol tetrasodium;	Phase III;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2004;	Diquafosol tetrasodium;	Phase III;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2004;	 INS37217   Intranasal;	Phase II;	P2Y receptor technology platform.;	29;	2;	;		2006;	-0.3091;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2004;	Denufosol tetrasodium;	Phase II;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2004;	 INS316 Diagnostic;	Phase III;	P2Y receptor technology platform.;	9;	29;	;		2006;	-0.3636;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2004;	Denufosol tetrasodium ;	Phase II;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2004;	INS50589 Cardiovascular;	Preclinical;	P2Y receptor technology platform.;	9;	21;	;		2007;	1.1111;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2005;	Elestat™;	Marketed;	N/A;	5;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2005;	Restasis®;	Marketed;	N/A;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2005;	Diquafosol tetrasodium;	NDA;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2005;	Diquafosol tetrasodium;	Phase II;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2005;	Denufosol tetrasodium;	Phase II;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2005;	Denufosol tetrasodium ;	Phase II;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2005;	Denufosol tetrasodium ;	Phase II;	P2Y receptor technology platform.;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2005;	INS50589 Antiplatelet;	Phase I;	P2Y receptor technology platform.;	9;	21;	;		2007;	0.7273;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2006;	Elestat™;	Marketed;	N/A;	5;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2006;	Restasis®;	Marketed;	N/A;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2006;	Diquafosol tetrasodium;	NDA;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2006;	Denufosol tetrasodium;	Phase II;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2006;	INS50589 Cardiovascular;	Phase I;	P2Y receptor technology platform.;	9;	21;	;		2008;	-0.4545;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2006;	Intranasal epinastine;	Preclinical;	 Boehringer Ingelheim- Liscense;	29;	;	;		2010;	-0.8333;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2006;	Outflow enhancer;	Preclinical;	 WARF;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2007;	Elestat™;	Marketed;	N/A;	5;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2007;	Restasis®;	Marketed;	N/A;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2007;	ProlacriaTM;	NDA;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2007;	Denufosol tetrasodium;	Phase III;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2007;	INS115644;	Phase I;	 WARF;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2007;	Intranasal epinastine;	Phase II;	 Boehringer Ingelheim- Liscense;	29;	;	;		2010;	-0.8333;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2007;	AzaSite™;	Phase III;	 InSite Vision -Technology;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2007;	Bilastine;	Phase III;	 oral H1-antihistamine compound ;	29;	;	;		2009;	-0.9372;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2008;	Elestat™;	Marketed;	N/A;	5;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2008;	Restasis®;	Marketed;	N/A;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2008;	AzaSite™;	Marketed;	 InSite Vision -Technology;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2008;	ProlacriaTM;	NDA;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2008;	Denufosol tetrasodium;	Phase III;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2008;	Intranasal epinastine;	Phase III;	 Boehringer Ingelheim- Liscense;	29;	;	;		2010;	-0.9091;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2008;	INS115644;	Phase I;	 WARF;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2009;	Elestat™;	Marketed;	N/A;	5;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2009;	Restasis®;	Marketed;	N/A;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2009;	AzaSite™;	Marketed;	 InSite Vision -Technology;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2009;	ProlacriaTM;	NDA;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2009;	AzaSite™;	Phase II;	 InSite Vision -Technology;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2009;	Denufosol tetrasodium;	Phase III;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2009;	INS115644;	Phase I;	 WARF;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2010;	Elestat™;	Marketed;	N/A;	5;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2010;	Restasis®;	Marketed;	N/A;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2010;	AzaSite™;	Marketed;	 InSite Vision -Technology;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2010;	ProlacriaTM;	NDA;	P2Y receptor technology platform.;	29;	1;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2010;	AzaSite™;	Phase II;	 InSite Vision -Technology;	1;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2010;	Denufosol tetrasodium;	Phase III;	P2Y receptor technology platform.;	29;	;	;		;	;		
wvcs20000001040416;	INSPIRE PHARMACEUTICALS INC;	10-K;	2000;	2010;	INS115644;	Phase I;	 WARF;	1;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	INGN 201;	Phase III;	INTROGEN ENABLING TECHNOLOGIES;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	INGN 201;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	INGN 241;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	INGN 251;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	0.3158;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	INGN 251;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	40;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	INGN 231;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2002;	9.2105;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	 BAK PROGRAM      ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	0;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	P16 PROGRAM     ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	-1;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	 DBCCR1* PROGRAM  ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		2002;	3;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	S-1;	2000;	2000;	RSK3* PROGRAM   ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2002;	-1;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	INGN 201;	Phase III;	INTROGEN ENABLING TECHNOLOGIES;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	INGN 201;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	INGN 241;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	INGN 251;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	0.3158;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	INGN 251;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	40;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	INGN 231;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2002;	9.2105;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	 BAK PROGRAM      ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	0;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	P16 PROGRAM     ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	-1;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	 DBCCR1* PROGRAM  ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		2002;	3;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	424B4;	2000;	2000;	RSK3* PROGRAM   ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2002;	-1;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2001;	INGN 201;	Phase III;	INTROGEN ENABLING TECHNOLOGIES;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2001;	INGN 201;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2001;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2001;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2001;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2001;	INGN 241;	Preclinical;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2001;	INGN 251;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	0.3158;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2001;	INGN 251;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	40;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2001;	 BAK PROGRAM      ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	0;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2001;	P16 PROGRAM     ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	-1;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	INGN 201;	Phase III;	INTROGEN ENABLING TECHNOLOGIES;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	INGN 201;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	INGN 201;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	INGN 201;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	INGN 241;	Phase I;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	INGN 251;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	0.3158;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	INGN 251;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	40;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	 BAK PROGRAM      ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	0;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2002;	P16 PROGRAM     ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	-1;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	ADVEXIN® Gene Therapy ;	Phase III;	INTROGEN ENABLING TECHNOLOGIES;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	INGN 241;	Preclinical;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	INGN 251;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	-0.6429;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	INGN 251;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	40;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	 BAK PROGRAM      ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	-1;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	P16 PROGRAM     ;	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	-1;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	FUS-1 Program;	Research;	3p21.3 family of genes.;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2003;	Mebendazole ( INGN 601);	Research;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		2005;	-0.8;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	ADVEXIN® Gene Therapy ;	Phase III;	INTROGEN ENABLING TECHNOLOGIES;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	40;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	ADVEXIN® Gene Therapy ;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	5;	20;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	INGN 225 ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	INGN 225 ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	INGN 241;	Preclinical;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	INGN 401;	Phase I;	3p21.3 family of genes.;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2004;	INGN 007;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	ADVEXIN® Gene Therapy ;	Phase III;	INTROGEN ENABLING TECHNOLOGIES;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	40;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	ADVEXIN® Gene Therapy ;	Preclinical;	INTROGEN ENABLING TECHNOLOGIES;	5;	20;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	INGN 225 ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	INGN 225 ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	INGN 234 (p53 topical);	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	INGN 241;	Preclinical;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	INGN 401;	Phase I;	3p21.3 family of genes.;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	INGN 007;	Preclinical;	Replication Competent Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2005;	INGN 402 nanoparticle formulation (p53);	Preclinical;	Nanoparticle Systemic Delivery Platform;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	ADVEXIN® Gene Therapy ;	Phase III;	INTROGEN ENABLING TECHNOLOGIES;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	40;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	INGN 225 ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	INGN 225 ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	INGN 234 (p53 topical);	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	INGN 241;	Preclinical;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	INGN 241;	Phase III;	Nanoscale Viral Delivery Systems;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	INGN 401;	Phase I;	3p21.3 family of genes.;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	INGN 007;	Preclinical;	Replication Competent Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2006;	INGN 402 nanoparticle formulation (p53);	Preclinical;	Nanoparticle Systemic Delivery Platform;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	ADVEXIN® Gene Therapy ;	Phase III;	INTROGEN ENABLING TECHNOLOGIES;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	40;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 225 ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 225 ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 234 (p53 topical);	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 241;	Preclinical;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 241;	Phase III;	Nanoscale Viral Delivery Systems;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 401;	Phase I;	3p21.3 family of genes.;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 007;	Preclinical;	Replication Competent Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 402 nanoparticle formulation (p53);	Preclinical;	Nanoparticle Systemic Delivery Platform;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2007;	INGN 225,;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	ADVEXIN® Gene Therapy ;	Phase III;	INTROGEN ENABLING TECHNOLOGIES;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	3;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	ADVEXIN® Gene Therapy ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	ADVEXIN® Gene Therapy ;	Phase I;	INTROGEN ENABLING TECHNOLOGIES;	22;	40;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 225 ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 225 ;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 234 (p53 topical);	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 241;	Preclinical;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 241;	Phase II;	Nanoscale Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 241;	Phase III;	Nanoscale Viral Delivery Systems;	22;	2;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 401;	Phase I;	3p21.3 family of genes.;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 007;	Preclinical;	Replication Competent Viral Delivery Systems;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 402 nanoparticle formulation (p53);	Preclinical;	Nanoparticle Systemic Delivery Platform;	22;	;	;		;	;		
wvcs20000001018710;	INTROGEN THERAPEUTICS INC ;	10-K;	2000;	2008;	INGN 225,;	Phase II;	INTROGEN ENABLING TECHNOLOGIES;	22;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	S-1;	2000;	2000;	GENEWARE Technology ;	Research;	GENEWARE Technology ;	;	;	;		2005;	0.6667;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	S-1;	2000;	2000;	GENEWARE Technology ;	Research;	GENEWARE Technology ;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	S-1;	2000;	2000;	GENEWARE Technology ;	Research;	GENEWARE Technology ;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	S-1;	2000;	2000;	ProGEx System;	Research;	ProGEx System ;	;	;	;		2002;	4.3333;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	S-1;	2000;	2000;	ProGEx System;	Research;	ProGEx System ;	;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	S-1;	2000;	2000;	ProGEx System;	Research;	ProGEx System ;	70;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	S-1;	2000;	2000;	ProGEx System;	Research;	ProGEx System ;	;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	424B;	2000;	2000;	GENEWARE Technology ;	Research;	GENEWARE Technology ;	;	;	;		2005;	0.6667;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	424B;	2000;	2000;	GENEWARE Technology ;	Research;	GENEWARE Technology ;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	424B;	2000;	2000;	GENEWARE Technology ;	Research;	GENEWARE Technology ;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	424B;	2000;	2000;	ProGEx System;	Research;	ProGEx System ;	;	;	;		2002;	4.3333;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	424B;	2000;	2000;	ProGEx System;	Research;	ProGEx System ;	;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	424B;	2000;	2000;	ProGEx System;	Research;	ProGEx System ;	70;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	424B;	2000;	2000;	ProGEx System;	Research;	ProGEx System ;	;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2001;	Marker Proteins ;	Research;	ProGEx System ;	;	;	;		2005;	-0.375;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2001;	Human Protein Index, or HPI, databas;	Research;	ProGEx System ;	;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2001;	Protein Chips;	Research;	ProGEx System ;	70;	;	;		2003;	-0.375;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2001;	Molecular Anatomy and Pathology, or MAP, database;	Research;	ProGEx System ;	;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2001;	Molecular Effects of Drugs, or MED, database;	Research;	ProGEx System ;	;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2001;	GENEWARE Technology ;	FDA Pending;	GENEWARE Technology ;	;	;	;		2005;	0.6667;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2001;	GENEWARE Technology ;	Research;	GENEWARE Technology ;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2001;	GENEWARE Technology ;	Research;	GENEWARE Technology ;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2002;	NHL vaccines;	Phase I;	GENEWARE Technology ;	27;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2002;	PLURIGEN CM;	Preclinical;	GENEWARE Technology ;	;	;	;		2005;	-1;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2002;	Rapid and Cost-Effective Protein and Vaccine Manufacturing.;	FDA Pending;	GENEWARE Technology ;	;	;	;		2005;	0.6667;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2002;	Protein BioChips;	Research;	ProGEx System ;	70;	;	;		2004;	6.6667;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2002;	Marker Proteins ;	Marketed;	ProGEx System ;	;	;	;		2005;	-0.375;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2002;	Plant Functional Genomics, Forestry and Agriculture;	Research;	GENEWARE Technology ;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2003;	Alpha-Galactosidase A.;	Preclinical;	GENEWARE system;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2003;	Aprotinin;	Preclinical;	GENEWARE Technology ;	;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2003;	NHL vaccines;	Phase I;	GENEWARE Technology ;	27;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2003;	PLURIGEN CM;	Preclinical;	GENEWARE Technology ;	;	;	;		2005;	-1;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2003;	Rapid and Cost-Effective Protein and Vaccine Manufacturing.;	Marketed;	GENEWARE Technology ;	;	;	;		2005;	4;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2003;	Marker Proteins ;	Marketed;	GENEWARE Technology ;	;	;	;		2005;	4;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2003;	Plant Functional Genomics, Forestry and Agriculture;	Research;	GENEWARE Technology ;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2004;	Alpha-Galactosidase A.;	Preclinical;	GENEWARE system;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2004;	Aprotinin;	Preclinical;	GENEWARE Technology ;	;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2004;	NHL vaccines;	Phase I;	GENEWARE Technology ;	27;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2004;	Human lysosomal acid lipase;	Preclinical;	GENEWARE Technology ;	24;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2004;	BAMF Diagnostics;	Marketed;	BAMF Diagnostics;	22;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2004;	GRAMMR Gene Shuffling—;	Marketed;	GRAMMR Gene Shuffling;	30;	70;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2005;	Alpha-Galactosidase A.;	IND;	GENEWARE system;	30;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2005;	Aprotinin;	Marketed;	GENEWARE Technology ;	;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2005;	NHL vaccines;	Phase I;	GENEWARE Technology ;	27;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2005;	Human lysosomal acid lipase;	Preclinical;	GENEWARE Technology ;	24;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2005;	BAMF Diagnostics;	Marketed;	BAMF Diagnostics;	22;	;	;		;	;		
wvcs20000001108951;	LARGE SCALE BIOLOGY CORP;	10-K;	2000;	2005;	GRAMMR Gene Shuffling—;	Marketed;	GRAMMR Gene Shuffling;	30;	70;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	S-1;	2000;	2000;	Angiomax;	 NDA;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	S-1;	2000;	2000;	Angiomax;	Phase II;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	S-1;	2000;	2000;	Angiomax;	Phase II;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	S-1;	2000;	2000;	Angiomax;	Phase I;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	S-1;	2000;	2000;	Angiomax;	PreMarket;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	S-1;	2000;	2000;	CTV-05;	Phase II;	GyneLogix, Inc;	23;	70;	3;		2005;	-0.5556;		
wvcs20000001113481;	MEDICINES CO;	424B3;	2000;	2000;	Angiomax;	 NDA;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	424B3;	2000;	2000;	Angiomax;	Phase II;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	424B3;	2000;	2000;	Angiomax;	Phase II;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	424B3;	2000;	2000;	Angiomax;	Phase I;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	424B3;	2000;	2000;	Angiomax;	PreMarket;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	424B3;	2000;	2000;	CTV-05;	Phase II;	GyneLogix, Inc;	23;	70;	3;		2005;	-0.5556;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2001;	Angiomax;	Phase IIIB;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2001;	Angiomax;	Phase III;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2001;	Angiomax;	Phase II;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2001;	Angiomax;	Marketed;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2001;	Angiomax;	Phase II;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2001;	Angiomax;	Phase II;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2001;	CTV-05;	Phase II;	GyneLogix, Inc;	23;	70;	3;		2005;	-0.5556;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2001;	CLEVIDIPINE;	Phase III;	calcium channel inhibitors;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2001;	IS-159;	N/a;	 Immunotech S.A. ;	21;	;	;		2005;	-1;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2003;	Angiomax;	mARKETED;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2003;	Angiomax;	Phase III;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2003;	Angiomax;	Phase II;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2003;	Angiomax;	Marketed;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2003;	Angiomax;	Phase II;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2003;	Angiomax;	Phase II;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2003;	CTV-05;	Phase II;	GyneLogix, Inc;	23;	70;	3;		2005;	-0.9898;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2003;	CLEVIDIPINE;	Phase III;	calcium channel inhibitors;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2003;	IS-159;	N/a;	 Immunotech S.A. ;	21;	;	;		2005;	-1;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2004;	Angiomax;	mARKETED;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2004;	Angiomax;	Phase II;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2004;	Angiomax;	Phase II;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2004;	Angiomax;	Phase III;	inhibits thrombin;	9;	21;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2004;	Angiomax;	Phase II;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2004;	Clevelox;	Phase III;	calcium channel inhibitors;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2004;	cangrelor;	Preclinical;	AstraZeneca;	9;	21;	25;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2005;	Angiomax;	Marketed;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2005;	Angiomax;	Phase III;	inhibits thrombin;	9;	21;	25;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2005;	Angiomax;	Phase II;	inhibits thrombin;	21;	70;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2005;	Clevelox;	Phase III;	calcium channel inhibitors;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2005;	cangrelor;	Phase II;	AstraZeneca;	9;	21;	25;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2006;	Angiomax;	Marketed;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2006;	Angiomax;	Phase III;	inhibits thrombin;	9;	21;	25;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2006;	Angiomax;	Phase II;	inhibits thrombin;	21;	70;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2006;	Clevidipine;	Phase III;	calcium channel inhibitors;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2006;	cangrelor;	Phase III;	AstraZeneca;	9;	21;	25;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2007;	Angiomax;	Marketed;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2007;	Cleviprex™ ;	Phase III;	calcium channel inhibitors;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2007;	cangrelor;	Phase III;	AstraZeneca;	9;	21;	25;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2008;	Angiomax;	Marketed;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2008;	Cleviprex™ ;	Phase III;	calcium channel inhibitors;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2008;	cangrelor;	Phase III;	AstraZeneca;	9;	21;	25;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2009;	Angiomax;	Marketed;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2009;	Cleviprex™ ;	Phase III;	calcium channel inhibitors;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2009;	cangrelor;	Phase III;	AstraZeneca;	9;	21;	25;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2009;	oritavancin;	Phase III;	 novel semi-synthetic lipoglycopeptide ;	23;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2009;	 CU-2010,;	Preclinical;	 small molecule serine protease inhibitor;	;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2010;	Angiomax;	Marketed;	inhibits thrombin;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2010;	Cleviprex™ ;	Marketed;	calcium channel inhibitors;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2010;	cangrelor;	Phase III;	AstraZeneca;	9;	21;	25;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2010;	oritavancin;	Phase III;	 novel semi-synthetic lipoglycopeptide ;	23;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2010;	 CU-2010,;	Phase I;	 small molecule serine protease inhibitor;	;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2010;	ApoA-I Milano;	Phase I;	Naturally occurring variant of a protein found in HDL;	21;	;	;		;	;		
wvcs20000001113481;	MEDICINES CO;	10-K;	2000;	2010;	Argatroban;	Phase III;	Direct thrombin inhibitor;	21;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	S-1;	1999;	1999;	Minocycline Periodontal Therapeutic System. MPTS;	Phase III;	American Home Products, or AHP;	2;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	S-1;	1999;	1999;	OC-1012;	Preclinical;	protein osteopontin;	2;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	S-1;	1999;	1999;	OC-1016;	Preclinical;	Brigham and Women's Hospital of Boston;	20;	2;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	S-1;	1999;	1999;	Minocycline Periodontal Therapeutic System. MPTS;	Preclinical;	American Home Products, or AHP;	25;	2;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	424B;	1999;	2000;	Minocycline Periodontal Therapeutic System. MPTS;	Phase III;	American Home Products, or AHP;	2;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	424B;	1999;	2000;	OC-1012;	Preclinical;	protein osteopontin;	2;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	424B;	1999;	2000;	OC-1016;	Preclinical;	Brigham and Women's Hospital of Boston;	20;	2;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	424B;	1999;	2000;	Minocycline Periodontal Therapeutic System. MPTS;	Preclinical;	American Home Products, or AHP;	25;	2;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2001;	Arestin(TM);	Marketed ;	American Home Products, or AHP;	2;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2001;	OC-1012;	Preclinical;	protein osteopontin;	2;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2001;	OC-1016;	Preclinical;	Brigham and Women's Hospital of Boston;	20;	2;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2001;	Minocycline Periodontal Therapeutic System. MPTS;	Preclinical;	American Home Products, or AHP;	25;	2;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2002;	Arestin(TM);	Marketed ;	American Home Products, or AHP;	2;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2002;	OC-1012;	Phase I;	protein osteopontin;	2;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2002;	OC-1016;	Preclinical;	Brigham and Women's Hospital of Boston;	20;	2;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2002;	Drug Delivery System for Large and Small Molecule Drugs;	Research;	N/a;	22;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2002;	Drug Delivery System for Large and Small Molecule Drugs;	Research;	N/a;	42;	;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2002;	Drug Delivery System for Large and Small Molecule Drugs;	Research;	N/a;	62;	9;	;		;	;		
wvcs20000001028065;	ORAPHARMA INC ;	10-K;	1999;	2002;	Minocycline Periodontal Therapeutic System. MPTS;	Preclinical;	American Home Products, or AHP;	25;	2;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	S-1;	2000;	2000;	NATURA;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	S-1;	2000;	2000;	CONFORMA;	Marketed;	 patented digital signal processing;	2;	;	;		2005;	1.5;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	424B4;	2000;	2000;	NATURA;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	424B4;	2000;	2000;	CONFORMA;	Marketed;	 patented digital signal processing;	2;	;	;		2005;	1.5;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2001;	NATURA;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2001;	CONFORMA;	Marketed;	 patented digital signal processing;	2;	;	;		2005;	1.5;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2001;	ALTAIR(TM);	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2002;	NATURA;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2002;	TributeTM;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2002;	ALTAIR(TM);	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2002;	QuartetTM ;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2002;	CONFORMA;	Marketed;	 patented digital signal processing;	2;	;	;		2005;	1.5;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2002;	Adesso;	Marketed;	 patented digital signal processing;	2;	;	;		2005;	0;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2003;	NATURA;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2003;	TributeTM;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2003;	ALTAIR(TM);	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2003;	QuartetTM ;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2003;	CONFORMA;	Marketed;	 patented digital signal processing;	2;	;	;		2005;	0.25;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2003;	Adesso;	Marketed;	 patented digital signal processing;	2;	;	;		2005;	0;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2004;	NATURA;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2004;	TributeTM;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2004;	ALTAIR(TM);	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2004;	QuartetTM ;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2005;	NATURA;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2005;	TributeTM;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2005;	ALTAIR(TM);	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2005;	QuartetTM ;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2006;	 Innova;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2006;	Applause;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2006;	NATURA;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2006;	TributeTM;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2006;	QuartetTM ;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2006;	Otogram;	Marketed;	 patented digital signal processing;	20;	2;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2007;	 Innova;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2007;	Applause;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2007;	NATURA;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2007;	TributeTM;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2007;	QuartetTM ;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2007;	, Balance,;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2007;	Ion;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2008;	 Innova;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2008;	Applause;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2008;	NATURA;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2008;	TributeTM;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2008;	QuartetTM ;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2008;	, Balance,;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2008;	Ion;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2008;	Velocity;	Marketed;	DIRECTIONALfocus® technology;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2009;	 Innova;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2009;	Applause;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2009;	NATURA;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2009;	TributeTM;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2009;	QuartetTM ;	Marketed;	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2009;	, Balance,;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2009;	Ion;	Marketed;	 patented digital signal processing;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2009;	Velocity;	Marketed;	DIRECTIONALfocus® technology;	2;	;	;		;	;		
wvcs20000001105982;	OTIX GLOBAL, INC.;	10-K;	2000;	2009;	Touch;	Marketed;	DIRECTIONALfocus® technology;	2;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	S-1;	2000;	2000;	 MT 100;	Phase III;	metoclopramide hydrochloride;	61;	62;	;		2007;	-0.5864;		
wvcs20000001059790;	POZEN INC ;	S-1;	2000;	2000;	MT 300 ;	Phase III;	dihydroergotamine mesylate, or DHE;	61;	62;	;		2008;	0;		
wvcs20000001059790;	POZEN INC ;	S-1;	2000;	2000;	MT 500;	Phase II;	locks a type of serotonin brain receptor;	61;	62;	;		2003;	-0.7073;		
wvcs20000001059790;	POZEN INC ;	S-1;	2000;	2000;	MT 400;	Phaes II;	triptan drug with that of a commercially approved long-acting, non-steroidal;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	424B4;	2000;	2000;	 MT 100;	Phase III;	metoclopramide hydrochloride;	61;	62;	;		2007;	-0.5864;		
wvcs20000001059790;	POZEN INC ;	424B4;	2000;	2000;	MT 300 ;	Phase III;	dihydroergotamine mesylate, or DHE;	61;	62;	;		2008;	0;		
wvcs20000001059790;	POZEN INC ;	424B4;	2000;	2000;	MT 500;	Phase II;	locks a type of serotonin brain receptor;	61;	62;	;		2003;	-0.7073;		
wvcs20000001059790;	POZEN INC ;	424B4;	2000;	2000;	MT 400;	Phaes II;	triptan drug with that of a commercially approved long-acting, non-steroidal;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2001;	 MT 100;	Phase III;	metoclopramide hydrochloride;	61;	62;	;		2007;	-0.5864;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2001;	MT 300 ;	Phase III;	dihydroergotamine mesylate, or DHE;	61;	62;	;		2008;	0;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2001;	MT 500;	Phase II;	locks a type of serotonin brain receptor;	61;	62;	;		2003;	-0.75;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2001;	MT 400;	Phaes II;	triptan drug with that of a commercially approved long-acting, non-steroidal;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2002;	 MT 100;	Phase III;	metoclopramide hydrochloride;	61;	62;	;		2007;	-0.5864;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2002;	MT 300 ;	Phase III;	dihydroergotamine mesylate, or DHE;	61;	62;	;		2008;	0;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2002;	MT 400;	Phaes II;	triptan drug with that of a commercially approved long-acting, non-steroidal;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2003;	 MT 100;	Phase III;	metoclopramide hydrochloride;	61;	62;	;		2007;	-0.5864;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2003;	MT 300 ;	Phase III;	dihydroergotamine mesylate, or DHE;	61;	62;	;		2008;	0;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2003;	MT 400;	Phase III;	triptan drug with that of a commercially approved long-acting, non-steroidal;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2004;	 MT 100;	Phase IIIB;	metoclopramide hydrochloride;	61;	62;	;		2007;	-0.5864;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2004;	MT 300 ;	NDA ;	dihydroergotamine mesylate, or DHE;	61;	62;	;		2008;	0;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2004;	MT 400;	Phase III;	triptan drug with that of a commercially approved long-acting, non-steroidal;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2005;	 MT 100;	NDA ;	metoclopramide hydrochloride;	61;	62;	;		2007;	-0.5563;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2005;	MT 300 ;	NDA ;	dihydroergotamine mesylate, or DHE;	61;	62;	;		2008;	0;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2005;	MT 400;	Phase III;	 MT 400 technology;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2005;	Trexima;	Phase III;	 MT 400 technology;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2005;	Lornoxicam Program;	Phase I;	 NSAID;	61;	62;	;		2010;	-0.8571;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2005;	PN (PPI / NSAID) Program;	Phase I;	 PPI with an NSAID ;	5;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2006;	MT 300 ;	NDA ;	dihydroergotamine mesylate, or DHE;	61;	62;	;		2008;	-0.6444;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2006;	Trexima;	Phase III;	 MT 400 technology;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2006;	Lornoxicam Program;	Phase I;	 NSAID;	61;	62;	;		2010;	-0.8571;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2006;	PN (PPI / NSAID) Program;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2007;	Trexima;	Phase III;	 MT 400 technology;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2007;	Lornoxicam Program;	Phase II;	 NSAID;	61;	62;	;		2010;	-0.8571;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2007;	PN 400;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2007;	PN 200;	Phase I;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2007;	PA 325;	Phase I;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2008;	Trexima;	Phase III;	 MT 400 technology;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2008;	Lornoxicam Program;	Phase II;	 NSAID;	61;	62;	;		2010;	-0.9934;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2008;	PN 400;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2008;	PN 200;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2008;	PA32540;	Phase I;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2008;	PN 100;	Phase I;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2009;	Trexima;	Marketed;	 MT 400 technology;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2009;	PN 400;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2009;	PN 200;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2009;	PA32540;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2009;	PN 100;	Phase I;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2010;	Trexima;	Marketed;	 MT 400 technology;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2010;	 VIMOVO;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2010;	PN 200;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2010;	PA32540;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2010;	PN 100;	Phase I;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2011;	Trexima;	Marketed;	 MT 400 technology;	61;	62;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2011;	 VIMOVO;	Marketed;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2011;	PN 200;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2011;	PA32540;	Phase III;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001059790;	POZEN INC ;	10-K;	2000;	2011;	PN 100;	Phase I;	 PPI with an NSAID ;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	S-1;	2000;	2000;	abarelix-depot-M;	Phase III;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	S-1;	2000;	2000;	abarelix-depot-F;	Phase II;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	S-1;	2000;	2000;	Latranal;	Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	20;	;		2003;	-0.875;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	S-1;	2000;	2000;	Apan;	Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	40;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	424b4;	2000;	2000;	abarelix-depot-M;	Phase III;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	424b4;	2000;	2000;	abarelix-depot-F;	Phase III;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	424b4;	2000;	2000;	Latranal;	Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	20;	;		2003;	-0.875;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	424b4;	2000;	2000;	Apan;	Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	40;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2001;	abarelix-depot-M;	Phase III;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2001;	abarelix-depot-F;	Phase III;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2001;	abarelix-depot-M;	Phase III;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2001;	abarelix-depot-F;	Phase III;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2001;	Latranal;	Phase II;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	20;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2001;	Apan;	Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	40;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2001;	CCR5 Antagonist;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	23;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2001;	PPI 3088  ;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	5;	20;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2001;	Androgen ReceptorHormone-Independent Antagonist;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2001;	Endometriosis Diagnostic;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	70;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2002;	Plenaxis  ;	NDA ;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2002;	Plenaxis  ;	Phase III;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2002;	Plenaxis  ;	Phase III;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2002;	Plenaxis  ;	Phase III;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2002;	Apan;	Phase I;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	40;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2002;	CCR5 Antagonist;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	23;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2002;	PPI 3088  ;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	20;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2002;	PPI 3088  ;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	5;	20;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2002;	Androgen ReceptorHormone-Independent Antagonist;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2002;	Endometriosis Diagnostic;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	70;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2003;	Plenaxis  ;	NDA ;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2003;	Plenaxis  ;	Phase II;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2003;	Plenaxis  ;	NDA ;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2003;	Plenaxis  ;	Phase II;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2003;	Apan;	Phase I;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	40;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2003;	Antiviral Antagonist;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	23;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2003;	PPI-2458;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	27;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2003;	PPI-2458;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	5;	27;	20;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2003;	Androgen ReceptorHormone-Independent Antagonist;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2003;	Endometriosis Diagnostic;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	70;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2004;	Plenaxis  ;	NDA ;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2004;	Plenaxis  ;	Phase II;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2004;	Plenaxis  ;	NDA ;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2004;	Plenaxis  ;	Phase II;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2004;	Apan;	Phase I;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	40;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2004;	Antiviral Antagonist;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	23;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2004;	PPI-2458;	Phase I;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	27;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2004;	PPI-2458;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	5;	27;	20;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2004;	Androgen ReceptorHormone-Independent Antagonist;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2004;	Endometriosis Diagnostic;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	62;	70;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2005;	Plenaxis  ;	Approved;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2005;	Plenaxis  ;	Approved;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2005;	Apan;	Phase I;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	40;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2005;	PPI-2458;	Phase I;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	27;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2005;	PPI-2458;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	5;	27;	20;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2005;	Plenaxis;	Phase I;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2006;	PPI-2458;	Phase I;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	22;	27;	;		;	;		
wvcs20000001033025;	PRAECIS PHARMACEUTICALS INC;	10K;	2000;	2006;	PPI-2458;	Research/Preclinical;	Ligand Evolution to Active Pharmaceuticals, or LEAP.;	5;	27;	20;		;	;		
wvcs20000001099414;	TANOX INC;	S-1;	2000;	2000;	 E25;	Phase III;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	S-1;	2000;	2000;	 E25;	Phase III;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	S-1;	2000;	2000;	HU-901;	Phase II;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	S-1;	2000;	2000;	5D12;	Phase II;	monoclonal antibody;	5;	;	;		2005;	0;		
wvcs20000001099414;	TANOX INC;	S-1;	2000;	2000;	 5A8 ;	Preclinical;	monoclonal antibody;	23;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	S-1;	2000;	2000;	166-32 ;	Research;	monoclonal antibody;	5;	9;	;		2005;	-1;		
wvcs20000001099414;	TANOX INC;	S-1;	2000;	2000;	163-93;	Research;	monoclonal antibody;	23;	;	;		2003;	-1;		
wvcs20000001099414;	TANOX INC;	424B4;	2000;	2000;	 E25;	Phase III;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	424B4;	2000;	2000;	 E25;	Phase III;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	424B4;	2000;	2000;	HU-901;	Phase II;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	424B4;	2000;	2000;	5D12;	Phase II;	monoclonal antibody;	5;	;	;		2005;	0;		
wvcs20000001099414;	TANOX INC;	424B4;	2000;	2000;	 5A8 ;	Preclinical;	monoclonal antibody;	23;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	424B4;	2000;	2000;	166-32 ;	Research;	monoclonal antibody;	5;	9;	;		2005;	-1;		
wvcs20000001099414;	TANOX INC;	424B4;	2000;	2000;	163-93;	Research;	monoclonal antibody;	23;	;	;		2003;	-1;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2001;	Xolair;	Bilogics License Application (BLA);	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2001;	Xolair;	Bilogics License Application (BLA);	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2001;	HU-901;	Phase II;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2001;	5D12;	Phase II;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2001;	 5A8 ;	Preclinical;	monoclonal antibody;	23;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2001;	166-32 ;	Preclinical;	monoclonal antibody;	5;	9;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2001;	163-93;	Research;	monoclonal antibody;	23;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2002;	Xolair;	Bilogics License Application (BLA);	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2002;	Xolair;	Phase III;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2002;	TNX-901;	Phase II;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2002;	TNX-100;	Phase II;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2002;	TNX-335 ;	Phase I;	monoclonal antibody;	23;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2002;	TNX-224 ;	Preclinical;	monoclonal antibody;	5;	9;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2003;	Xolair;	Bilogics License Application (BLA);	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2003;	Xolair;	Phase III;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2003;	TNX-901;	Phase II;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2003;	TNX-100;	Phase II;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2003;	TNX-335 ;	Phase IB;	monoclonal antibody;	23;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2003;	TNX-224 ;	Preclinical;	monoclonal antibody;	5;	9;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2004;	Xolair;	Marketed;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2004;	Xolair;	Phase II;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2004;	TNX-355;	Phase II;	monoclonal antibody;	23;	70;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2004;	Allergic mediator;	Preclinical;	MADP;	8;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2004;	Complement Factor D;	Preclinical;	MADP;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2004;	Complement C5a;	Research;	MADP;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2004;	Osteoblast signaling pathway;	Research;	MADP;	20;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2005;	Xolair;	Marketed;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2005;	Xolair;	Phase II;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2005;	TNX-355;	Phase II;	monoclonal antibody;	23;	70;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2005;	TNX-650;	Preclinical;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2005;	TNX-717;	Research;	monoclonal antibody;	20;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2005;	TNX-558;	Research;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2005;	TNX-668;	Research;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2005;	TNX-336;	Research;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2006;	Xolair;	Marketed;	monoclonal antibody;	5;	29;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2006;	TNX-355;	Phase II;	monoclonal antibody;	23;	70;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2006;	TNX-832;	Phase II;	monoclonal antibody;	5;	9;	25;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2006;	TNX-650;	IND;	monoclonal antibody;	5;	27;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2006;	TNX-650;	Preclinical;	monoclonal antibody;	5;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2006;	TNX-717;	Preclinical;	monoclonal antibody;	20;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2006;	TNX-833;	Preclinical;	monoclonal antibody;	22;	;	;		;	;		
wvcs20000001099414;	TANOX INC;	10K;	2000;	2006;	TNX-234;	Preclinical;	monoclonal antibody;	1;	;	;		;	;		
wvcu20020001139665;	XCEL PHARMACEUTICALS INC;	S-1;	2003;	2003;	Diastat;	marketed;	rectally administered gel ;	9;	43;	;		;	;		
wvcu20020001139665;	XCEL PHARMACEUTICALS INC;	S-1;	2003;	2003;	Mysoline;	marketed;	Oral tablets;	43;	;	;		;	;		
wvcu20020001139665;	XCEL PHARMACEUTICALS INC;	S-1;	2003;	2003;	Migranal ;	marketed;	Nasal spray ;	40;	;	;		;	;		
wvcu20020001139665;	XCEL PHARMACEUTICALS INC;	S-1;	2003;	2003;	D.H.E. 45;	marketed;	Intravenous, intramuscular or subcutaneous injection ;	9;	25;	40;		;	;		
wvcu20040001286517;	CELLDEX THERAPEUTICS INC;	S-1;	2004;	2004;	HCG-VAC;	IND;	APC targeting technology ;	22;	;	;		;	;		
wvcu20040001286517;	CELLDEX THERAPEUTICS INC;	S-1;	2004;	2004;	HCG-VAC;	IND;	APC targeting technology ;	22;	;	;		;	;		
wvcu20040001286517;	CELLDEX THERAPEUTICS INC;	S-1;	2004;	2004;	HCG-VAC;	IND;	APC targeting technology ;	22;	;	;		;	;		
wvcu20040001286517;	CELLDEX THERAPEUTICS INC;	S-1;	2004;	2004;	COL-VAC;	Preclinical;	APC targeting technology ;	22;	;	;		;	;		
wvcu20040001286517;	CELLDEX THERAPEUTICS INC;	S-1;	2004;	2004;	AFP-VAC;	Preclinical;	APC targeting technology ;	22;	28;	;		;	;		
wvcu20040001286517;	CELLDEX THERAPEUTICS INC;	S-1;	2004;	2004;	MEL-VAC;	Preclinical;	APC targeting technology ;	22;	;	;		;	;		
wvcu20040001286517;	CELLDEX THERAPEUTICS INC;	S-1;	2004;	2004;	PSA-VAC;	Research;	APC targeting technology ;	22;	;	;		;	;		
wvcu20040001286517;	CELLDEX THERAPEUTICS INC;	S-1;	2004;	2004;	GVHD-TOX;	Research;	APC targeting technology ;	27;	20;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Carbopol[nc_cad,176];	Marketed;	;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Pemulen[nc_cad,176];	Marketed;	;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Avalure[nc_cad,176];	Marketed;	;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Specialty silicones;	Marketed;	;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Colorants;	Marketed;	;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Polycarbophil;	Marketed;	;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Benzoates;	Marketed;	;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Colors;	Marketed;	;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Flavors and Fragrances;	Marketed;	;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	TempRite[nc_cad,176];	Marketed;	CPVC;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	FlowGuard[nc_cad,176];	Marketed;	CPVC;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	 Corzan[nc_cad,176];	Marketed;	CPVC;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	 TempRite™ PEX;	Marketed;	PEX;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Estane[nc_cad,176];	Marketed;	TPU;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	 Estaloc[nc_cad,176];	Marketed;	TPU;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	Hycar[nc_cad,176];	Marketed;	Reactive Liquid Polymers;	;	;	;		;	;		
nvcu20020001177317;	NOVEON INTERNATIONAL INC;	S-1;	2002;	2002;	  Good-Rite[nc_cad,176];	Marketed;	Antioxidants;	;	;	;		;	;		
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
															
